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Abstract 1 
Gastroparesis symptoms in Parkinson’s disease 
Background:  Parkinson’s disease (PD) can result in impaired motility throughout the 
gastrointestinal tract.  Delayed gastric emptying or gastroparesis is estimated to affect 
over 70% of all people with PD.  However, the prevalence of gastroparesis symptoms 
in people with PD is unknown.  This study sought to define the prevalence and 
associated features of gastroparesis symptoms in people with PD. 
Methods:  More than 1,000 people with PD completed the Gastroparesis Cardinal 
Symptom Index (GCSI), a validated structured questionnaire to assess the presence 
and severity of gastroparesis symptoms.  Two groups of patients were recruited to this 
UK wide study: those with recently diagnosed PD (within the last three years) and 
those with young onset disease (diagnosed before the age of 50). 
Results:  More than half of the 1,003 participants reported at least one gastroparesis 
symptom in the two weeks prior to completing the GCSI questionnaire.  In those with 
recently diagnosed PD (n = 691) only 4.1% had a GCSI total score consistent with 
significant gastroparesis.  In the young onset group 12.5% of participants had 
symptoms in keeping with gastroparesis.  Features associated with a greater 
gastroparesis symptom burden across both groups included more advanced PD 
features, more non-motor symptoms, autonomic symptoms, anxiety and depression. 
Conclusions:  Although delayed gastric emptying is estimated to affect over 70% of all 
people with PD, in this large study we found that significant gastroparesis symptoms 
were only reported by 4-12% of patients.  This suggests that although gastroparesis is a 
common abnormality in PD it may be largely asymptomatic. 
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Abstract 2 
Exploration of a novel treatment for delayed gastric emptying in 
Parkinson’s disease 
Background:  Delayed gastric emptying can impair Levodopa absorption and 
contribute to motor fluctuations in people with PD.  Prokinetic medications may 
improve gastric emptying and consequently Levodopa absorption and motor function.  
However, there are few licenced prokinetics suitable for use in PD.  This is an interim 
report of an on-going Phase II, double blind, placebo controlled study to assess the 
effect of a novel motilin agonist (Camicinal) on Levodopa absorption in people with PD, 
delayed gastric emptying and motor fluctuations. 
Methods:  15 patients with PD were enrolled in this study.  All had bilateral disease 
(Hoehn & Yahr stage II-IV) and troublesome motor fluctuations.  There were 9 men and 
6 women with a mean age of 64.40 (± 10.32) years.  Participants were randomised to 
Camicinal 50mg (n=10) or placebo (n=5) once daily for 7-9 days.  The treatment and 
placebo group were matched for clinical and demographic features.  Clinical and 
pharmacokinetic parameters were measured serially at baseline, on the first day of 
treatment and the final dosing day.  Statistical analyses were performed using non-
parametric tests. 
Results:  Camicinal was as well tolerated as placebo.  By the end of the dosing period 
there was a non-significant trend towards increased Levodopa absorption (Cmax) in 
the Camicinal treated group but not the placebo group.  Gastric emptying rates and 
gastroparesis symptoms did not change significantly in either group.  There was a 
significant improvement in motor function (reduced MDS UPDRS Part III score) in the 
treatment group by the end of the dosing period compared with baseline (P < 0.05).  
The percentage of the waking day spent in the ‘off’ state fell in the Camicinal group 
and rose in the placebo group. 
Conclusions:  These interim results suggest that Camicinal has potential as a novel 
therapy to enhance Levodopa absorption and motor function in people with PD.  
Therefore on-going study and evaluation of this agent is justified. 
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Chapter 1 Introduction 
Parkinson’s disease (PD) is the second commonest neurodegenerative disorder in the 
UK after Alzheimer’s disease (Tanner and Aston, 2000).  Diagnosis is based upon the 
identification of cardinal motor symptoms however non-motor symptoms are evident 
in all stages of the disease. 
Gastrointestinal (GI) dysfunction is one of the commonest examples of non-motor 
impairment associated with PD.  Pathological and functional abnormalities have been 
described at all levels of the GI tract.  Most GI abnormalities associated with PD are 
attributable to impaired motility in the tract (Cloud and Greene, 2011).  At the level of 
the stomach, impaired motility may cause delayed gastric emptying or gastroparesis.  
Gastroparesis has been demonstrated in all stages of PD.  However, the clinical 
presentation of delayed gastric emptying in people with PD is poorly understood. 
This introductory chapter will review the current literature relating to gastroparesis in 
PD.  An abridged version of this introduction has been published as a review article in 
Movement Disorders (Marrinan et al., 2014). 
The broad themes of this thesis are the exploration of gastroparesis symptoms in 
people with PD and the evaluation of a novel treatment for delayed gastric emptying in 
PD. 
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1.1 Parkinson’s disease 
1.1.1 Epidemiology 
PD is the second commonest neurodegenerative condition after Alzheimer’s disease 
and the commonest movement disorder after essential tremor (Tanner and Aston, 
2000).  Varied prevalence rates are reported, which is likely to reflect differences in 
study methodologies and diagnostic stipulations.  In Europe the prevalence of PD is 
estimated to be between 100 and 200 cases per 100,000 of the population (von 
Campenhausen et al., 2005; Alves et al., 2008).  Incidence rates, which may be more 
accurate than estimates of prevalence (Alves et al., 2008), range from 8.6 to 19.0 per 
100,000 of the population (Twelves et al., 2003). 
PD affects all ethnicities although some geographical variation in incidence has been 
described, with higher rates of the disease reported in the developed rather than the 
developing world.  However, this may simply reflect greater diagnostic accuracy and a 
longer life expectancy in countries with more developed health care systems (Alves et 
al., 2008). 
The greatest single risk factor for the development of PD is advancing age.  The 
average age of onset is 60 years old (Lees et al., 2009).  Approximately 1% of those 
aged over 60 years old are affected and in those aged over 80 years, the prevalence is 
estimated to be 4% (de Rijk et al., 1995; Fahn, 2003; Nussbaum and Ellis, 2003).  PD is a 
progressive, incurable neurodegenerative disease.  The average life expectancy from 
the point of diagnosis is approximately 12 years (Hely et al., 2008). 
1.1.2 Aetiology 
The aetiology of PD is unknown and is likely to be multifactorial.  In addition to 
advancing age, other risk factors identified include male gender, genetic 
predispositions and environmental exposures.  Although advancing age is the greatest 
risk factor for the development of PD, approximately 4% of all cases develop clinical 
signs of the disease prior to the age of 50 years old (Van Den Eeden et al., 2003).  
Genetic abnormalities may account for some of these young onset cases. 
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The risk of developing PD is generally reported to be greater for men than women, 
particularly so with advancing age (Taylor et al., 2007).  A meta-analysis which adjusted 
for age, reported the ratio of male to female incident PD cases was 1.46 : 1 (Taylor et 
al., 2007).  The reasons for this gender imbalance are unclear.  It has been postulated 
that female hormones may be neuroprotective or that men have greater risk of 
occupational exposure to neurotoxins (Alves et al., 2008). 
The extent to which genetic abnormalities contribute to the risk of developing PD is 
complex and an evolving area of understanding.  Individuals who have a first degree 
relative with PD have approximately a 3 to 4 fold increased risk of developing the 
disease (Autere et al., 2000; Kurz et al., 2003).  Monogenetic causes of PD account for 
fewer than 5% of cases (Alves et al., 2008).  However, the study of cases of familial PD 
has led to the identification of pathogenic mutations in several genes including: alpha-
synuclein, LRRK2, Parkin, DJ-1 and PINK-1.  A detailed description of these mutations 
and their functional consequences is beyond the scope of this thesis, but there is good 
evidence for both autosomal dominant (Gasser et al., 1998; Leroy et al., 1998; Paisan-
Ruiz et al., 2004; Zimprich et al., 2004) and autosomal recessive patterns of inheritance 
(Kitada et al., 1998; Valente et al., 2001; van Duijn et al., 2001).  The relevance of 
genetics to non-familial, idiopathic PD is less clear.  The LRRK2 mutation is the 
commonest identifiable cause of dominantly inherited PD (Gasser et al., 2011) and 
causes a parkinsonian phenotype very similar to idiopathic PD (Aasly et al., 2005; 
Haugarvoll et al., 2008).  However, some LRRK2 mutations may be better characterised 
as contributory rather than causal risk factors (Gasser et al., 2011).  In a study from 
China, the G2385R mutation of the LRRK2 gene was found in 9% of PD patients but was 
also identified in 3% of healthy controls (Farrer et al., 2007). 
Several environmental factors have been identified as potential risk factors for the 
development of PD.  Cumulative exposure to pesticides (Priyadarshi et al., 2000; Lai et 
al., 2002) and chemical solvents (Guehl et al., 1999) may increase the life-time risk of 
PD.  Repeated head injury has historically been cited as a risk factor for the 
development of PD but recent studies have called into question this aetiological 
association (Fang et al., 2012).  Conversely, some environmental exposures may 
actually reduce the risk of developing PD, namely cigarette smoking and high caffeine 
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intake (Ross et al., 2000; Hernan et al., 2002).  The role of nicotine and caffeine as 
potential neuroprotective targets is still being explored. 
In summary, the exact aetiology of PD is still uncertain.  However, it appears likely that 
there is not one single cause but perhaps a complex interplay of multiple risk factors 
including genetic and environmental factors. 
1.1.3 Pathology and pathogenesis 
The pathological hallmark of PD is abnormal accumulation of alpha-synuclein in the 
basal ganglia.  Alpha-synuclein is a neural protein which for unknown reasons mis-folds 
and aggregates in inclusion bodies.  In nerve cells, these inclusion bodies are called 
Lewy bodies (LBs) and in neural processes, the spindle-like aggregations are called 
Lewy neurites (LNs).  Some neurons appear particularly vulnerable to abnormal 
accumulation of Lewy pathology, namely long-axoned neurons with little or no 
myelination (Braak and Del Tredici, 2004).  There is evidence that alpha-synuclein can 
spread between adjacent neurons (Danzer et al., 2007; Danzer et al., 2009; Desplats et 
al., 2009; Angot et al., 2012) in a manner likened to some prion-mediated diseases 
(Olanow and Prusiner, 2009; Angot et al., 2010). 
The spread of alpha-synuclein through the brain occurs in a predictable and 
progressive manner.  The first region of the brain affected by Lewy pathology is the 
brainstem.  Thereafter alpha-synuclein spreads in an ascending caudo-rostral direction, 
affecting the basal ganglia and ultimately cortical regions of the brain.  Heiko Braak and 
colleagues have undertaken extensive post-mortem studies to characterise the 
topography of alpha-synuclein spread in PD.  This work led to the development of a 
pathological staging system for PD (Braak et al., 2003) (Table 1-1).  The proposed six 
step pathological staging system can be correlated with many of the clinical features of 
PD.  The first three stages, in which alpha-synuclein ascends through the brainstem 
and lower portions of the basal ganglia, correspond with the ‘pre-motor’ phase of the 
disease.  In the later three stages, as alpha-synuclein extends through the basal ganglia 
and higher cortical areas, motor signs appear and progress.
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Table 1-1 Pathological staging system for PD - adapted from (Braak et al., 2004) 
Pathological stage Site of Lewy pathology Disease phase 
1 
2 
3 
Dorsal motor nucleus of the vagus nerve 
Gain setting nuclei 
Substantia nigra & amygdala 
 
Pre-motor 
4 
5 
6 
Mesocortex & thalamus 
Neocortex 
Neocortex & premotor areas 
 
Motor 
Although the pattern of alpha-synuclein spread through the brain is specific to PD, 
Lewy pathology is also evident in other neurodegenerative diseases including 
Alzheimer’s disease and Dementia with Lewy bodies (DLB).  Although alpha-synuclein 
deposition is a prerequisite for the pathological diagnosis of PD, increasingly there is 
evidence to suggest that other abnormal proteins including β-amyloid and Tau may 
also contribute to the pathogenesis of PD (Jellinger, 2003).  Evidence of mitochondrial 
dysfunction in PD is also emerging (Schapira and Gegg, 2011; Schapira and Jenner, 
2011) and an area of increasing research interest. 
1.1.4 Diagnosis 
Current approaches to the diagnosis of idiopathic PD are imperfect.  There are no 
reliable serological or cerebrospinal fluid biomarkers in early disease.  Despite many 
advances in structural and functional brain imaging, these techniques are still only 
supportive to the clinical diagnosis.  PD can only be diagnosed with certainty after 
post-mortem examination of the brain.  Therefore despite advances in our 
understanding of the pathogenesis of PD, the diagnosis still hinges upon the 
recognition of cardinal clinical features. 
Although PD is diagnosed clinically, studies correlating ante-mortem features and post-
mortem pathological findings, have sought to refine and standardise the diagnostic 
process.  The most widely accepted clinical diagnostic criteria are those produced by 
the UK Parkinson’s Disease Society Brain Bank (Hughes et al., 1992).  These criteria 
were devised after the examination of brain specimens and clinical records from 100 
people diagnosed with PD by consultant neurologists.  From this work, a three step 
approach to the diagnosis of idiopathic PD has been advocated (Table 1-2).  The first 
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step requires identification of the motor features of Parkinsonism.  Secondly, features 
which may suggest an alternative cause of Parkinsonism should be excluded.  Thirdly, 
additional supportive features should be sought by the clinician although such 
supportive features largely rely upon the passage of time and hence are of less 
relevance when a patient first presents. 
Table 1-2 UK brain bank criteria for the clinical diagnosis of idiopathic Parkinson’s 
disease (Hughes et al., 1992) 
Step 1. Diagnosis of a Parkinsonian Syndrome 
Bradykinesia and at least one of the following: 
 Muscular rigidity 
 Rest tremor (4-6Hz) 
 Postural instability 
Step 2. Exclusion criteria for Parkinson’s disease 
 History of repeated strokes with stepwise progression of 
parkinsonian features 
 History of repeated head injury 
 History of definite encephalitis 
 Oculogyric crises 
 Neuroleptic treatment at onset of symptoms 
 More than one affected relative 
 Sustained remission 
 Strictly unilateral after three years 
 Supranuclear gaze palsy 
 Cerebellar signs 
 Early severe autonomic involvement 
 Early severe dementia 
 Babinskis sign 
 Presence of cerebral tumour or communication 
hydrocephalus on imaging 
 Negative response to large doses of levodopa in absence 
of malabsorption 
 MPTP exposure 
Step 3. Supportive prospective positive criteria for Parkinson’s 
disease 
Three or more required for diagnosis of definite Parkinson’s 
disease in combination with step 1: 
 Unilateral onset 
 Rest tremor present 
 Progressive disorder 
 Persistent asymmetry affecting side of onset most 
 Excellent response to levodopa 
 Severe levodopa-induced chorea 
 Levodopa response for 5 years or more 
 Clinical course of 10 years or more 
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Application of the UK Parkinson’s Disease Society Brain Bank criteria in routine clinical 
practice is associated with approximately a 90% diagnostic accuracy rate, when 
compared with post-mortem pathological diagnosis (Hughes et al., 2001).  Common 
misdiagnoses include other parkinsonian disorders such as multiple system atrophy 
(MSA), progressive supranuclear palsy (PSP) and vascular parkinsonism.  Tremor 
disorders such as essential tremor and dystonic tremor may also be erroneously 
diagnosed as PD (Meara et al., 1999; Schneider et al., 2007; Newman et al., 2009).  
Table 1-3 Differential diagnosis for parkinsonian disorders – adapted from (Alves et al., 
2008) 
Type of parkinsonism Subtype / Cause 
Parkinson’s disease  Idiopathic 
 Familial 
Symptomatic parkinsonism  Drug induced 
 Vascular disease 
 Toxic 
 Post-traumatic 
 Post-infectious 
 Neoplasm 
 Normal pressure hydrocephalus 
Parkinsonism secondary to 
other neurodegenerative 
diseases 
 Atypical parkinsonism 
o Multiple system atrophy (MSA) 
o Progressive supranuclear palsy (PSP) 
o Corticobasal degeneration (CBD) 
 Dementia with Lewy bodies (DLB) 
 Alzheimer’s disease 
1.1.5 Motor features 
As far back as 1817, when James Parkinson described the ‘shaking palsy’ (Parkinson, 
1817), the motor features of PD have been well characterised.  Bradykinesia, tremor, 
rigidity and postural instability are the hallmarks of Parkinsonism and underpin the 
clinical diagnosis (Hughes et al., 1992).  Despite the apparent simplicity of these four 
cardinal motor features, there is considerable heterogeneity in how these features 
present and progress. 
Resting tremor is the commonest presenting symptom in PD (Hughes et al., 1993) but 
is not universal; approximately one quarter of patients are never affected by tremor 
(Jankovic et al., 1990; Schrag et al., 2002).  Postural instability which encompasses 
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abnormalities of gait, posture and balance, is more typical of advanced PD but can also 
be a presenting feature (Alves et al., 2008).  The classification of patients according to 
their predominant motor features can overlook much of the phenotypic 
heterogeneity.  However, the distinction between tremor dominant (TD) and postural 
instability and gait difficulty (PIGD) subtypes has some prognostic relevance.  Tremor 
dominant patients tend to have slower rates of motor progression (Jankovic et al., 
1990) and a lower risk of developing dementia (Burn et al., 2003; Alves et al., 2006) 
compared with the PIGD subtype.  Therefore the TD subtype is sometimes felt to 
represent a more benign disease phenotype.  However, such classifications are broad 
and dynamic, as with advancing disease severity, the proportion of patients with PIGD 
predominant features increases (Alves et al., 2008). 
The motor features of PD usually progress along a predictable trajectory with respect 
to the distribution of symptoms and the rate of change.  Motor signs usually present 
unilaterally in the upper limbs (Uitti et al., 2005) before progressing to the ipsilateral 
lower limb after an interval of 1-3 years (Poewe and Wenning, 1998).  Thereafter, the 
contralateral side usually develops motor signs 3-8 years after diagnosis (Poewe and 
Wenning, 1998).  Despite the progressive nature of these abnormalities, some degree 
of asymmetry usually persists with the first affected side typically persisting as the 
most affected side (Hughes et al., 2001). 
In the later stages of PD, a variety of motor complications may occur; some are 
inherent to the disease process and others are complications of long-term treatment.  
In the maintenance phase of the disease, patients typically have a predictable and 
smooth response to medications.  However, the development of response fluctuations 
and dyskinesias, herald the onset of the ‘complex’ disease phase.  After 4-6 years, 40% 
of patients will have developed motor complications (Ahlskog and Muenter, 2001) and 
by 17 years they are near universal (Hely et al., 2005). 
Patients with response fluctuations experience unpredictable responses to their 
medications often culminating in less ‘on’ time and more ‘off’ time.  Additionally 
patients with fluctuations may experience ‘wearing off’ and ‘delayed on’ phenomena 
which can have a major impact upon their activities of daily living and quality of life.  
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Associated with response fluctuations, patients may also experience dyskinesias which 
are involuntary choreiform movements associated with long-term levodopa therapy. 
Figure 1-1 Diagram representing the development of motor complications in advancing 
PD - adapted from (Worth, 2013) 
The greater an individuals cumulative exposure to Levodopa, the greater their risk of 
motor complications.  Other pharmacokinetic and pharmacodynamic factors have 
been identified as risk factors for the development of motor complications (Table 1-4).  
The importance of delayed gastric emptying as a contributory factor to the 
development of motor fluctuations will be covered in detail in section 1.5. 
Table 1-4 Factors contributing to the development of motor complications – adapted 
from (Worth, 2013) 
Pharmacokinetic 
factors 
 Delayed gastric emptying (gastroparesis) 
 Dietary amino acids competing for absorption 
 Short Levodopa half-life (approx. 90 minutes) 
Pharmacodynamic 
factors 
o Loss of presynaptic ‘buffering’ as the nigrostriatal pathway 
degenerates 
o Plastic changes in the postsynaptic receptor population 
o Changes in striatal gene transcription 
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An array of postural, balance and gait abnormalities may also complicate the more 
advanced stages of the disease.  In the early phase of PD, falls are an atypical feature 
however they increase in frequency as the disease progresses , with up to 70% of all 
patients falling in any one year (Hely et al., 2005).  Aside from disease duration and 
severity, other risk factors for falls include female gender, older age, autonomic 
dysfunction and symmetrical symptoms at diagnosis (Williams et al., 2006).  Freezing 
of gait (FOG), where patients have difficulty in initiating or maintaining walking (Stolze 
et al., 2004), is a relatively poorly understood phenomenon which again becomes 
more frequent and severe as the disease process progresses (Alves et al., 2008). 
1.1.6 Non-motor symptoms 
A great many non-motor symptoms (NMS) are recognised as part of the broad clinical 
phenotype of idiopathic PD(Table 1-5).  Large out-patient based studies have 
demonstrated that NMS are extremely common in all stages of the disease.  In 2007, a 
large, international, multi-centre observational study assessed the prevalence of NMS 
in patients attending routine outpatient appointments (Martinez-Martin et al., 2007).  
A total of 545 patients with PD completed a 30 item questionnaire: the NMSQuest.  
Nearly all patients (98.4%) reported at least one NMS; the commonest symptoms were 
nocturia (61.90%), urinary urgency (55.81%) and constipation (52.48%).  Older age, 
longer disease duration and more advanced disease stage were all significantly 
associated with a greater NMS burden.  The PRIAMO study (Barone et al., 2009) also 
demonstrated a high prevalence of NMS in people with PD.  More than 1,000 patients 
attending clinic completed a structured NMS questionnaire, with 98.6% of patients 
reporting at least one NMS and the mean number of symptoms per patient was 
approximately 8.   
 
11 
 
Table 1-5 Non-motor symptoms of Parkinson’s disease - adapted from (Chaudhuri and 
Schapira, 2009) 
Neuropsychiatric  
 Cognitive impairment: mild cognitive impairment, 
dementia 
 Depression 
 Anxiety 
 Apathy, anhedonia 
 Hallucinations, illusions, delusions 
 Psychosis 
Sleep disorders 
 REM sleep behaviour disorder 
 Restless legs 
 Excessive daytime somnolence 
 Insomnia 
 Vivid dreaming 
 Sleep-disordered breathing 
Autonomic symptoms 
 Urinary urgency, frequency 
 Nocturia 
 Excessive sweating 
 Orthostatic hypotension 
 Erectile dysfunction 
Gastrointestinal symptoms 
 Sialorrhoea 
 Ageusia 
 Dysphagia 
 Gastroparesis 
 Constipation 
 Defecatory difficulty 
Sensory symptoms 
 Pain 
 Paraesthesia 
 Olfactory disturbance 
Other symptoms 
 Fatigue 
 Diplopia 
 Blurred vision 
 Weight loss or gain 
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Although the number of NMS increases with advancing disease duration (Chaudhuri et 
al., 2011), NMS are also evident in very early PD (Khoo et al., 2013) and may be 
present at diagnosis (O'Sullivan et al., 2008).  Some autonomic features including 
constipation, urinary dysfunction, erectile dysfunction and orthostatic hypotension 
have been shown to pre-date the diagnosis of PD by anything from 5 to 20 years 
(Postuma et al., 2013).  These pre-motor features are being examined in the on-going 
Parkinson’s at risk (PARS) study (Stern and Siderowf, 2010) which aims to identify 
groups of people at risk of PD who could then be studied for biomarkers and 
considered for neuroprotective interventions. 
Despite the prevalence of NMS in PD, in more than half of cases, symptoms go 
unreported by patients or unrecognised by physicians (Shulman et al., 2002; Chaudhuri 
et al., 2010; Gallagher et al., 2010).  Chaudhuri et al (Chaudhuri et al., 2010) explored 
some of the reasons underlying this and identified the following common 
explanations: 
 Patients were unaware that their symptoms related to PD 
 Patients reported feeling embarrassed at discussing their symptoms 
 Patients reported that the consultation focused upon their motor symptoms 
 
Recognition and management of NMS is important, as a greater NMS burden has been 
shown to correlate with worse quality of life scores and in some cases this effect was 
greater for NMS than for motor symptoms (Qin et al., 2009; Gallagher et al., 2010; 
Martinez-Martin et al., 2011; Hinnell et al., 2012; Sjödahl Hammarlund et al., 2012). 
The pathophysiology of NMS is still speculative.  However, it has been suggested that 
many NMS could be attributable to early abnormalities in the lower brainstem nuclei 
(Chaudhuri et al., 2011).  Neurochemically, there is evidence that both dopaminergic 
and non-dopaminergic dysfunction is contributory to many of the recognised NMS 
(Chaudhuri and Schapira, 2009). 
As PD progresses, the NMS burden increases (Chaudhuri et al., 2011) and certain 
categories of impairment become more prominent.  Cognitive impairment is an 
important non-motor complication and is not merely a feature of late disease.  The 
point-prevalence of Parkinson’s disease dementia (PDD) is estimated to be 25-30% 
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(Aarsland et al., 2005) and ultimately approximately 80% of all patients will develop 
dementia (Hely et al., 2008).  Identification of those individuals most at risk of future 
dementia is important and it is now evident that mild cognitive impairment (PD-MCI) 
may be present at diagnosis (Foltynie et al., 2004; Khoo et al., 2013). 
In summary, the non-motor features of PD are diverse and common.  They occur in all 
stages of the disease and may commence in the pre-motor period of the disease.  
However, despite their detrimental impact upon quality of life, non-motor symptoms 
are often under-recognised in clinical practice. 
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1.2 Gastrointestinal dysfunction in Parkinson’s disease 
This thesis focuses upon gastric dysfunction in PD however there are many other types 
of gastrointestinal (GI) abnormalities associated with this condition.  As will be 
discussed, GI dysfunction in PD is anatomically extensive, common and evident in all 
stages of the disease. 
1.2.1 Clinical features of gastrointestinal dysfunction in Parkinson’s disease 
Symptoms resulting from GI dysfunction are among the commonest examples of NMS 
associated with PD.  Almost the entire length of the GI tract is vulnerable to 
dysfunction (Table 1-6). 
Table 1-6 Sites and types of gastrointestinal dysfunction associated with Parkinson’s 
disease 
Level of GI tract Site Type of dysfunction 
Upper GI tract Mouth  Sialorrhoea 
 Dental deterioration 
Pharynx  Oropharyngeal dysphagia 
Oesophagus  Oesophageal dysphagia 
 Gastro-oesophageal 
reflux 
Stomach  Delayed gastric emptying 
(gastroparesis) 
 Weight loss 
Lower GI tract Small intestine o Dilatation 
Large intestine o Dysmotility 
o Constipation 
o Volvulus 
o Megacolon 
o Perforation 
Rectum o Defecatory difficulties 
 
1.2.2 Epidemiology of gastrointestinal dysfunction in Parkinson’s disease 
In large international outpatient, questionnaire-based studies (Martinez-Martin et al., 
2007; Barone et al., 2009; Rodriguez-Violante et al., 2010) approximately 30% of PD 
patients report at least one GI symptom at any point in time.  Although GI symptoms 
are common in other chronic conditions and in the general population, they are 
significantly more prevalent in people with PD (Edwards et al., 1991).   
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GI dysfunction is evident in all stages of disease including very early disease.  A recent 
study (Khoo et al., 2013) which assessed NMS in 159 newly diagnosed patients 
(median disease duration 4.4 months) and 99 age and sex-matched healthy controls, 
reported significantly higher rates of troublesome GI symptoms in those with early PD 
compared with controls.  Even in later stages of the disease, the prevalence of GI 
symptoms in people with PD is greater than that reported by controls (Cersosimo et 
al., 2013). 
A wide array of GI symptoms are described in the context of PD but sialorrhoea, 
dysphagia, gastroparesis, weight loss and constipation are amongst the most common.  
Sialorrhoea; a sensation of excessive saliva is estimated to affect up to 70% of patients 
(Edwards et al., 1991).  Dysphagia is reported to occur in anything from 30% to 80% of 
people with PD (Pfeiffer, 2011).  This wide range in prevalence is likely to be a 
consequence of different definitions of dysphagia; although symptomatic swallowing 
difficulties are common in PD, even greater numbers have evidence of mechanical 
swallowing difficulties when assessed by video fluoroscopy or barium swallow.   
Gastroparesis will be described in detail in later sections of this chapter but estimates 
suggest that 70 to 100% of all patients with PD may have delayed gastric emptying 
(Heetun and Quigley, 2012).  Approximately half of all people with PD are estimated to 
have significant weight loss attributable to the disease (Abbott et al., 1992).  
Constipation is arguably the most widely recognised GI symptom associated with PD, 
estimated to affect up to 89% of patients (Pfeiffer, 2011) with prevalence rates rising 
as the disease advances (Edwards et al., 1991; Sakakibara et al., 2001). 
1.2.3 Aetiopathogenesis of gastrointestinal dysfunction in Parkinson’s disease 
Almost all examples of GI dysfunction in PD can be attributed to underlying impaired 
motility in the GI tract (Cloud and Greene, 2011).  Sialorrhoea is a perception of 
excessive saliva but in fact salivary production in people with PD is normal or even 
reduced; rather it is a reduced frequency of swallow that accounts for this symptom 
(Bagheri et al., 1999).  Swallowing is a complex process and several stages may be 
vulnerable to impaired function in PD (Pfeiffer, 2003).  The aetiopathogenesis of 
weight loss is still speculative and likely multifactorial.  Proposed underlying 
mechanisms include: reduced energy intake, increased energy expenditure, 
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dyskinesias, hyposmia, dysphagia and depression (Pfeiffer, 2003; Bachmann and 
Trenkwalder, 2006).  Constipation is one symptom clearly attributable to slowed 
colonic motility.  Retrospective and prospective studies have demonstrated that 
constipation can be a premotor feature of PD (Abbott et al., 2001; Abbott et al., 2007; 
Savica et al., 2009).  This association offers an interesting perspective on the aetiology 
of PD.  Constipation in the premotor period of PD may be a very early symptom or a 
risk factor. It is postulated that an ingested pathogen may trigger PD and if this is the 
case then slower GI transit could increase the exposure time to such a pathogen 
(Pfeiffer, 2003).   
1.2.4 Pathophysiology of gastrointestinal dysfunction in Parkinson’s disease 
The aetiology of GI dysfunction in PD is unknown but is likely attributable to 
pathological changes in both the dorsal motor nucleus of the vagus nerve (DMNV) and 
the enteric nervous system (ENS) (Cersosimo and Benarroch, 2012).  The GI tract is 
under both intrinsic and extrinsic neural control.  Intrinsic innervation is via the ENS 
and extrinsic innervation involves preganglionic sympathetic and parasympathetic 
fibres of the vagus and sacral nerve plexuses (Cersosimo and Benarroch, 2008). 
The ENS is an extensive neural network which runs the entire length of the GI tract and 
is sometimes referred to as the ‘second brain’ (Langley, 1903) as it contains nearly 100 
million neurons and can function independently of the central nervous system (CNS) 
(Derkinderen et al., 2011).  The ENS consists of two ganglionated nerve plexuses; the 
myenteric (or Auerbach’s) plexus and the submucosal (or Meissner’s) plexus.  The 
myenteric plexus primarily controls smooth muscle activity in the GI tract and the 
submucosal plexus regulates mucosal secretions and blood supply (Derkinderen et al., 
2011).  These two plexuses are embedded within the walls of the GI tract: the 
myenteric plexus sits between the longitudinal and circular muscle layers and the 
submucosal plexus is located between the submucosa and circular muscle layer (Figure 
1-2).  Although the ENS can function autonomously, the vagus nerve synapses with the 
myenteric plexus in the stomach, creating a direct link between the DMNV in the 
medulla and the gastric ENS.  This two-way interaction between the ENS and the CNS 
has been termed the ‘brain-gut axis.’ 
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Figure 1-2 Interaction of the enteric nervous system and the vagus nerve in the stomach 
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One of the first cerebral sites infiltrated by Lewy pathology is the DMNV in the 
brainstem (Braak et al., 2003).  We now know that this earliest pathological feature is 
mirrored by alpha-synuclein aggregation beginning in the gastric ENS (Braak et al., 
2006).  The synchronous appearance of alpha-synuclein in the DMNV and the gastric 
ENS and the fact that these two anatomically disparate sites are linked by the vagus 
nerve, underpins the so called ‘dual hit hypothesis’ of PD (Hawkes et al., 2007; Hawkes 
et al., 2009).  It is hypothesised that PD is caused by a putative pathogen which may be 
carried in nasal secretions.  When swallowed this pathogen could then have direct 
access to the ENS in the stomach with subsequent trans-synaptic spread via the vagus 
nerve to the DMNV.  It is suggested that there is simultaneous spread to the olfactory 
bulb from nasal secretions which may accounting for the olfactory deficits sometimes 
seen in early PD (Hawkes et al., 2007). 
If there is an infective trigger underlying the onset of PD, identification of it remains 
elusive.  However, another infective agent which has been considered as potentially 
relevant to the pathogenesis of PD is the gastric bacterium Helicobacter pylori 
(H.pylori).  H.pylori infection has been reported to be a risk factor for PD (Bjarnason et 
al., 2005; Nielsen et al., 2012) and yet the prevalence of H.pylori infection in those with 
PD is not significantly higher than in the general population (Rees et al., 2011; Fasano 
et al., 2013).  It may be that H.pylori infection is not a cause of PD but a determinant of 
its progression.  There are reports of improved Levodopa absorption and better motor 
control in H.pylori infected patients with motor fluctuations who receive eradication 
therapy (Pierantozzi et al., 2006; Lee et al., 2008; Fasano et al., 2013).  However, 
interestingly the prevalence of H.pylori infection in people with fluctuations is reported 
to be just over 36% (Pierantozzi et al., 2006) which is not significantly higher than in 
those without fluctuations or than the general population at large (Rees et al., 2011).   
As the distal bowel is relatively readily accessible to biopsy via endoscopy, several 
recent studies have sought to characterise the deposition of alpha-synuclein in the 
bowel.  Lewy pathology is evident in the colonic ENS of patients with established PD 
(Lebouvier et al., 2010) and interestingly is also present in people with early untreated 
PD (Shannon et al., 2011).  Furthermore these pathological abnormalities develop in 
the pre-motor period.  A recent study (Shannon et al., 2012) retrospectively assessed 
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the colonic biopsies of three patients with PD who had undergone colonoscopy several 
years prior to their diagnosis of PD.  In all three cases, an abnormal pattern of alpha-
synuclein deposition was evident in the colon prompting suggestions that alpha-
synuclein in the colon could be exploited as a potential pre-motor biomarker (Olanow, 
2012). 
Studies of GI function and pathology in animal models of PD have also helped to 
develop understanding of the likely pathogenesis of GI dysfunction in this condition.  
Rotenone is a cytotoxic agent which if administered to rodents results in reduced 
striatal dopamine and serotonin, thereby replicating parkinsonism (Heikkila et al., 
1985).  Rotenone-treated rats develop alpha-synuclein aggregates in the myenteric 
plexus (Drolet et al., 2009a), along with delayed gastric emptying and reduced stool 
frequency (Greene et al., 2009); changes which precede the appearance of alpha-
synuclein in the brain.  This reinforces the suggestion that PD may begin in the GI tract 
rather than the brain.  Study of transgenic mice that over-express alpha-synuclein has 
also yielded valuable insights into the role of the gut in PD.  Such transgenic mice have 
been reported to have impaired colonic motility (Wang et al., 2008; Kuo et al., 2010) 
and delayed gastric emptying (Noorian et al., 2012).  Additionally transgenic mice that 
over-express human alpha-synuclein develop alpha-synuclein aggregates in the ENS 
before their appearance in the brain (Kuo et al., 2010).  One particularly interesting 
study reported that in addition to finding alpha-synuclein in the gastric myenteric 
plexus of transgenic mice, they also identified alpha-synuclein in cholinergic efferent 
vagal nerve processes (Noorian et al., 2012).  A sub-study then reported that when 
transgenic mice underwent vagotomy, alpha-synuclein did not accumulate in the 
gastric ENS (Noorian et al., 2012).  This demonstrates the importance of the vagus 
nerve as the neural bridge in the ‘brain-gut axis.’ 
Animal studies focusing on the appearance and spread of alpha-synuclein from the GI 
tract have also provided new insights into the pathogenesis of PD and the role of the 
stomach in this process.  Mice chronically exposed to rotenone have been shown to 
develop alpha-synuclein inclusions within the myenteric plexus (Drolet et al., 2009b).  
Additionally direct intra-gastric rotenone administration in rodents not only led to 
alpha-synuclein accumulation in the ENS but also remotely in the DMNV (Pan-Montojo 
et al., 2010).  However, when this experiment was repeated after lesioning the 
20 
 
sympathetic and parasympathetic nerves, the spread of alpha-synuclein from the ENS 
to the brain was halted (Pan-Montojo et al., 2012).  Whilst animal models of PD have 
inherent limitations, these studies are strongly supportive of the hypothesis that the 
abnormal aggregation of alpha-synuclein may originate in the stomach. 
The vagus nerve and the ENS work in synchrony to regulate normal GI motility.  
Abnormal accumulation of alpha-synuclein in both of these sites is an early feature of 
idiopathic PD.  It is therefore reasonable to hypothesise that these pathological 
changes may explain many if not all of the GI motility disturbances associated with PD 
(Cersosimo and Benarroch, 2012).  However, there is an apparent discrepancy 
between pathology, functional impairment and symptoms in the GI tracts of people 
with PD.  Whilst abnormal accumulation of alpha-synuclein in the GI tract is thought to 
account for impaired motility the relationship between alpha-synuclein burden and GI 
symptoms is not linear.  A recent study (Cersosimo et al., 2013) looked at the 
prevalence of upper and lower GI symptoms in PD patients and controls.  They also 
attempted to address the chronology of these symptoms in relation to the onset of 
motor dysfunction.  Although upper GI symptoms preceded motor dysfunction in more 
than half of PD participants questioned, the prevalence was not significantly different 
to the control group.  The authors suggest that in the upper GI tract there is a 
mismatch between functional impairment and symptoms. 
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Gastric motility and gastroparesis 
In the context of PD, the primary example of gastric dysfunction is delayed gastric 
emptying, also called gastroparesis.  This section describes patterns of gastric motility 
and factors which regulate the process of gastric emptying under normal conditions, 
before considering gastroparesis. 
 
22 
 
1.3 Gastric motility 
1.3.1 Gastric structure and function 
The stomach plays an early but vital role in the complex process of digestion.  The 
stomach acts as a large receptive chamber for ingested substances and manages the 
mechanical and chemical breakdown of particles, in readiness for the on-going 
digestion.  Although the stomach has only one chamber, within it there are distinct 
anatomical areas with different properties and functions (Figure 1-3). 
Figure 1-3 Anatomical structure of the human stomach 
 
 
The stomach is functionally divided into three areas: the proximal stomach, distal 
stomach and pylorus (Yamada et al., 2009).  The proximal stomach consists of the 
cardia, fundus and proximal part of the stomach body.  The distal stomach includes the 
distal part of the stomach body and the antrum.  The pylorus is an anatomically small 
region just proximal to the duodenum but it has a major role in regulating gastric 
emptying. 
The stomach is also an important hormonal organ; it secretes many chemicals and 
peptides and also responds to hormones produced elsewhere in the GI tract and other 
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parts of the body.  There are a great many known GI hormones and there are likely to 
be other GI peptides that have yet to be identified.  Several hormones are involved in 
the regulation of gastric emptying, with secretion occurring in the fed and fasted 
states. 
1.3.2 Gastric motility in the fed state 
After a meal, the first role of the stomach is to act as a receptive chamber which 
adapts in size to receive the ingested volume whilst maintaining a stable intra-gastric 
pressure: the so-called gastric accommodation reflex (Cannon WB, 1911).  Gastric 
accommodation is mediated by a vagovagal reflex pathway (Kindt and Tack, 2006).  
Impaired relaxation of the proximal stomach may contribute to the symptoms of 
functional dyspepsia and various agents including; nitrates, sildenafil, paroxetine, 
cisapride & clonidine have been explored as potential therapies to improve proximal 
stomach relaxation (Kindt and Tack, 2006).  In diabetic patients, an association 
between impaired gastric accommodation and impaired gastric emptying has been 
suggested (Samsom et al., 1998) and therefore it is possible that agents targeted at 
augmenting proximal stomach relaxation, may also have a role in the management of 
gastroparesis. 
After ingestion of a meal, the stomach exhibits a repetitive pattern of contractile 
motor waves which begin proximally and travel distally, breaking-up and mixing 
particles (Hellstrom et al., 2006).  Strong contractions against the closed pylorus help 
to grind and break down large food particles. 
The rate of emptying for solids and liquids varies considerably.  Liquids with no 
nutritional value leave the stomach almost immediately and at a rate proportional to 
their volume (Hellstrom et al., 2006).  However, gastric emptying of solids follows a 
biphasic pattern: in the first ‘lag phase’ particles are broken down to approximately 1-
2mm diameter so that in the second ‘linear emptying phase’ they can pass through the 
pylorus easily (Hellstrom et al., 2006). 
Gastric emptying rate is at least partially responsive to the caloric content of a meal, 
such that a feedback system operates between the duodenum and stomach so that 
nutrients are delivered to the small bowel at a steady rate (Hunt and Stubbs, 1975; 
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Brener et al., 1983; Collins et al., 1984).  This feedback system is primarily regulated by 
the hormone cholecystokinin (CCK) (Hellstrom et al., 2006).  Other peptides which 
contribute to this regulatory process are glucagon-like peptide-1 (GLP-1) and peptide 
YY (PYY), both of which are secreted by intestinal L-cells and act via afferent vagal 
pathways to exert an inhibitory effect upon gastric emptying (Hellstrom et al., 2006). 
These mechanical and hormonal changes take place over a four hour period after 
ingestion of a meal (Quigley et al., 1997).  Thereafter, the stomach remains active but a 
‘fasting state’ pattern of motility is ensues. 
1.3.3 Gastric motility in the fasted state 
Gastric motility in the fasted state follows a three phase cyclical pattern called the 
migrating motor complex (MMC).  These stereotypic motor complexes help to clear 
the stomach of digestive remnants and are vital for the maintenance of normal gastric 
emptying.  Phase I of the MMC is a quiescent period, in phase II there are irregular but 
escalating gastric contractions and in phase III regular intense contractions spread 
from the gastric body to the pylorus, clearing the stomach of any large (>2mm) 
digestive remnants (Hellstrom et al., 2006; Yamada et al., 2009).  This three phase 
cycle repeats approximately every 90 minutes during inter-digestive periods.  Once 
again, hormonal regulation is important in this process.  Table 1-7 summarises some of 
the hormones known to be active in the fed and fasted states.  More attention will be 
given to the peptides motilin and ghrelin in the following sections, as both act to 
stimulate the MMC and both have the potential to be utilised as treatments for 
delayed gastric emptying.
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Table 1-7 Gastrointestinal hormones secreted in the fed and fasted state adapted from 
(Sanger and Lee, 2008; Khoo et al., 2010) 
Hormones secreted in response            
to a meal 
Hormones secreted in the fasting 
state 
 Gastrin 
 Cholecystokinin (CCK) 
 Leptin 
 Enterostatin 
 Peptide YY (PYY) 
 Apolipoprotein A-IV  
 Glucagon-like peptide-1 (GLP-1) 
 Glucagon-like peptide-2 (GLP-2) 
 Glucose dependent insulinotropic 
polypeptide (GIP) 
 Pancreatic polypeptide 
 Oxyntomodulin  
 Amylin 
o Motilin 
o Ghrelin 
o Somatostatin 
o Xenin 
o Orexin A and B 
1.3.4 Motilin 
Motilin is an endogenous peptide which was first described in the early 1970s (Brown 
et al., 1971; Brown et al., 1972; Schubert and Brown, 1974).  Motilin and its receptors 
are found throughout the GI tract but are mostly concentrated in the duodenum (De 
Smet et al., 2009).  Motilin receptors have also been found in lower numbers 
elsewhere in the body, including in brain, thyroid and bone marrow (De Smet et al., 
2009).  Soon after the identification of motilin, it was demonstrated that this peptide 
helps trigger phase III of the MMC and hence can enhance gastric emptying 
(Christofides et al., 1979; Christofides et al., 1981).  However, it appears likely that the 
prokinetic effect of motilin and its agonists is mediated by changes in cholinergic and 
vagal activity (Sanger, 2014).  Low doses of motilin have been reported to result in 
increased activity in vagal afferent fibres of the stomach (Sanger et al., 2013) and 
motilin agonists may modify vagal activity in the upper GI tract (Mathis and Malbert, 
1998; Suzuki et al., 1998). 
Macrolide antibiotics (including erythromycin, azithromycin and clarithromycin) are 
motilin agonists and have been shown to enhance gastric emptying rates (Janssens et 
al., 1990; Urbain et al., 1990; Arts et al., 2005; Abell et al., 2006; Larson et al., 2010; 
Moshiree et al., 2010).  Two non-antimicrobial motilin agonists (ABT-229 and 
Mitemcinal) have been studied in diabetic and idiopathic gastroparesis.  However, in a 
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randomised, double blind trial comparing ABT-229 with placebo in patients with type 1 
diabetes and GI symptoms, the motilin agonist did not significantly improve symptoms 
compared with placebo (Talley et al., 2001).  Two randomised controlled trials looking 
at Mitemcinal, reported improved GI symptoms (McCallum and Cynshi, 2007b) and 
significantly increased gastric emptying rates in in people with diabetic and idiopathic 
gastroparesis (McCallum and Cynshi, 2007a).  The success of motilin agonists in the 
treatment of gastroparesis have to date been modest but there is evidence to suggest 
that more selective, small molecule motilin agonists, given at low doses may be 
effective prokinetic agents (Sanger, 2014).  Chapter 3 of this thesis considers a novel 
motilin agonist (Camicinal) as a treatment for delayed gastric emptying in people with 
PD and motor fluctuations. 
1.3.5 Ghrelin 
Ghrelin is an endogenous 28 amino acid peptide, first described in 1999 (Kojima et al., 
1999).  It is produced in the stomach but the growth hormone secretagogue receptor 
(GHSR) at which it acts has been identified at numerous sites in the GI tract, the ENS 
and also parts of the CNS.  In the GI tract ghrelin exerts prokinetic effects and centrally 
it enhances appetite (Ejskjaer et al., 2009).  Ghrelin levels peak before eating and fall 
rapidly as ingestion starts.  The hormone is regarded as a key orexigenic hormone.  
Although ghrelin is a gastric derived hormone, its secretion appears to be at least in 
part dependent upon vagal activity as following vagotomy in rodents, the expected 
pattern of ghrelin secretion is not seen (Williams et al., 2003).  This may occur because 
GHSRs are located distally in the dorsal vagal complex (Unger et al., 2011a). 
Ghrelin has a structural homology with the gastric-derived peptide motilin (Tomasetto 
et al., 2000) and both enhance upper GI motility.  Several studies have evaluated 
ghrelin and ghrelin agonists as therapeutic options for diabetic gastroparesis (Murray 
et al., 2005; Ejskjaer et al., 2009; Ejskjaer et al., 2013b; Shin et al., 2013).  In 2009 
favourable results for infusions of a ghrelin receptor agonist (TZP-101) were reported 
in people with diabetic gastroparesis (Ejskjaer et al., 2009).  Significant improvements 
in both gastric emptying rates and gastroparesis symptoms were described.  More 
recently, the same group (Ejskjaer et al., 2013b) published results of a randomised, 
placebo-controlled, double-blind study of an oral ghrelin receptor agonist (TZP-102).  
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Gastric emptying parameters did not differ significantly between groups but 
gastroparesis symptoms improved in the group receiving active treatment.  A further 
study (Shin et al., 2013) looked at a different oral ghrelin agonist (RM-131) and 
reported significant increases in gastric emptying rates compared with placebo.  More 
recent studies have failed to replicate these positive findings (Ejskjaer et al., 2013a; 
McCallum et al., 2013) however there remains potential for ghrelin to be a useful 
therapy for gastroparesis (Camilleri and Acosta, 2013). 
The importance of ghrelin as a peptide operating along the ‘brain-gut axis’ is 
emphasised by the finding of ghrelin receptors in dopaminergic neurons within the 
substantia nigra (Guan et al., 1997; Zigman et al., 2006; Andrews et al., 2009).  
Furthermore, from work with MPTP animal models of PD, there is evidence to suggest 
that ghrelin could have a neuroprotective role in augmenting dopamine cell loss 
(Williams et al., 2003; Jiang et al., 2008; Andrews et al., 2009; Moon et al., 2011). 
1.3.6 Neural control of gastric emptying 
Both intrinsic and extrinsic nerve pathways are involved in the regulation of gastric 
emptying.  Intrinsic innervation comes from the ENS, which has already been 
extensively described (section 1.2.4).  Extrinsic innervation of the stomach comes via 
the vagus and splanchnic nerves, both of which relay efferent and afferent fibres to 
and from the stomach.  The vagus nerve supplies three types of efferent fibres to the 
stomach; preganglionic parasympathetic excitatory cholinergic fibres, preganglionic 
inhibitory fibres and sympathetic fibres (Liedberg et al., 1973; Lundberg et al., 1976; 
Larson and Hixenbaugh, 1983).  The splanchnic nerve also provides sympathetic 
innervation to the stomach, and has both excitatory and inhibitory roles, but the 
excitatory component dominates (Yamada et al., 2009). 
The number of afferent vagal and splanchnic fibres supplied to the stomach vastly 
outnumbers the efferent component (Yamada et al., 2009).  Vagal afferents travel to 
the nucleus of the tractus solitarius which, in turn, sends projections to the DMNV 
(Gwyn et al., 1979; Sawchenko, 1983).  The importance of an intact vagus nerve for the 
normal regulation of gastric emptying has been demonstrated through human and 
animal studies after vagotomy.  Post-vagotomy gastric emptying for liquids increases 
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but gastric emptying of solids is delayed (Wilbur and Kelly, 1973; MacGregor et al., 
1977; Lavigne et al., 1979). 
In summary gastric emptying is a complex process influenced by neural and hormonal 
factors.  Neural regulation requires intact vagal and enteric nervous systems but both 
of these are vulnerable to dysfunction early in the pathogenesis of PD. 
1.3.7 Measuring gastric motility - gastric emptying studies 
There are several methods by which gastric emptying can be measured (Table 1-8).  
Scintigraphy is sometimes referred to as the gold standard however this technique 
requires the use of a gamma camera at regular intervals over a four hour period.  This 
is impractical or simply impossible in some non-specialist settings and may prove 
inappropriate for certain patient groups, for example elderly or frail individuals.  It may 
be a particularly difficult test in people with advanced PD and dyskinesias, who may 
struggle to lie still during the repeated scans, which could influence the results (Goetze 
et al., 2005).  Breath testing can be performed more readily in non-specialist centres as 
it requires no imaging or specialist equipment on site.  Breath testing results are 
comparable to those obtained via scintigraphy (Ghoos et al., 1993; Braden et al., 1995) 
and the technique has good reproducibility (Choi et al., 1998; Arts et al., 2005).  Breath 
testing typically involves ingestion of a meal labelled with Carbon13 (C13) derived from 
octanoic acid (Perri et al., 2005) or spirulina, a naturally occurring cyanobacterium.  
The spirulina breath test gives results comparable with those obtained by scintigraphy 
(Lee et al., 2000). 
All validated methods for measuring gastric emptying require the subject to consume a 
test meal.  This may be solid, liquid or a mixed consistency.  Increasingly it appears that 
solid test meals are more sensitive for detecting delayed gastric emptying and also 
appear to correlate better with reported symptom severity (Sachdeva et al., 2011). 
It is important to highlight that whichever technique is used to measure gastric 
emptying, there is no universally accepted definition of what constitutes impaired or 
delayed gastric emptying.  For each technique, normality must be defined through 
study of healthy controls who then serve as a reference point for defining abnormal 
according to that particular method. 
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Table 1-8 Techniques to measure gastric emptying 
Testing method Description Advantages Disadvantages 
Scintigraphy 
 Solid or liquid test meal labelled 
with a radioisotope (usually Tc-
99m). 
 Gamma camera used to scan the 
stomach at regular intervals for up 
to 4 hours. 
 Often felt to be the gold-standard 
for testing. 
 Reliable and reproducible. 
 Specialist equipment and staff 
required. 
 Patient movement can 
influence results. 
Breath testing 
o Solid or liquid test meal labelled 
with a non-radioactive isotope 
(13Carbon). 
o Once ingested, it is absorbed in 
the duodenum, metabolised in the 
liver, oxidised to 13CO2 and 
exhaled. 
o Breath samples collected at 
regularly over 4 hours. 
o Non-invasive. 
o No imaging or specialist 
equipment required at the site of 
testing. 
o Results are comparable with 
scintigraphy. 
o Reliable and reproducible.  
o Reproducibility may be slightly 
inferior to scintigraphy. 
Other imaging 
modalities 
 MRI and ultrasound have been 
piloted but are as yet not widely 
accepted tests. 
 Non-invasive.  Experienced radiologists 
required to interpret images. 
 Reliability and reproducibility 
unknown. 
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1.3.8 The effect of age and gender on gastric motility 
Before discussing the impact of pathological processes on gastric motility, it is 
important to consider the effect of age and gender upon gastric emptying in healthy 
individuals. 
One study has reported advancing age to be associated with slower gastric emptying 
(Brogna et al., 1999).  However, gastric emptying in this study was measured via 
ultrasonography which at present is not a validated technique.  Other studies using 
scintigraphy reported no significant effect of age upon gastric emptying (Moore et al., 
1983; Madsen and Graff, 2004). 
Evidence regarding the effects of gender upon gastric motility is also equivocal.  Some 
studies have reported slower gastric emptying rates in women compared with men 
(Madsen and Graff, 2004). 
 
1.4 Gastroparesis 
1.4.1 Definition 
Gastroparesis is defined as a chronic, symptomatic disorder of delayed gastric 
emptying without an underlying obstructive cause (Parkman et al., 2004).  The term is 
sometimes attributed to patients with suggestive symptoms and risk factors for 
gastroparesis.  In order to definitely diagnose gastroparesis, gastric emptying studies 
must be performed (Quigley, 2000).  However, these tests are not widely available in 
clinical practice and can be difficult to perform in some patients  Therefore, the 
symptoms of gastroparesis are often used as a marker for at risk groups or individuals. 
1.4.2 Epidemiology and aetiology 
Relatively few studies have addressed the epidemiology of gastroparesis in the general 
population.  A large community study in the USA (Jung et al., 2009) reported an age-
adjusted incidence of 2.4 per 100,000 person-years for men (95% CI, 1.2-3.8) and 9.8 
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for women (95% CI, 7.5-12.1).  From this same study, the reported prevalence of 
gastroparesis for men was 9.6 per 100,000 (95% CI, 1.8-17.4) and for women 37.8 per 
100,000 (95% CI, 23.3-52.4).  Other studies have also shown gastroparesis to be more 
common in women (Soykan et al., 1998; Dudekula et al., 2011), which may reflect the 
tendency for slower gastric emptying rates even in healthy women (Graff et al., 2001).  
Table 1-9 summarises some of the recognised causes of gastroparesis.  The 
commonest aetiologies are idiopathic (36-61%) and diabetic (10-13%), with PD 
estimated to account for 7.5% of cases (Soykan et al., 1998; Dudekula et al., 2011). 
Table 1-9 Causes of gastroparesis - Adapted from (Quigley, 2000) 
Endocrine / Metabolic 
disturbances 
 Diabetes mellitus 
 Hypothyroidism 
 Uraemia 
 Amyloidosis 
 Pregnancy 
Neurological disease o Parkinson’s disease 
o Muscular dystrophy 
o Spinal cord disease 
o Brain stem tumours 
o Peripheral neuropathy 
Connective tissue 
disorders 
 Scleroderma 
 Systemic lupus erythematosus  
Gastrointestinal 
disorders 
o Gastro-oesophageal reflux 
o Peptic ulcers 
o Viral gastritis 
o Chronic intestinal pseudo-obstruction 
Medications  Anticholinergic agents 
 Opiates 
 Dopaminergic drugs 
 Chemotherapeutic agents 
Other o Idiopathic 
o Post- surgery 
o Following radiation therapy 
o Chronic liver disease 
o Anorexia nervosa 
1.4.3 Clinical features 
Gastroparesis can result in a variety of upper GI symptoms including; nausea, vomiting, 
retching, early satiety, bloating, loss of appetite and epigastric pain.  A retrospective 
study (Parkman et al., 2011) considered the presenting symptoms in 243 patients with 
idiopathic gastroparesis.  The three commonest presenting symptoms were nausea 
32 
 
(34%), abdominal pain (23%) and vomiting (19%).  Another recent study (Rey et al., 
2012) reported that in 104 patients with established gastroparesis, the commonest 
persistent upper GI symptoms were nausea and vomiting (92.3%), early satiety 
(84.6%), regurgitation (72.1%), loss of appetite (70.2%) and bloating (65.4%). 
One of the difficulties in assessing patients with possible gastroparesis is that many of 
the associated symptoms are shared by other disorders of the upper GI tract, namely 
functional dyspepsia (Parkman et al., 2004).  One study (Sarnelli et al., 2003) which 
measured gastric emptying rates in people with apparent functional dyspepsia, 
reported that over one third actually had evidence of delayed gastric emptying.  Hence 
there is a degree of overlap between these two diagnoses. 
1.4.4 Quantified assessment of gastroparesis symptoms 
In clinical practice and research settings, it is important to have a consistent method 
for assessing and quantifying the symptoms associated with gastroparesis.  The patient 
assessment of upper gastrointestinal symptom severity index (PAGI-SYM) (Rentz et al., 
2004) was designed as a self-reporting tool to be used by patients with a variety of 
upper GI disorders.  From this general tool, a more specific instrument was 
constructed specifically for gastroparesis symptoms.  The gastroparesis cardinal 
symptom index (GCSI) (Revicki et al., 2003) is a nine item questionnaire which sub-
divides into three symptom clusters (Appendix B).  Patients complete three questions 
regarding nausea and vomiting, four questions regarding fullness and two questions 
about bloating.  They are instructed to recall their typical symptoms over the 
preceding two-weeks.  Each symptom is graded in severity on an incremental six-point 
scale (0 = none, through to 5 = very severe).  The GCSI was validated in 169 patients 
with gastroparesis and correlated well with patients’ overall perceptions of symptom 
severity and with physicians’ assessments (Revicki et al., 2003). 
A global measure of gastroparesis symptom severity can be calculated from the nine-
item questionnaire.  The ‘GCSI total score’ is a composite score that is derived from the 
mean of the three subsections.  The GCSI total score ranges from 0 to 5 with higher 
scores representing a greater symptom burden.  Revicki et al (Revicki et al., 2003) 
reported 2.56 to be the mean GCSI total score for the 169 patients in their validation 
study hence this score is often taken to represent significant gastroparesis symptoms.  
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A GCSI total score of ≥1.90 has also been proposed as a marker of significant 
gastroparesis symptoms (Kofod-Andersen and Tarnow, 2012). 
A daily diary version of the GCSI has also been devised (the GCSI-DD) (Revicki et al., 
2009) which includes two additional questions regarding upper abdominal discomfort 
and pain (Appendix B).  The GCSI-DD has been validated for reliability and 
responsiveness to changing symptoms (Revicki et al., 2012) and is recommended for 
use in a clinical trial setting. 
The GCSI was designed as a tool to assess symptoms in people with known 
gastroparesis but in the context of diabetes, it has been used as a screening tool with 
which to identify possible gastroparesis (Kofod-Andersen and Tarnow, 2012).  
Although the GCSI was not intended as a screening tool, it is the most comprehensive 
method for assessing gastroparesis symptoms and hence is utilised in this way in 
clinical and research settings. 
1.4.5 Relationship between gastric emptying delay and symptoms 
The relationship between the severity of gastric emptying delay and symptoms is only 
partially understood.  One reason may be that studies have often used different 
methods to measure gastric emptying and to assess symptoms.  However, certain 
upper GI symptoms recurrently emerge as correlating with delayed gastric emptying, 
namely, nausea and vomiting, post-prandial fullness, early satiety and inability to finish 
a normal sized meal (Stanghellini et al., 1996; Sarnelli et al., 2003; Stanghellini et al., 
2003; Talley et al., 2006; Cassilly et al., 2008; Grad et al., 2012).  A recent study 
(Olausson et al., 2013) assessed gastric emptying and symptoms in 115 patients with 
insulin treated diabetes and either GI symptoms, a clinical suspicion of gastroparesis, 
or poor glycaemic control.  They used the GCSI to assess gastroparesis symptoms and 
reported that the subsections of this tool which significantly correlated with severity of 
gastric emptying delay were the nausea and vomiting items (r = 0.30; P < 0.001) and 
the fullness questions (r = 0.34, P < 0.0001).  Such paired evaluations of gastric 
emptying and gastroparesis symptoms has not previously been performed in the 
context of PD but will be addressed in this thesis. 
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1.4.6 Non-interventional management of gastroparesis 
The mainstay of management for gastroparesis is pharmacological therapy although 
the agents currently available remain somewhat suboptimal. 
Dopamine receptor antagonists such as metoclopramide and domperidone have been 
shown to improve gastric emptying rates and gastroparesis symptoms (Abell et al., 
2006) however both agents have their limitations.  Metoclopramide is a systemically 
acting dopamine receptor antagonist and can cross the blood brain barrier.  This 
means that with long-term use it can cause extrapyramidal side effects.  Domperidone 
is a peripherally acting dopamine antagonist and as such can be used in the context of 
PD, although it is not currently approved for use in the United States. 
Cisapride is a 5-HT4 receptor agonist with a potent prokinetic effect.  It was used 
extensively in the 1990s to manage gastroparesis however it was later shown to be 
associated with an increased risk of arrhythmia and sudden death and was therefore 
withdrawn from the market in 2000 (Smalley et al., 2000; Quigley, 2011). 
As previously described, macrolide antibiotics such as erythromycin, azithromycin and 
clarithromycin are motilin agonists and as such can be used in the treatment of 
delayed gastric emptying (Arts et al., 2005; Abell et al., 2006; Larson et al., 2010; 
Moshiree et al., 2010).  Motilin agonists without antimicrobial activity have been 
explored in only a few studies to date with mixed results reported (Talley et al., 2001; 
McCallum and Cynshi, 2007a; McCallum and Cynshi, 2007b).  Ghrelin agonists are not 
currently licenced for the treatment of gastroparesis, but initial studies suggest that 
they may have potential as a novel therapeutic option (Murray et al., 2005; Ejskjaer et 
al., 2009; Ejskjaer et al., 2013b; Shin et al., 2013). 
The fact that gastric emptying can be measured in a variety of ways means that meta-
analysis to compare the effects of different prokinetics on gastric motility is extremely 
difficult.  However, a systematic review published in 1999 (Sturm et al., 1999) 
suggested that in terms of joint improvements in gastric emptying and symptoms, the 
motilin agonist erythromycin was probably superior to dopamine receptor antagonists. 
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1.4.7 Interventional management of gastroparesis 
Interventional management strategies for gastroparesis are reserved for those rare 
cases that are refractory to all available medical therapies.  Implantation of a gastric 
electrical stimulator (GES) or gastric pacemaker has been reported to improve 
symptoms and to a lesser degree gastric emptying rate, although complication rates 
are relatively high (Abell et al., 2003; Lin et al., 2005).  Intra-pyloric injection of 
botulinum toxin (botox) has also been tried in several studies but a recent systematic 
review suggests that there is currently insufficient evidence to recommend this as a 
routine treatment for gastroparesis (Bai et al., 2010). 
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Gastroparesis in Parkinson’s disease 
Gastroparesis is the commonest example of gastric dysfunction in PD.  The features and 
clinical associations of gastroparesis in the context of PD will be discussed in this 
section including its wider implications for the absorption of Levodopa and PD motor 
control more generally. 
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1.5 Gastroparesis in Parkinson’s disease 
1.5.1 Epidemiology 
The prevalence of delayed gastric emptying in PD is unknown.  The main studies to 
have considered gastric emptying and gastroparesis in PD are summarised in Table 
1-10.  The sample size in these studies is relatively small; the largest included 80 
patients (Goetze et al., 2006).  This reflects the complexity and time-consuming nature 
of gastric emptying studies, particularly in people with PD where motor dysfunction 
may prove a challenge to some testing methods. 
The mixed methodologies of previous studies, prevents a meta-analysis.  However a 
recent systematic review of the literature concluded that gastroparesis is likely to 
affect 70-100% of all people with PD (Heetun and Quigley, 2012).  This suggests that 
gastroparesis is a common problem, although it is arguably under-recognised. 
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Table 1-10 Summary of existing studies evaluating gastroparesis in Parkinson’s disease 
Author 
(reference) 
Key aim of the study Subject demographics 
 
Gastric emptying study 
method 
Key results Limitations / comments 
Djaldetti 
(Djaldetti et al., 
1996) 
Comparison of GE 
rates in PD patients 
(with and without 
motor fluctuations) 
and healthy controls. 
PD without motor 
fluctuations(n=15): 
o Age: 64.8±9.9y. 
o DD: 4.0±3.3y. 
PD with motor 
fluctuations(n=15): 
o Age: 62.0±9.0y. 
o DD: 8.8±4.6y. 
Healthy controls (n=22): 
o Age: 45.0±3.5y. 
 Scintigraphy. 
 Solid test meal 
(99m-technetium 
colloid). 
 Fasted prior to test. 
 
o Delayed GE defined as 
the upper limit of the 
controls. 
o All 30 PD patients had 
delayed GE. 
o GE delay was 
significantly greater in 
those with motor 
fluctuations than in 
those without. 
 
 Controls not age 
matched. 
 GE rates for PD 
patients more 
heterogeneous than 
controls. 
 Scintigraphy results 
are affected by 
patient movement. 
 Not all non-
fluctuators were on 
levodopa. 
 Timing of last 
levodopa dose not 
stated. 
Hardoff 
(Hardoff et al., 
2001) 
Comparison of GE 
rates in PD patients 
(mild and moderate 
disease stage) and 
age-matched healthy 
controls. 
Mild PD (H&Y:1-2) (n=29): 
o Age: 61.5±5.9y. 
Moderate PD (H&Y:2.5-3) 
(n=22): 
o Age: 65.1±5.6y. 
Healthy controls (n=22): 
o Age: 61.9±6.1y. 
 Scintigraphy. 
 Solid test meal 
(99m-technetium 
colloid). 
 Fasted prior to test. 
 PD patients 
assessed in ‘on’ 
state. 
o Delayed GE defined 
by the upper limit of 
the controls.  
o 48.3% of those with 
mild PD & 36.4% of 
those with moderate 
PD had delayed GE. 
o Patients with motor 
fluctuations had 
quicker GE rates than 
those without. 
 
 Heterogeneous GE 
results amongst all 
PD patients. 
 Assessments 
undertaken in the 
‘on’ state, unlike 
most other studies 
which may explain 
why fluctuators had 
better GE rates. 
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Goetze 
(Goetze et al., 
2005) 
Comparison on GE 
rates in PD patients (of 
different disease 
stages) and age-
matched healthy 
controls. 
PD patients (n=36): 
o Age: 63.6±11.2y. 
Healthy controls (n=22): 
o Age: 63.6±6.8y. 
 13C-octanoic acid 
breath test.  
 Solid test meal. 
 Breath samples 
obtained for 4 
hours after 
ingestion of meal. 
 Fasted overnight. 
o GE delayed in 97% of 
PD patients. 
o Disease duration did 
not correlate with 
degree of GE delay 
but more severe PD 
was associated with 
worse GE delay. 
 
● GE rates in PD 
patients very 
heterogeneous, 
which may reflect 
small subject 
numbers. 
Thomaides 
(Thomaides et al., 
2005) 
Assessed GE rates in 
PD, MSA and healthy 
controls. 
PD patients (n=12): 
o Age: 57.9±10.1y. 
MSA patients (n=12): 
o Age: 59.1±9.8y. 
Healthy controls (n=12): 
o Age: 58.4±9.2 
 Scintigraphy. 
 Semi-solid test 
meal labelled with 
99m-technetium 
colloid. 
 All patients were 
off anti-
parkinsonian 
medications for 4 
days before test. 
o MSA & PD patients 
had significantly 
slower rates of GE 
than controls. 
 A semi-solid test meal 
was used, which 
differs from the 
majority of studies.   
 Direct comparison 
with other studies is 
therefore limited. 
 
Goetze 
(Goetze et al., 
2006) 
Comparison of solid 
and liquid GE rates in 
patients with PD and 
healthy controls. 
PD patients given liquid test 
meal (n=40): 
o Age: 65±8y. 
o DD: 5.8±4.0y. 
PD patients given solid test 
meal (n=40): 
o Age: 63±11y. 
o DD: 6.2±4.8y. 
Healthy controls given liquid 
and solid test meals (n=40): 
o Age: 61y. 
 Fasted and off 
medications for at 
least 12 hours. 
 Oral breath test 
with 13C-acetate 
labelled liquid or 
13C-octanoic acid 
labelled solid meal. 
o No significant 
difference in liquid GE 
between PD and 
controls. 
o GE of solid test meal 
was significantly 
slower in PD than 
controls. 
o Slower GE of solids, 
associated with 
advancing PD, tremor 
& rigidity. 
 No clear definition of 
delayed GE offered 
by authors. 
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Krygowska-Wajs 
(Krygowska-Wajs 
et al., 2009) 
Comparison of GE 
rates in familial PD, 
sporadic PD and 
healthy controls. 
Familial PD defined as 2 or 
more affected individuals 
within 3 generations, 
without a recognisable 
genetic aetiology. 
Familial PD (n=10): 
o Age: 59±8.2y. 
Sporadic PD (n=35): 
o Age: 60.5±9.9y. 
Healthy controls (n=15): 
o Age:59.5±9.7y. 
 Scintigraphy 
following a solid 
test meal labelled 
with 99m-
technetium. 
o GE was slower than 
controls in 70% of 
those with familial PD 
but only 55% of those 
with sporadic PD. 
 Scintigraphy images 
were only obtained 
for 92 minutes after 
the test meal was 
ingested.   
 The timing of the last 
dose of levodopa was 
not specified. 
Tanaka 
(Tanaka et al., 
2009) 
Comparison on GE 
rates in PD patients 
(with and without 
motor fluctuations) 
and healthy controls. 
PD patients with motor 
fluctuations (n=20). 
PD patients without motor 
fluctuations (n=20). 
o median age of all 40 
patients: 67.0y. 
Healthy controls (n=20): 
o median age: 69.0y. 
 
 
 Overnight fast. 
 No levodopa for 24 
hours prior to 
testing. 
 Oral breath test 
following a 13C-
sodium acetate 
labelled liquid test 
meal. 
o GE was significantly 
delayed in PD 
patients. 
o No significant 
difference between 
fluctuators and non-
fluctuators. 
 The liquid test meal 
may be less sensitive 
than solid meal in 
detecting GE delay in 
PD. 
 
Tanaka 
(Tanaka et al., 
2011) 
Comparison of GE 
rates in early PD 
patients (untreated), 
patients with 
advanced (treated) PD 
and healthy controls. 
Early, untreated PD (n=20): 
median age: 70.5y. 
Advanced, treated PD 
(n=40): median age: 67y. 
Healthy controls (n=20): 
median age: 69y. 
 Overnight fast. 
 No levodopa for 24 
hours prior to 
testing. 
 Oral breath test 
following a 13C 
sodium acetate 
labelled liquid test 
meal. 
o Delayed GE was 
evident in early 
untreated and 
advanced cases of PD. 
 
 Liquid test meal may 
be less sensitive than 
solid meals. 
Key: DD = disease duration, GE = gastric emptying, age and disease duration given as mean ± standard deviation unless otherwise specified 
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1.5.2 Aetiology 
As previously described (section 1.2.4) impaired GI motility in PD is likely attributable 
to abnormal pathology in the ENS and the DMNV.  The same pathophysiology is 
implicated in PD associated gastroparesis.  
1.5.3 The relationship between gastric emptying delay and gastroparesis symptoms 
in Parkinson’s disease 
Exploration of the association between symptom severity and gastric emptying delay is 
important for two reasons.  Firstly it is relevant to our understanding of the links 
between pathology, physiology and symptoms.  Secondly, as gastric emptying studies 
are time consuming and may be impractical for some patients (e.g. those with frailty or 
advanced motor symptoms), the exploration of symptoms which are predictive of 
gastric emptying delay could help to identify patients at risk of gastroparesis without 
the need for prolonged testing. 
Based upon the current evidence, it is difficult to draw any definitive conclusions 
regarding associations between gastric emptying delay and GI symptoms in PD.  Two 
studies have reported no correlation (Hardoff et al., 2001; Goetze et al., 2005) whilst 
one suggested that upper GI symptoms were commoner in those patients with 
delayed gastric emptying (Goetze et al., 2006). 
Although not a clinical feature of gastroparesis, constipation has been reported to be 
more common in patients with delayed gastric emptying (Unger et al., 2011b).  This is 
an interesting association which has also been demonstrated in rodent models 
(Greene et al., 2009).  It is likely that this represents a continuum of impaired motility 
extending through the upper and lower GI tracts. 
Little work has been done to assess if particular parkinsonian features are associated 
with delayed gastric emptying.  To date one study (Goetze et al., 2006) has reported 
that rigidity and tremor are independent predictors of delayed gastric emptying (r = 
0.68, P < 0.001).  This is an area worthy of further exploration and has practical 
relevance in the identification of patients at risk of gastroparesis. 
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1.5.4 Disease duration and gastric emptying in Parkinson’s disease 
One might hypothesise that as disease duration advances and Lewy pathology 
becomes more extensive, gastric emptying speed may consequently deteriorate.  
However, almost all of the research to date has found no significant association 
between disease duration and gastric emptying delay (Djaldetti et al., 1996; Hardoff et 
al., 2001; Goetze et al., 2005; Thomaides et al., 2005; Goetze et al., 2006; Tanaka et al., 
2011; Unger et al., 2011b). 
One study (Tanaka et al., 2011) which elegantly demonstrated the apparent lack of 
association between disease duration and gastroparesis, assessed gastric emptying in 
three groups: 20 patients with early untreated PD (median age 70.5 years, median 
disease duration 0.9 years), 40 patients with established treated PD (median age 67.0 
years, median disease duration 6.0 years, median daily Levodopa intake 400mg) and 
20 healthy controls (median age 69.0 years).  The gastric emptying half time (GE t1/2) of 
people with early untreated PD was significantly slower than controls (median 2.04 vs. 
1.44 hours, P < 0.001) but there was no significant difference between GE t1/2 in those 
with early PD and those with advanced disease (P = 0.77). 
Another group (Unger et al., 2011b) assessed gastric emptying in people with 
idiopathic REM sleep behaviour disorder (iRBD), a recognised pre-motor feature of PD.  
Gastric emptying was measured in 13 people with iRBD, 21 drug-naïve PD patients, 18 
people with established treated PD and 20 healthy controls.  Once again, significantly 
slower gastric emptying rates were evident in PD patients compared to controls (P < 
0.001) but there was no significant difference between early and advanced PD and 
iRBD subjects were not significantly different to controls.   
1.5.5 Disease severity and gastric emptying in Parkinson’s disease 
As PD is a progressive degenerative disease, disease duration and severity are 
inherently linked.  Although disease duration does not appear to be a predictor of 
delayed gastric emptying, there is evidence to suggest that disease severity does 
influence gastric emptying. 
A 2005 study by Goetze et al (Goetze et al., 2005) compared gastric emptying in 36 
patients with PD and 22 age-matched controls.  When the PD cohort were stratified by 
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disease severity (according to UPDRS part III score and Hoehn & Yahr stage), those 
with more severe PD had significantly slower gastric emptying.  A later, larger study by 
the same group (Goetze et al., 2006) reported significantly longer GE t1/2 in subjects 
with higher UPDRS part III scores (≥45) compared to those with lower scores (<45) (181 
± 49 mins vs. 156 ± 30 mins, respectively, P < 0.05).  When compared according to 
Hoehn & Yahr stage, the same trend was evident (H&Y 3-5: GE t1/2 191 ± 44 mins vs. 
H&Y 1-2.5: GE t1/2 149 ± 28 mins, P < 0.01). 
One study (Hardoff et al., 2001) has reported that delayed gastric emptying is more 
prevalent in mild rather than severe PD.  However, this study assessed patients’ gastric 
emptying in the ‘on’ state, with no medication wash-out period whereas the majority 
of studies have assessed gastric emptying after a 12 hour medication-free period.   
Overall, the available evidence would seem to suggest that more advanced disease 
severity is associated with slower gastric emptying. 
1.5.6 The effect of Levodopa on gastric emptying 
The relationship between Levodopa ingestion and gastric emptying is interdependent.  
Levodopa affects gastric emptying but additionally gastric emptying rates affect 
Levodopa absorption.  Both aspects of this bidirectional relationship will be 
considered.  
Levodopa is the oldest but still one of the commonest treatments for PD.  For several 
decades it has been suggested that Levodopa delays gastric emptying.  In 1980, it was 
reported that healthy young men (mean age 42 years) given oral Levodopa (single dose 
of 1,000mg) had delayed gastric emptying which was reversible with co-administration 
of metoclopramide (Berkowitz and McCallum, 1980).  A subsequent study (Robertson 
et al., 1990) assessed gastric emptying after ingestion of a more typical therapeutic 
dose of oral Levodopa (125mg) and also reported delayed gastric emptying although 
the effect was not exacerbated by repeated doses (Waller et al., 1991).  In healthy 
older men (mean age 73 years) Levodopa administration has also been shown to result 
in slower gastric emptying (Robertson et al., 1992). 
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Although Levodopa may contribute to delayed gastric emptying in PD it is certainly not 
the sole cause as gastroparesis has been described in early untreated PD (Tanaka et al., 
2011; Unger et al., 2011b). 
1.5.7 The effect of delayed gastric emptying on Levodopa absorption 
Levodopa is a large amino acid which is de-carboxylated into dopamine and O-
methylated into 3-O-methyldopa (Nyholm and Lennernas, 2008).  Absorption of 
Levodopa is confined to the small intestine (Gundert-Remy et al., 1983; Kim et al., 
2007) and importantly there is no gastric absorption (Rivera-Calimlim et al., 1971); 
hence gastric emptying has been described as the rate limiting step in the absorption 
of Levodopa (Nyholm and Lennernas, 2008).   
Although the pharmacokinetic properties of Levodopa would suggest that gastric 
emptying and levodopa absorption are closely interrelated, surprisingly few studies 
have undertaken simultaneous assessment of these two parameters in the context of 
PD.  Using an animal model, the co-administration of Levodopa with an anticholinergic 
to replicate conditions of delayed gastric emptying, resulted in reduced Levodopa 
absorption.  In humans, similar findings have been described in two studies to date.  
Muller et al (Muller et al., 2006) measured plasma Levodopa levels and gastric 
emptying in 11 patients with PD (mean age 58 ± 10 years).  They reported that patients 
with slower gastric emptying had lower plasma Levodopa levels.  A more recent, larger 
study (Doi et al., 2012) undertook similar assessments in 31 people with PD (mean age 
68.1 ± 7.8 years, mean disease duration 4.2 ± 3.8 years, mean UPDRS part III score 
18.37 ± 8.60).  Patients were retrospectively stratified into those with an early (1 hour) 
peak in serum Levodopa levels (58% of subjects) and those with a late (2 hour) peak in 
Levodopa (42%).  Patients with slow gastric emptying were significantly more likely to 
have a later peak in serum Levodopa (P < 0.05). 
Additionally, there is indirect evidence to support the importance of gastric emptying 
for Levodopa absorption, from studies of prokinetics in PD.  Cisapride, a serotonin 5-
HT4 receptor agonist, is a prokinetic agent which is no longer licenced but was 
previously studied in the context of PD.  An open-label study (Neira et al., 1995) of 
cisapride in 20 people with PD and motor fluctuations, reported that co-administration 
of cisapride resulted in a 37% increase in peak plasma Levodopa levels and a 13% 
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increase in mean plasma Levodopa levels.  A recent randomised, cross-over design 
study (Nishikawa et al., 2012) compared plasma Levodopa levels in 18 people with PD, 
with and without co-administration of domperidone.  All measures of Levodopa 
absorption were significantly increased by the co-administration of domperidone. 
Further supportive evidence of the importance of gastric emptying upon Levodopa 
absorption comes from studies of direct duodenal delivery of Levodopa.  Comparison 
of continuous intra-duodenal Levodopa infusion versus optimal oral dosing has 
demonstrated improved levels of absorption (Nyholm et al., 2003; Nyholm et al., 2005) 
and importantly improved motor function as a consequence (Puente et al., 2010). 
In summary, there is strong evidence to suggest that delayed gastric emptying in PD 
can result in impaired Levodopa absorption, which may contribute to response 
fluctuations in the complex phase of the disease. 
1.5.8 Gastric emptying and motor fluctuations in advanced Parkinson’s disease 
Several studies have assessed gastric emptying in patients with and without motor 
fluctuations.  Djaldetti (Djaldetti et al., 1996) evaluated 15 patients with motor 
fluctuations (mean age 62 ± 9 years, mean disease duration 8.8 ± 4.6 years), 15 
patients without fluctuations (mean age 65 ± 10 years, mean disease duration 4.0 ± 3.3 
years) and 22 healthy controls (mean age 45 ± 3.5 years).  All fluctuating patients were 
on combination therapy consisting of Levodopa plus at least one other dopaminergic 
agent, whilst eight of the non-fluctuators were taking regular Levodopa and seven 
were receiving Selegiline only.  Gastric emptying was significantly slower in those with 
fluctuations compared to those without (77.4 ± 15.5% test meal retention at 1 hour vs. 
64.0 ± 14.3%, respectively, P < 0.05). 
Conversely a later study (Hardoff et al., 2001) comparing gastric emptying rates in 
fluctuators and non-fluctuators found slower emptying rates in the non-fluctuating 
participants.  However, this study assessed gastric emptying in the ‘on’ state where 
most similar studies have assessed gastric emptying in the practically defined ‘off’ 
state after a medication free overnight period. 
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A recent study (Tanaka et al., 2009) compared fluctuators and non-fluctuators on 
comparable doses of Levodopa (425mg and 400 mg daily respectively, P = 0.55).  This 
group reported no significant difference in gastric emptying rates between fluctuators 
and non-fluctuators. 
In summary, there is physiological and pharmacological evidence to suggest that 
gastroparesis may contribute to response fluctuations in PD.  However, the evidence 
base is still small and further research is required to clarify this relationship.  This thesis 
will describe the relationship between gastric emptying and Levodopa absorption in 
people with PD and motor fluctuations. 
1.5.9 Management of delayed gastric emptying in Parkinson’s disease 
The evidence base for the management of delayed gastric emptying in the context of 
PD is relatively limited compared with the extensive number of studies looking at this 
issue in people with diabetes. 
As previously described, cisapride was shown to improve levodopa absorption and 
motor control in patients with PD and fluctuations (Djaldetti et al., 1995; Neira et al., 
1995).  Mosapride, another 5-HT4 receptor agonist, was also reported to improve 
gastroparesis in PD (Asai et al., 2005). 
Systemic dopamine antagonists such as metoclopramide may be highly effective in the 
management of delayed gastric emptying associated with diabetic or idiopathic 
gastroparesis, but are contraindicated in people with PD as they can cause extra-
pyramidal side effects. 
Currently the only licenced therapy suitable for long-term use in the context of PD is 
domperidone.  Domperidone has been reported to improve Levodopa absorption 
(Nishikawa et al., 2012), gastric emptying and GI symptoms (Soykan et al., 1997) in 
people with PD.  However, this medication is not licenced in all countries. 
Injection of botulinum toxin into the gastric pylorus of two people with PD was 
positively reported in a case series (Gil et al., 2011) but has yet to be evaluated on a 
larger scale. 
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A recent pilot study evaluated the selective histamine H2-receptor antagonist 
Nizatidine as a therapy for delayed gastric emptying in PD (Doi et al., 2013).  This open 
label study involved 20 subjects with PD and gastroparesis symptoms.  GI symptoms 
and gastric emptying rate were evaluated before and after three months of treatment 
with Nizatidine.  At the conclusion of the study there was a significant improvement in 
gastric emptying and GI symptoms in those with baseline gastroparesis however the 
effects upon Levodopa absorption and motor function were not reported. 
There is a clear need for more effective treatments for delayed gastric emptying in 
people with PD.  The implications of such therapies would be far reaching as they hold 
the potential to improve not only GI symptoms but also the absorption of Levodopa 
and hence motor fluctuations.  The number of currently available agents is very limited 
and hence the need to identify novel agents is great.  
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1.6 Conclusions 
Parkinson’s disease results in abnormal pathology and symptoms that extend the 
entire length of the GI tract.  Gastroparesis has been demonstrated in early and 
advanced PD and is estimated to affect 70-100% of all patients.  However, the 
prevalence of gastroparesis symptoms in people with PD is unknown. 
Delayed gastric emptying can impair the absorption of Levodopa and contribute to 
motor fluctuations in the later stages of the disease.  Although improved gastric 
emptying has been shown to enhance Levodopa absorption, there are currently very 
few licenced prokinetics suitable for use in PD.  Exploration of alternative agents to 
enhance gastric emptying and Levodopa absorption is therefore indicated. 
1.7 Overview of thesis structure and content 
The underlying theme and focus of this thesis is gastroparesis in PD.  A critical review 
of the literature led to the identification of the following unanswered research 
questions: 
 What is the prevalence of gastroparesis symptoms in people with PD and what 
clinical features are associated? 
 Can a novel motilin agonist improve Levodopa absorption in people with PD and 
delayed gastric emptying? 
 Are gastroparesis symptoms predictive of gastric emptying delay in people with 
PD? 
 
These research questions are addressed in the subsequent three chapters as outlined 
in Figure 1-4. 
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Figure 1-4 Overview of thesis structure and content 
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Chapter 2 Gastroparesis symptoms in Parkinson’s disease 
2.1 Background 
Delayed gastric emptying has been demonstrated in all stages of PD with an overall 
prevalence estimated at 70-100% (Heetun and Quigley, 2012).  However, the 
prevalence of gastroparesis symptoms associated with delayed gastric emptying is 
unknown in people with PD. 
2.2 Aims and objectives 
The aim of this study was to evaluate the occurrence of gastroparesis symptoms in 
people with PD.  Three patient groups were considered: recently diagnosed PD, young 
onset PD and unselected PD patients attending for routine movement disorder clinic 
follow-up.  The prevalence of significant gastroparesis symptoms in each group was 
described.  Correlations between gastroparesis symptoms, motor and non-motor 
features of the disease were examined.  The broad intention was to better characterise 
the symptoms of gastroparesis in people with PD. 
2.2.1 Hypotheses 
A priori hypotheses of this study were as follows: 
1. Gastroparesis symptoms will be more prevalent and severe in female PD 
patients compared to males. 
2. Age at the time of assessment will not be a significant determinant of 
gastroparesis symptoms in PD. 
3. Longer PD disease duration will not be associated with a greater gastroparesis 
symptom burden. 
4. Gastroparesis symptoms will be more severe in those participants with more 
advanced PD. 
5. Participants with the PIGD motor subtype will have a greater gastroparesis 
symptom burden than those with the TD phenotype. 
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6. Gastroparesis symptoms form part of a wider spectrum of NMS.  PD 
participants with more NMS will be more likely to report gastroparesis 
symptoms. 
7. Participants with autonomic symptoms or evidence of autonomic dysfunction 
will have a greater gastroparesis symptom burden. 
8. Gastroparesis symptoms will be more marked in participants with constipation. 
9. Participants with more severe gastroparesis symptoms will have a greater 
measureable deficit in olfactory function. 
2.3 Data collection 
The assessment of gastroparesis symptoms in recently diagnosed and young onset 
cases of PD was performed as a sub-study of a multi-centre research project.  The 
Parkinson’s Repository of Biosamples and Networked Datasets (PRoBaND) study is an 
on-going prospective observational study which will be described in the following 
section. 
A smaller data set was obtained as part of a service evaluation study to assess 
gastroparesis symptoms in consecutive PD patients attending a movement disorder 
clinic at the Newcastle upon Tyne Hospitals NHS Foundation Trust. 
2.4 Parkinson’s Repository of Biosamples and Networked Datasets (PRoBaND) 
The PRoBaND study (also known as Tracking Parkinson’s) is an on-going prospective, 
observational, multicentre study funded by Parkinson’s UK and co-ordinated by NHS 
Greater Glasgow and Clyde and The University of Glasgow.  Ethical approval for this 
study was obtained from the West of Scotland Research Ethics Committee 1 in January 
2012.  Patient recruitment began in January 2012 and the study is expected to run for 
a total of five years.  A brief overview of the aims and structure of the PRoBaND study 
are provided here as context to the gastroparesis sub-study.
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2.4.1 Hypothesis and aims for the PRoBaND study 
The primary hypothesis of the PRoBaND study was that genetic and biomarker 
variability underpins the phenotypic heterogeneity of PD.  Variation in the following 
four clinical domains was assessed prospectively and serially: 
1. Motor features. 
2. Cognitive status. 
3. Therapy responsiveness. 
4. Non-motor features. 
 
Alongside the collection of clinical and demographic data, genetic and biomarker 
analysis was performed to identify markers which may explain observed clinical 
variations. 
2.4.2 PRoBaND study population 
Three subject groups were eligible for inclusion in the study: two cohorts of people 
with PD and selected first degree relatives of participants in these two patient groups 
(Table 2-1). 
Table 2-1 Overview of participant groups in the PRoBaND study 
Study participants Description Target number 
of subjects 
Recent onset PD patients PD diagnosed within the 
preceding three years 
2,000 
Young onset PD patients PD diagnosed before the age 
of 50 years 
240 
First degree relatives Siblings of the above two 
patient groups 
840 
  Total 3,080 
 
This thesis will consider baseline data from a subset of participants in the recent onset 
PD group and all participants in the young onset PD group.  No results from the first 
degree relatives are considered in this thesis. 
53 
 
2.4.3 Eligibility criteria for the PRoBaND study 
Patient participants in this study were diagnosed as having idiopathic PD according to 
the UK Brain Bank Criteria (Hughes et al., 1992) and had this diagnosis established by a 
specialist, either within the preceding three years or prior to the age of 50 years old.  
All participants were aged 18 to 90 years old (inclusive) and were willing and able to 
provide written informed consent.  Participants were allowed to already be taking anti-
parkinsonian medications prior to entry into the study.  The main exclusion criteria for 
the PRoBaND study included: severe co-morbid illness that would limit participation, 
features suggestive of another cause of degenerative parkinsonism (e.g. progressive 
supranuclear palsy, multiple system atrophy), drug-induced parkinsonism or 
symmetrical lower body parkinsonism suggestive of underlying vascular aetiology.  
Neuroimaging was not a pre-requisite of enrolment however patients who previously 
had negative or normal functional imaging of the presynaptic dopamine system were 
excluded. 
2.4.4 Identification of participants for the PRoBaND study 
Over 50 sites (hospitals, universities and research centres) around the United Kingdom 
were involved in the identification, consent and assessment of study participants.  The 
PRoBaND study was co-ordinated and led by a research team in Glasgow.  Newcastle 
acted as the second leading site with a research doctor (SM) undertaking all 
recruitment and baseline assessments of participants. 
2.4.5 PRoBaND study procedures 
Patients in the recently diagnosed cohort were assessed every six months over a three 
year period (seven study visits in total).  Patients in the young onset group were 
assessed on two occasions approximately six months apart.  Assessments relevant to 
this thesis are detailed in section 2.5. 
Genetic testing as part of the PRoBaND study included testing for the LRRK2 and GBA 
mutations in all participants.  Those patients with young onset PD were additionally 
tested for abnormalities in Parkin (PARK 2) & PINK-1 (PARK 6).  The results of these 
genetic tests are not considered in this thesis. 
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2.4.6 PRoBaND study timeline 
Recruitment of subjects to the PRoBaND study began in January 2012 and the first 
patient assessment was performed on 2 February 2012.  The national recruitment 
target of 240 patients for the young onset PD cohort was surpassed (n = 337) in 
December 2012.  Recruitment to the recently diagnosed PD cohort was on-going at the 
time of writing this thesis.  Current recruitment rates suggest that patient enrolment 
will conclude in early 2014 with the study completing in 2017. 
The data presented in this thesis represent an interim analysis of the first PRoBaND 
participants recruited to the study between January 2012 and July 2013. 
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Evaluation of gastroparesis symptoms in a UK-wide cohort of patients 
with recent or young onset Parkinson’s disease – the PRoBaND study 
2.5 General study methodology 
Between 2 February 2012 and 22 July 2013, 1,084 people with PD (recently diagnosed 
or young onset) were recruited to the PRoBaND study.  All patients provided written 
informed consent and met the study eligibility criteria previously summarised (section 
2.4.3).  A total of 57 sites around the UK contributed patients to the study.  The lead 
study site (Glasgow) contributed 134 patients (12.4% of participants) and Newcastle 
contributed 103 (9.5%) (Figure 2-1). 
Figure 2-1 Number of patients recruited to the PRoBaND study per site (from February 
2012 to July 2013) 
 
 
Glasgow (n=134) 
Newcastle (n=103) 
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2.5.1 Baseline clinical assessment 
At baseline, demographic and clinical data were obtained from each participant by 
trained study staff.  Details of individuals’ past medical history and family history were 
obtained via patient self-completed questionnaires.  All current medications (for the 
treatment of PD and all other concomitant medications) were recorded by study staff.  
Height and weight were measured and used to calculate participants’ body mass index 
(BMI = weight in Kg / height in metres2).  Postural blood pressure measurements were 
recorded manually or with an automated sphygmomanometer following three minutes 
in a supine position and again after two minutes of standing.  Orthostatic hypotension 
was defined as a lying to standing systolic deficit of ≥20mmHg or a diastolic deficit of 
≥10mmHg ('Consensus statement on the definition of orthostatic hypotension, pure 
autonomic failure, and multiple system atrophy. The Consensus Committee of the 
American Autonomic Society and the American Academy of Neurology,' 1996). 
Clinical assessment was performed by experienced raters and included use of the 
revised Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS 
UPDRS) (Goetz et al., 2008).  The MDS UPDRS includes clinician rated sections and 
patient or carer completed questions.  The MDS UPDRS comprises four sections; Part I: 
Non-motor experiences of daily living (score range 0-52), Part II: Motor experiences of 
daily living (score range 0-52), Part III: Motor examination (score range 0-132), Part IV: 
Motor complications (score range 0-24).  Scores for each part of the MDS UPDRS as 
well as the total score (potential range 0-260) were reported as measures of disease 
severity, with higher scores reflecting more severe disease parameters.  Scores from 
the baseline MDS UPDRS assessment were used to categorise patients according to 
their motor phenotype: tremor dominant (TD), postural instability and gait difficulty 
(PIGD) or indeterminate (ID).  Calculation of the mean tremor score and mean postural 
instability and gait score for each subject, allowed classification into motor subtypes 
where a ratio of ≥ 1.15 was deemed TD and ≤ 0.90 was PIGD with intervening ratio 
values classified as ID (Stebbins et al., 2013).  Disease stage was reported according to 
the modified Hoehn and Yahr (mH&Y) staging system (Hoehn and Yahr, 1967; Jankovic 
et al., 1990). 
At baseline patients completed a series of validated questionnaires to provide a wider 
context to their PD symptoms.  The presence and severity of non-motor symptoms was 
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evaluated with the 30-item Non-Motor Symptom Scale (NMSS) (Chaudhuri et al., 2007).  
This was used to calculate a global score as well as scores for nine individual NMS 
domains (Cardiovascular & falls, Sleep, Mood & cognition, Perceptual problems & 
hallucinations, Attention & memory, Gastrointestinal, Urinary, Sexual function and 
Miscellaneous).  Autonomic symptoms associated with PD were assessed using the 
SCOPA-AUT tool (Visser et al., 2004).  This questionnaire was used to calculate a global 
score reflective of the total autonomic symptom burden and domain sub-scores 
(Gastrointestinal, Urinary, Cardiovascular, Thermoregulatory, Pupillomotor, Sexual).  
Symptoms of anxiety and depression were assessed with the Leeds scales for the self-
assessment of Anxiety and Depression (LADS) (Snaith et al., 1976) with scores ≥ 7 for 
the anxiety or depression questions respectively taken to represent significant anxiety 
or depression.  Quality of life (QoL) was evaluated using the PDQ8 (Jenkinson et al., 
1997) which is a brief 8-item tool specifically designed to assess PD-related QoL 
parameters.  All responses were combined to give a global severity score; the PDQ8 
summary index (range 0-100%) (Katsarou et al., 2004). 
Alongside the baseline assessments described, one piece of follow-up data is included 
in this thesis.  At the six-month follow-up visit, olfactory testing was performed and 
where available (for the recently diagnosed cases), this was evaluated alongside 
baseline gastroparesis data.  It was hypothesised that olfactory impairment and 
gastroparesis symptoms would correlate as according to the ‘Dual hit hypothesis’ of PD 
the olfactory bulb and DMNV are the earliest sites of abnormal pathology in the 
pathogenesis of PD (Hawkes et al., 2007).  For the PRoBaND study olfactory testing was 
performed in a standardised, quantitative manner using a British version of the 
University of Pennsylvania Smell Identification Test (UPSIT), produced by Sensonics Inc, 
New Jersey, USA.  This 40-item validated test of olfactory function (Doty et al., 1984) 
has been used reliably in established PD (Hawkes et al., 1997) as well as early 
untreated disease (Doty et al., 1992).  For those participants aged ≥60, an UPSIT score 
of ≤23/40 was deemed abnormal and for those aged <60, a higher threshold (≤28/40) 
was set as a marker of significant hyposmia (Silveira-Moriyama et al., 2009). 
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2.5.2 Assessment of gastroparesis symptoms 
The presence and severity of gastroparesis symptoms was assessed in all patients at 
baseline using the Gastroparesis Cardinal Symptom Index (GCSI) (Revicki et al., 2003).  
The GCSI is a structured questionnaire in which patients self-report the severity of 9 
symptoms typically associated with gastroparesis (Table 2-2).  Participants were asked 
to report the symptoms they experienced in the preceding two week period. 
Table 2-2 Components of the Gastroparesis Cardinal Symptom Index 
Symptom cluster Question / symptom 
Nausea & vomiting 1  Nausea 
2  Retching 
3  Vomiting 
Fullness & early satiety 4  Stomach fullness 
5  Early satiety 
6  Post-prandial fullness 
7  Loss of appetite 
Bloating 8  Bloating 
9  Stomach visibly larger 
The severity of each of the 9 symptoms was graded on an ordinal numeric scale as 
follows: None = 0, Very mild = 1, Mild =2, Moderate = 3, Severe = 4 and Very severe = 5.  
Each symptom was subsequently re-coded as either ‘present’ (score ≥1) or ‘absent’ 
(score = 0).  This was used to describe the prevalence but not severity of each of the 9 
gastroparesis symptoms.  Similarly, answers to all 9 questions were summated to give 
a cumulative score (0 – 45).  Again, participants were re-coded as either ‘gastroparesis 
symptoms present’ (scores ≥1) or ‘no gastroparesis symptoms’ (score 0).
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Gastroparesis symptom severity was described with the GCSI total score.  The GCSI 
validation study (Revicki et al., 2003) described a calculation for the GCSI total score 
combining all 9 questions of the GCSI to give a global measure of gastroparesis 
symptom severity (Equation 1). 
 
Equation 1 Formula for calculating the GCSI total score 
 
Higher GCSI total scores reflected a greater burden of gastroparesis symptoms.  The 
GCSI total score could range from 0 to 5.  A large community based study of 
gastroparesis symptoms in people with type 1 diabetes suggested that a GCSI total 
score of ≥ 1.90 is abnormal (Kofod-Andersen and Tarnow, 2012).  A validation study in 
169 people with known gastroparesis (Revicki et al., 2003) suggested that scores 
of >2.56 are consistent with severe symptoms of delayed gastric emptying. 
GCSI responses from those participants with young onset PD were dichotomised into 
those diagnosed with PD before the age of 40 and those diagnosed aged ≥ 40 and <50 
years old.  It was speculated that those with very young onset PD would be more likely 
to have a monogenetic cause and hence comparison of GCSI total scores between 
young and very young onset cases may hint towards a genetic influence upon rates of 
gastroparesis in PD. 
2.5.3 Assessment of other gastrointestinal symptoms 
The bowel function of all participants was evaluated at baseline alongside 
gastroparesis symptoms.  Participants were asked to report their typical daily bowel 
motion frequency during the preceding week (less than once daily, once daily, twice 
daily or more than twice daily).  Furthermore, Part I of the MDS UPDRS includes a 
question on the severity of constipation difficulties on a scale from 0 to 4, where 0 is 
normal (no problems) and 4 is severe (requiring physical help from others to empty 
their bowels).  Additionally, participants were asked if they had used laxatives in the 
last week, if they had undertaken any exercise in the last week. 
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2.6 Statistical analysis 
Statistical analyses were performed using SPSS 19 (SPSS, Chicago, IL).  Normality of the 
data was assessed visually with histograms and objectively with the Kolmogorov-
Smirnov test. 
Normally distributed data are presented as mean and standard deviation (SD).  Means 
between groups were compared with un-paired Student t-tests.  Relationships 
between normative data series were assessed with Pearson’s correlation. 
Non-normally distributed data are presented as median and inter quartile range (IQR).  
Non-parametric tests (Mann-Whitney or Kruskal-Wallis test) were used for non-
normally distributed data.  Relationships within non-normative data were assessed 
with Spearman’s rank correlation. 
Where multiple comparisons of the data were undertaken, post hoc pairwise 
comparisons were undertaken with Bonferroni’s correction and significance reported 
according to the revised P value. 
Logistic regression was used to evaluate binary outcome measures.  Linear regression 
was used to model the effect of continuous predictor variables on the GCSI total score.  
Multiple regression was used to model the influence of mixed predictor variables on 
the GCSI total score. 
Frequencies of categorical variables between groups were compared with the Chi-
Square test, with Odds Ratios (OR) with 95% confidence intervals (95% CI) reported for 
significant differences. 
All P values are presented a two-tailed unless otherwise stated; where one-tailed tests 
were used because a directional effect was hypothesised a P value of < 0.05 was 
deemed significant. 
61 
 
2.7 Selection of cases for analysis 
Of the first 1,084 patients recruited to the PRoBaND study, 747 were recently 
diagnosed cases (clinical diagnosis of PD within three years) and 337 were young onset 
cases (diagnosed before the age of 50).  A small number of participants (n = 81) did not 
complete the full GCSI questionnaire.  Results of the GCSI were taken as the primary 
outcome measure for this study of gastroparesis symptoms in PD.  Therefore those 
who did not complete the GCSI were excluded from subsequent analyses.  There were 
no significant differences with respect to age, gender, cognition (MoCA score) or 
motor disease severity (MDS UPDRS Part III) in the 1003 participants who fully 
completed the GCSI compared with the 81 subjects who did not.  Full details of these 
statistical comparisons are provided later in the appropriate results sections (Table 2-3 
and Table 2-17). 
Figure 2-2 Overview of cases selected for analysis by type 
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2.8 Results – Gastroparesis symptoms in people with recently diagnosed 
Parkinson’s disease 
2.8.1 Baseline characteristics of study participants – recently diagnosed Parkinson’s 
Disease 
747 patients diagnosed with PD within the preceding three years were recruited to the 
PRoBaND study between 2 February 2012 and 22 July 2013.  Of these, 691 completed 
the GCSI questionnaire in its entirety and 56 had either partially or wholly incomplete 
questionnaires.  There were no significant differences in age, gender, cognition (MoCA 
score) or motor severity (MDS UPDRS Part III) between these two groups (Table 2-3).  
All subsequent analyses will focus solely on the 691 participants with recently 
diagnosed PD who at baseline fully completed the GCSI. 
Table 2-3 Comparison of included vs excluded recently diagnosed PD cases 
Characteristic All recently diagnosed cases 
n = 747 
P value 
Included 
n = 691 
Excluded  
n = 56 
Age (years)  
 
68.09 (7.76) 68.75 (10.37) 0.642a 
Male gender (%) 
 
466 (67.3%) 39 (69.6%) 0.724b 
MoCA score        
 
25.00 (4.00) 25.00 (3.00) 0.403c 
MDS UPDRS Part III  
 
19.00 (15.00) 19.5 (19) 0.085c 
Data presented as: mean age (SD), number (%) male, median MoCA & MDS UPDRS Part III 
scores (IQR).  Statistical tests:  aUnpaired t-test, bChi-Square, cMann Whitney test. 
 
Baseline characteristics of the 691 recently diagnosed PD participants are summarised 
in Table 2-4.  Participants were staged according to the modified Hoehn and Yahr 
(mH&Y) staging system.  85% of participants were mH&Y stage 2 or less with nearly 
half of all participants only showing unilateral signs only (49.8% mH&Y stage 0, 1 or 
1.5).  When classified according to motor phenotype, 46.7% of participants were of the 
tremor dominant (TD) subtype, 40.8% postural instability and gait disorder (PIGD) 
subtype and 12.4% were indeterminate. 
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Table 2-4 Baseline characteristics of participants with a recent diagnosis of PD 
Characteristic Descriptors  
Age  68.1 (7.8, 49.4 - 89.0) 
Male gender 465 (67.3%) 
Age at diagnosis 66.7 (7.8, 48.9 - 87.3) 
Disease duration (yrs)* 1.3 (1.7, 0 - 3.6) 
Caucasian ethnic origin 677 (98.0%) 
mH&Y stage  0 
                        1 
                        1.5 
                        2 
                        2.5 
                        3 
                        4 
                        5 
10 (1.5%) 
210 (32.1%) 
106 (16.2%) 
231 (35.3%) 
64 (9.8%) 
31 (4.7%) 
0 (0%) 
2 (0.3%) 
MDS UPDRS*     Part I 
                             Part II 
                             Part III 
                             Part IV 
                             Total 
9 (7, 0 - 34) 
9 (9, 0 - 48) 
19 (15, 0 - 66) 
0 (0.0, 0 - 12) 
38 (24.0, 6 - 141) 
Anxiety 165 (24.3%) 
Depression  150 (22.2%) 
Data presented as mean (SD, range), except non-normally distributed variables indicated by * 
which are reported as median (IQR, range).  Categorical variables are presented as frequency 
(%). 
 
Patients self-reported their past medical history as summarised in Table 2-5.  The most 
commonly reported comorbidities were hypertension and hypercholesterolaemia 
(33.0% and 32.2% of participants, respectively). 
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Table 2-5 Comorbidities reported by study participants with a recent diagnosis of PD 
Comorbid condition Positive history reported 
Hypertension 33.0% 
Hypercholesterolaemia 32.2% 
Asthma 10.4% 
Angina 8.6% 
Diabetes (Type 1 or 2) 8.5% 
Stroke or TIA 4.8% 
Myocardial infarction 4.2% 
Heart failure 3.1% 
Rheumatoid arthritis 2.5% 
Breast cancer 2.2% 
Prostate cancer 2.0% 
Bronchitis  2.0% 
Emphysema 1.2% 
Bowel cancer 1.2% 
Lung cancer 0.1% 
 
A majority of participants (90.4%) was taking some form of antiparkinsonian therapy at 
baseline assessment (Table 2-6).  The most commonly prescribed medication was 
Levodopa-based therapy (64.2%) followed by dopamine agonists (42.2%).  48% of 
participants were taking monotherapy whilst 41.6% were taking two or more 
antiparkinsonian drugs. 
Table 2-6 Medications of recently diagnosed study participants at baseline assessment 
Medication type Number of patients Percentage 
Levodopa 641 64.2% 
Dopamine agonist 421 42.2% 
MAOBI 296 29.7% 
Amantadine 74 7.4% 
COMT Inhibitor 48 4.8% 
Anticholinergic 22 2.2% 
None 96 9.6% 
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2.8.2 Presence of gastroparesis symptoms – recently diagnosed PD 
More than half of all patients (62.5%) reported at least one symptom associated with 
gastroparesis (Figure 2-3).  The most commonly reported gastroparesis symptom was 
stomach fullness, present in 36.5% of participants with early PD.  Post-prandial fullness 
(32.7%), bloating (32.1%) and the stomach being visibly larger or distended (30%) were 
the next most frequently reported symptoms Table 2-7. 
Figure 2-3 Number of gastroparesis symptoms positively reported on the GCSI 
questionnaire per patient with a recent diagnosis of PD 
 
Table 2-7 Prevalence of positive gastroparesis symptoms reported in the GCSI 
questionnaire by participants with recently diagnosed PD 
Gastroparesis symptom Patients reporting symptoms in 
the preceding 2 weeks 
Stomach fullness 36.5% 
Post-prandial fullness 32.7% 
Bloating 32.1% 
Stomach larger / distended 30.0% 
Loss of appetite 23.0% 
Early satiety 22.1% 
Nausea 20% 
Retching 9.6% 
Vomiting 3.0% 
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An analysis was undertaken to compare those participants who reported at least one 
gastroparesis symptom (n = 432, 62.5%) with those who reported no symptoms (n = 
259, 37.5%) (Table 2-8).  Gastroparesis symptoms were significantly more likely to be 
reported by women compared to men (Chi-square test, P = 0.001, OR 1.77, 95% CI 1.26 
– 2.50).  Patients classified as PIGD motor subtype were more likely to report 
gastroparesis symptoms than those of a TD phenotype (Chi-square test, P < 0.001, OR 
0.510, 95% CI 0.36 – 0.73).  Those patients who reported gastroparesis symptoms had 
significantly more severe PD (higher MDS UPDRS Part III score) (Mean 21.9 vs 19.9, t-
test, P = 0.034).  Patients who reported less than one bowel motion per day were also 
significantly more likely to have experienced gastroparesis symptoms than those who 
opened their bowel at least once daily (Chi-square test, P = 0.022, OR 1.58, 95% CI 0.36 
– 0.73).  Accordingly, those patients who reported more severe constipation difficulties 
in the MDS UPDRS (question 1.11; none vs slight - severe) were significantly more likely 
to also experience gastroparesis symptoms (Chi-square test, P < 0.001, OR 2.25, 95% CI 
1.64 – 3.08).  After Bonferroni correction for multiple comparisons; gender, motor 
phenotype and constipation difficulties (MDS UPDRS question 1.1) all remained 
significant variables at the new level of significance (P = 0.01).
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Table 2-8 Comparison of demographic and clinical differences between those recently 
diagnosed participants with and without gastroparesis symptoms 
Variable Gastroparesis 
symptoms reported 
n = 432 
No gastroparesis 
symptoms reported 
n = 259 
P value 
Female gender 161 (23.3%) 65 (9.4%) 0.001a 
Age* 68.1 (7.9) 68.0 (7.6) 0.837b 
Age at diagnosis* 66.7 (7.9) 66.6 (7.5) 0.911 b 
Disease duration* 1.4 (0.9) 1.4 (0.9) 0.436 b 
PIGD phenotype 182 (29.0%) 74 (11.8%) <0.001a 
MDS UPDRS III* 21.9 (11.8) 19.9 (10.4) 0.034 b 
Bowel motion <1/d 103 (14.9%) 43 (6.2%) 0.022a 
Constipation problems 265 (38.5%) 108 (15.7%) <0.001a 
Orthostatic hypotension 71 (10.6%) 34 (5.1%) 0.218a 
mH&Y stage ≥ 2 211 (32.3%) 117 (17.9%) 0.234a 
Weight: 
   Underweight (BMI: <18.5) 
   Normal (BMI: ≥18.5, <25) 
   Overweight (BMI: ≥25, <30) 
   Obese (BMI: ≥30) 
 
7 (1.0%) 
129 (19.2%) 
181 (26.9%) 
104 (15.5%) 
 
2 (0.3%) 
88 (13.1%) 
113 (16.8%) 
49 (7.3%) 
0.281a 
Data are presented as frequency (% of all cases) for categorical variables, continuous variables 
(indicated by *) are reported as mean (SD).  aChi-square test, bUnpaired t-test. 
 
Stepwise logistic regression was used to determine the predictors of gastroparesis 
symptoms being present or absent in patients with recently diagnosed PD.  Female 
gender, constipation problems and a greater Non-motor symptom burden predicted 
the presence of gastroparesis symptoms accounting for over 17% of the variance.  The 
model had a high specificity (83.0%) but a low sensitivity (38.1%) (Nagelkere R square 
0.177)(Table 2-9).  
Table 2-9 Logistic regression model for predictors of gastroparesis symptoms in early 
PD 
Variable β S.E. P value Exp (β) 
Female gender 0.530 0.224 0.018 0.589 
Constipation problems  -0.605 0.214 0.005 0.546 
UPDRS part I score 0.133 0.025 0.000 1.142 
Constant  0.023 0.321 0.942 1.024 
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2.8.3 Severity of gastroparesis symptoms – recently diagnosed PD 
The GCSI total score was calculated as a global marker of gastroparesis symptom 
severity.  For the 691 participants with a recent diagnosis of PD, the GCSI total scores 
were non-normally distributed (Kolmogorov-Smirnov P<0.001), with a median score of 
0.17 (0 - 3.42) and a mean of 0.45 (0.61) (Figure 2-4). 
Figure 2-4 Baseline GCSI total scores for 691 PRoBaND participants with a recent 
diagnosis of PD 
 
As diabetes mellitus is a well-recognised cause of delayed gastric emptying, it was 
necessary to establish if the presence of diabetes as a co-morbidity was a significant 
factor influencing GCSI scores.  A total of 58 participants (8.5%) reported having 
diabetes but their median GCSI total score (0.25) was not significantly different to that 
of participants without diabetes (0.17) (Mann-Whitney, U = 19,424, z = 0.89, P = 0.376, 
r = 0.001). 
28 participants (4.1%) had a GCSI total score of ≥ 1.90 which is regarded as abnormally 
high and consistent with gastroparesis (Kofod-Andersen and Tarnow, 2012).  Only four 
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participants (0.6%) had a GCSI total score of > 2.56 consistent with severe 
gastroparesis (Revicki et al., 2003). 
Higher GCSI total scores were associated with female gender, PIGD motor phenotype, 
a lack of recent exercise, symptoms of anxiety and depression, constipation and recent 
laxative use (Table 2-10).  Participants age, age at the time of diagnosis and disease 
duration were not significantly associated with GCSI total scores (Spearman’s rho, P = 
0.563, 0.466 and 0.262, respectively). 
Table 2-10 Comparison of GCSI total scores according to patient characteristics 
Patient characteristic Median GCSI total score of 
participants with 
characteristic 
Median GCSI total 
score of participants 
without characteristic 
P 
value 
Female gender 0.28 0.17 0.001 
PIGD phenotype 0.33 0.08 <0.001 
OH 0.25 0.17 0.33 
No exercise in past week 0.25 0.17 0.009 
Laxativesused in last week 0.50 0.11 <0.001 
Anxiety (LAD ≥7) 0.53 0.08 <0.001 
Depression (LADS≥7) 0.67 0.10 <0.001 
Data presented: Mann-Whitney test.  OH: orthostatic hypotension (postural drop in systolic 
blood pressure ≥ 20mmHg or diastolic blood pressure drop ≥ 10mmHg). 
 
The influence of anti-parkinsonian medications on gastroparesis symptoms was 
evaluated with non-parametric tests.  Taking of Levodopa medication and 
anticholinergics did not significantly influence GCSI total score (Mann-Whitney test, P = 
0.844 and 0.227, respectively).  The use of dopamine agonist medications was however 
associated with a higher GCSI total score (Mann-Whitney test, P < 0.001). 
The GCSI total score was significantly influenced by modified H&Y disease stage 
(Kruskall-Wallis, P = 0.038) with a trend towards higher GCSI total scores with 
advancing disease stage (Table 2-11). 
70 
 
Table 2-11 GCSI total scores according to disease stage 
mH&Y stage Number of participants Median GCSI total score 
0 10 0.08 
1 210 0.11 
1.5 106 0.17 
2 231 0.17 
2.5 64 0.28 
3 31 0.42 
5 2 1.56 
 
Advancing disease severity significantly correlated with more severe gastroparesis 
symptoms.  Higher scores in each sub-section of the MDS UPDRS were associated with 
higher GCSI total scores (Table 2-12 and Figure 2-5).  Using a stepwise linear regression 
model, MDS UPDRS Part I scores had the greatest influence on GCSI total scores (R2 = 
0.171) 
 
Table 2-12 Correlation between MDS UPDRS scores and the GCSI total score 
MDS UPDRS 
sub-section 
Descriptor of the sub-section Correlation 
coefficient 
P value 
Part I Non-motor experiences of daily living 0.395 <0.001 
Part II Motor experiences of daily living 0.258 <0.001 
Part III Motor examination 0.093 0.010 
Part IV Motor complications 0.136 <0.001 
Total score  0.256 <0.001 
Data are presented as Spearman’s rho, 1-tailed significance.  After Bonferroni’s correction for 
multiple comparisons, all variables remained significant (P < 0.0125). 
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Figure 2-5 Scatter plots demonstrating the relationship between GCSI total scores and 
sub-sections of the MDS UPDRS (with R2 values for linear regression model) 
 
 
R2 = 0.171 
R2 = 0.058 
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R2 = 0.023 
R2 = 0.005 
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There was a positive correlation between non-motor aspects of daily living (MDS 
UPDRS Part I scores) and greater gastroparesis symptom severity.  This relationship 
was explored further using the 30-item Non-Motor Symptom Scale (NMSS).  This 
questionnaire has nine symptom domains, each of which was evaluated for an 
association with the GCSI total score (Table 2-13).  Higher symptom scores in all nine 
NMSS domains significantly correlated with higher GCSI total scores.  Using a stepwise 
linear regression model, the NMSS total scores accounted for 16.3% of the variance in 
GCSI total scores (Figure 2-6). 
 
R2 = 0.064 
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Table 2-13 Association between the domains of the NMSS (non-motor symptoms 
questionnaire) and GCSI total scores in participants with recently diagnosed PD 
NMSS domain 
number 
Domain type Correlation 
coefficient 
P value 
1 Cardiovascular & falls 0.247 <0.001 
2 Sleep & fatigue 0.322 <0.001 
3 Mood & cognition 0.274 <0.001 
4 Perceptual & hallucinations 0.187 <0.001 
5 Attention & memory 0.200 <0.001 
6 Gastrointestinal 0.277 <0.001 
7 Urinary 0.229 <0.001 
8 Sexual 0.117 0.001 
9 Miscellaneous 0.280 <0.001 
Total All domains combined 0.365 <0.001 
Data are presented as Spearman’s rho, 1-tailed significance. 
 
Figure 2-6 Scatter plot to show the relationship between the NMSS total score and the 
GCSI total score  
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Correlation between autonomic dysfunction and gastroparesis symptoms was further 
explored through analysis of the SCOPA-AUT questionnaire.  All six items of this 
autonomic symptom questionnaire positively correlated with higher GCSI total scores 
(Table 2-14), the strongest relationship was seen with the gastrointestinal and urinary 
domain scores (Figure 2-7). 
Table 2-14 Association between domains of the SCOPA-AUT (autonomic symptoms 
questionnaire) and GCSI total score in recently diagnosed PD  
SCOPA-AUT domain Correlation 
coefficient 
P value 
Gastrointestinal 0.409 <0.001 
Urinary 0.282 <0.001 
Cardiovascular 0.280 <0.001 
Thermoregulatory 0.303 <0.001 
Pupillomotor 0.232 <0.001 
Sexual 0.071 0.031 
Total 0.426 <0.001 
Data are presented as Spearman’s rho, 1-tailed significance.  
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Figure 2-7 Association between domain scores of the SCOPA-AUT and GCSI total scores 
in participants with recently diagnosed PD 
 
Best fit lines are presented with corresponding linear regression models (R2 values) for 
each component of the SCOPA-AUT and the relationship with GCSI total score. 
 
The PDQ8 summary index was used as a measure of PD-related quality of life with 
higher scores (0-100%) reflecting a greater disease burden (worse QoL).  The median 
summary index score for participants was 15.6% (21.8, 0-75%).  Increasing 
gastroparesis symptom severity correlated with worse QoL (Spearman’s rho, 
correlation coefficient = 0.314, P < 0.001). 
Variables identified as being significantly associated with the GCSI total score were 
entered into a stepwise multiple regression model (summarised in Table 2-15).  
Autonomic symptoms, gender and MDS UPDRS Parts I, II and IV scores all contributed 
significantly to the prediction of GCSI total scores.  When these variables were 
combined in a stepwise multiple regression model, they accounted for 31.3% of the 
variability in GCSI total scores. 
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▬ Urinary 
▬ Gastrointestinal 
▬ Thermoregulatory 
▬ Cardiovascular 
▬ Sexual 
▬ Pupilomotor  
R2 = 0.104 
R2 = 0.191 
R2 = 0.153 
R2 = 0.120 
R2 = 0.004 
R2 = 0.062 
GCSI total score 
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Table 2-15 Multiple regression model for predicting the GCSI total score in recently 
diagnosed PD participants 
Variables  B S.E. B β 
Constant -0.393 0.091  
SCOPA-AUT total score 0.036 0.005 0.388* 
MDS UPDRS Part I score 0.030 0.007 0.260* 
Male gender 0.189 0.055 0.144** 
MDS UPDRS Part II score -0.014 0.005 -0.159** 
MDS UPDRS Part IV score 0.038 0.017 0.096** 
R2 = 0.313 for the model, *P<0.001, **P<0.005 
 
2.9 Olfactory function and association with gastroparesis symptoms in recently 
diagnosed Parkinson’s disease 
Of the 691 recently diagnosed cases included in the main analysis, 580 participants had 
fully completed the olfactory function test at the time of this analysis.  The mean UPSIT 
score (out of a possible total of 40) was 20.27 (SD 6.93) with a median of 20 (IQR 11).  
Hyposmia defined according to age was evident in the majority of study participants 
(Figure 2-8). 
Figure 2-8 Summary of olfactory testing results from 580 participants with recently 
diagnosed Parkinson’s disease 
 
Amongst those patients aged under 60 years old, 65.7% of those with hyposmia 
reported at least one gastroparesis symptom with the equivalent figure for those 
without hyposmia being 64.7%, but there was no statistically significant difference in 
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the absolute rates of gastroparesis symptoms between those with and without 
hyposmia (Chi square test, P = 0.576).  Similarly the proportion of patients reporting at 
least one gastroparesis symptom did not differ significantly between those with and 
without hyposmia in the older age group (≥ 60 years) (Chi square test, P = 0.513).  The 
median GCSI total scores did not differ significantly between those participants with 
and without hyposmia (Table 2-16). 
Table 2-16 GCSI total scores in participants with and without hyposmia. 
 GCSI total scores P value 
Hyposmia No hyposmia 
Age < 60 years 0.22 (0.92) 0.08 (1.29) 0.923 
Age ≥ 60 years 0.17 (0.58) 0.25 (0.67) 0.479 
Data are presented as median (inter quartile range).  Mann-Whitney test to compare medians 
between those with and without hyposmia according to age. 
 
Comparison of GCSI total scores and UPSIT scores across the whole group (n = 580) did 
not show a significant relationship between these two variables, disproving the a priori 
hypothesis that higher gastroparesis scores would be associated with worse olfactory 
function. 
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2.10 Results – Gastroparesis symptoms in young onset PD cases 
2.10.1 Baseline characteristics of study participants – young onset PD 
337 patients diagnosed with PD prior to the age of 50 were recruited to the PRoBaND 
study between 2 February 2012 and 22 July 2013.  Of these, 312 completed the GCSI 
questionnaire in its entirety and 25 had either partially or wholly incomplete 
questionnaires.  There were no significant differences in age, gender, cognition (MoCA 
score) or motor severity (MDS UPDRS Part III) between these two groups (Table 2-17).  
All subsequent analyses will focus on the 312 participants with young onset PD who at 
baseline fully completed the GCSI. 
Table 2-17 Comparison of included vs excluded young onset PD cases 
Characteristic All young onset cases 
n = 337 
P value 
Included 
n = 312 
Excluded 
n = 25 
Age (years)  51.87 (7.55) 50.49 (11.21) 0.578a 
Male gender (%) 200 (64.7%) 15 (68.2%) 0.821b 
MoCA score  26.00 (4.00) 25.00 (8.00) 0.123c 
MDS UPDRS III score  23.00 (20.00) 20.00 (19.00) 0.663c 
Data presented as: mean age (SD), number (%) male, median MoCA & MDS UPDRS III scores 
(IQR).  Statistical tests:  aUnpaired t-test, bChi-Square, cMann Whitney test. 
 
Baseline characteristics of the 312 participants with young onset PD are summarised in 
Table 2-18.  The mean age of participants was 51.9 years old with a median age at 
diagnosis of 44.8 years.  67 participants (21.5%) were diagnosed prior to the age of 40 
with the remainder (245, 78.5%) diagnosed aged over 40 but under 50.  Disease 
duration was non-normally distributed across the 312 participants with a median 
number of years since diagnosis of 6.7 years and a range from just one month through 
to 35.4 years.  More than half of young onset cases had bilateral signs (61% mH&Y ≥2) 
in keeping with the longer disease duration of this cohort relative to the previously 
described recently diagnosed cases.  Accordingly, average MDS UPDRS section scores 
were also higher than seen in the recently diagnosed participants.  The commonest 
motor phenotype was the PIGD subtype (59.1%), with 29.5% classed as TD and 11.4% 
indeterminate. 
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Table 2-18 Baseline characteristics of participants with young onset PD 
Characteristic Descriptors  
Age  51.9 (7.57, 28.23-75.07) 
Male gender 202 (64.7%) 
Age at diagnosis* 44.8 (7.63, 20.12-52.30) 
Disease duration (yrs)* 6.7 (9.05, 0.05-35.46) 
Caucasian ethnic origin 296 (94.9%) 
mH&Y stage  0 
                        1 
                        1.5 
                        2 
                        2.5 
                        3 
                        4 
                        5 
4 (1.4%) 
65 (22.6%) 
43 (14.9%) 
94 (32.6%) 
42 (14.6%) 
26 (9.0%) 
13 (4.5%) 
1 (0.3%) 
MDS UPDRS*     Part I 
                             Part II 
                             Part III 
                             Part IV 
                             Total 
12 (10, 1-38) 
15 (13, 1-41) 
22 (21, 0-74) 
4 (8, 0-20) 
56 (42, 10-138) 
Anxiety 147 (48.2%) 
Depression  128 (42.0%) 
Data presented as mean (SD, range), except non-normally distributed variables indicated by * 
which are reported as median (IQR, range).  Categorical variables are presented as frequency 
(%). 
 
Significant symptoms of anxiety and depression (as reported in the LADS questionnaire) 
were common (48% and 42% respectively), other comorbidities are summarised in 
Table 2-19. 
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Table 2-19 Comorbidities reported by study participants with young onset PD 
Co-morbid condition Positive history reported 
Hypertension 10.6% 
Hypercholesterolaemia 10% 
Asthma 7.1% 
Angina 3.2% 
Stroke / TIA 2.3% 
Diabetes (Type 1 or 2) 1.9% 
Heart failure 1.9% 
Rheumatoid arthritis 1.6% 
Bronchitis 1.6% 
Myocardial infarction 1.3% 
Prostate cancer 1% 
Breast cancer 1% 
Emphysema  0.3% 
Lung cancer 0.3% 
Bowel cancer 0.3% 
 
A majority of participants (95.5%) were taking at least one antiparkinsonian 
medication.  The most commonly prescribed medications were Levodopa (74.9%) and 
dopamine agonists (62.7%).  45% were prescribed a Monoamine-oxidase B inhibitor, 
21.2% amantadine and 4.8% anticholinergics. 
2.10.2 Presence of gastroparesis symptoms – young onset PD 
Of all 312 young onset PD cases analysed, 242 (77.6%) reported at least one symptom 
associated with gastroparesis (Figure 2-9).  The most commonly reported symptoms 
were bloating and stomach fullness (Table 2-20).
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Figure 2-9 Bar chart of the number of gastroparesis symptoms positively reported on 
the GCSI questionnaire per patient with young onset PD 
 
Table 2-20 Prevalence of positive gastroparesis symptoms reported in the GCSI 
questionnaire by participants with young onset PD 
Gastroparesis symptom Patients reporting positive symptoms in 
the preceding 2 weeks 
Bloating 48.4% 
Stomach fullness 46.2% 
Stomach larger / distended 43.6% 
Postprandial fullness 42.0% 
Nausea 35.9% 
Early satiety 32.4% 
Loss of appetite 30.4% 
Retching 16.7% 
Vomiting 7.1% 
 
An analysis was undertaken to compare the clinical characteristics of those 
participants who reported at least one gastroparesis symptom (n = 242) with those 
who reported none (n = 70).  There were no significant gender differences between 
these two groups (Chi square test, P = 0.847).  Patients with and without gastroparesis 
symptoms did not differ significantly with regard to motor subtype (Chi square test 
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P=0.742) or disease stage (mH&Y <2 vs ≥ 2, Chi square test P =0.232).   Bowel 
frequency (<1 motion/day vs ≥1 motion/day) did not differ significantly between those 
with and without gastroparesis symptoms (Chi square test, P = 0.058). However, 
gastroparesis symptoms were significantly more likely in those participants who 
reported constipation problems on the MDS UPDRS Part I (Chi square test, P = 0.010).  
This association remained significant after Bonferroni’s correction for multiple 
comparisons (P < 0.0125).  There was a nearly two-fold increased risk of gastroparesis 
symptoms in those who experienced constipation problems (OR 1.97, 95% CI 1.15 – 
3.37).  The effects of age, disease duration and MDS UPDRS scores upon the reporting 
of gastroparesis symptoms are summarised in Table 2-21.  The mean MDS UPDRS Part 
I score was significantly higher in those with gastroparesis symptoms that those with 
no symptoms but other components of the MDS UPDS did not differ significantly 
between the two groups. 
Table 2-21 Comparison of demographic and clinical differences between those young 
onset participants with and without gastroparesis symptoms 
Variable Gastroparesis 
symptoms reported 
No gastroparesis 
symptoms reported 
P value 
Age 51.5 (7.6) 53.1 (7.3) 0.124 
Age at diagnosis  43.9 (5.5) 43.7 (4.7) 0.802 
Disease duration 7.7 (6.6) 9.4 (6.7) 0.051 
MDS UPDRS Part I 14.2 (6.9) 9.8 (6.3) <0.001 
MDS UPDRS Part II 16,9 (9.3) 13.5 (9.5) 0.009 
MDS UPDRS Part III 25.7 (14.7) 23.5 (15.7) 0.302 
MDS UPDRS Part IV 4.8 (4.8) 4.6 (4.8) 0.816 
Total MDS UPDRS 61.2 (28.5) 51.1 (29.6) 0.020 
Data presented as mean (standard deviation) with un-paired t-tests used to compare means 
between the two groups. 
 
Stepwise logistic regression modelling was used to assess the predictive value of 
constipation problems and the MDS UPDRS Part I score in predicting the GCSI total 
score.  However, constipation problems did not add significantly to the value of the 
MDS UPDRS Part I score alone in predicting the GCSI total score. 
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2.10.3 Severity of gastroparesis symptoms – young onset PD 
The GCSI total scores of the 312 participants were non-normally distributed 
(Kolmogorov-Smirnov test P < 0.001) with a median score of 0.43 (IQR 1.16), a mean of 
0.76 (SD 0.82) and a reported range from 0 to 3.58 (Figure 2-10).  39 participants 
(12.5%) had GCSI total scores of ≥ 1.90, consistent with gastroparesis and 11 (3.5%) 
had GCSI total score of > 2.56 consistent with severe gastroparesis. 
Figure 2-10 Baseline GCSI total scores for 321 PRoBaND participants with young onset 
PD 
 
Diabetes mellitus, a recognised cause of gastroparesis, was present in 6 (1.9%) 
participants.  However, diabetes did not influence the severity of gastroparesis 
symptoms; the median GCSI total score of those with diabetes (0.93 ± 2.15) was not 
significantly different to those without diabetes (0.44 ± 1.25) (Mann-Whitney test, P = 
0.285). 
GCSI total scores of participants did not differ significantly by gender or motor subtype.  
However, GCSI total scores were significantly higher in those participants with anxiety 
and depression and also those who had reported recent laxative use (Table 2-22).
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Table 2-22 Comparison of GCSI total scores according to patient characteristics 
Patient  characteristic Median GCSI total 
score of participants 
with characteristic 
Median GCSI total 
score of participants 
without characteristic 
P value 
Female gender 0.44 (1.50) 0.42 (1.14) 0.225 
PIGD phenotype 0.44 (1.28) 0.42 (1.10) 0.581 
Orthostatic hypotension 0.67 (1.44) 0.42 (1.25) 0.247 
No exercise in last  week 0.50 (1.17) 0.33 (1.29) 0.987 
Laxative use in last week 0.83 (1.60) 0.42 (0.94) 0.026 
Anxiety (LADS ≥ 7) 0.71 (1.40) 0.28 (0.83) <0.001 
Depression (LADS ≥ 7) 0.79 (1.49) 0.28 (0.83) <0.001 
Data presented as group medians with the Mann-Whitney test for comparisons between 
groups. 
 
The influence of medication type upon gastroparesis symptom severity was evaluated, 
but for all categories (Levodopa, Dopamine Agonist, Monoamine-oxidase B inhibitor, 
Amantadine, COMT Inhibitor, Anticholinergic) GCSI total scores did not differ 
significantly between those taking or not taking the medication (Mann-Whitney, P > 
0.05 for all comparisons).  The total number of anti-parkinsonian therapies taken by 
participants was evaluated but did not significantly influence the GCSI total score 
(Kruskall-Wallis, P = 0.215). 
The age of participants and their age at diagnosis did not correlate with the GCSI total 
score (Spearman’s rho, P = 0.936 and 0.406, respectively).  Disease duration was also 
not significantly associated with gastroparesis symptom severity (Spearman’s rho, P = 
0.508).  Disease stage, according to the mH&Y staging system was not a significant 
determinant of GCSI total score in participants (Kruskall-Wallis, P = 0.072).  However, 
disease severity and gastroparesis symptom severity were positively associated.  
Higher scores in each subsection of the MDS UPDRS, as well as the total score 
correlated significantly with increasing GCSI total scores (Table 2-23), with the 
strongest correlation seen with Non-motor activities of daily living (MDS UPDRS Part I).  
In a linear regression model, MDS UPDRS Part I scores accounted for 18% of the 
variance in GCSI total scores (R2 = 0.180). 
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Table 2-23 Correlation between MDS UPDRS scores and the GCSI total score 
MDS UPDRS 
sub-section 
Descriptor of the sub-section Correlation 
coefficient 
P value 
Part I Non-motor experiences of daily living 0.425 <0.001 
Part II Motor experiences of daily living 0.294 <0.001 
Part III Motor examination 0.105 0.046 
Part IV Motor complications 0.115 0.029 
Total score  0.268 <0.001 
Data are presented as Spearman’s rho, 1-tailed significance. 
 
The relationship between non-motor features of PD and the severity of gastroparesis 
symptoms in participants with young onset PD was further explored with analysis of 
the NMSS questionnaire.  All 9 domains of the NMSS as well as the total score 
positively correlated with the GCSI total score (Table 2-24). 
Table 2-24 Association between the domains of the NMSS (non-motor symptoms 
questionnaire) and GCSI total scores in participants with young onset PD 
NMSS domain 
number 
Domain type Correlation 
coefficient 
P value 
1 Cardiovascular & falls 0.353 <0.001 
2 Sleep & fatigue 0.358 <0.001 
3 Mood & cognition 0.357 <0.001 
4 Perceptual & hallucinations 0.225 <0.001 
5 Attention & memory 0.281 <0.001 
6 Gastrointestinal 0.267 <0.001 
7 Urinary 0.221 <0.001 
8 Sexual 0.209 <0.001 
9 Miscellaneous 0.304 <0.001 
Total All domains combined 0.427 <0.001 
Data are presented as Spearman’s rho, 1-tailed significance. 
 
The association between autonomic features of PD and gastroparesis symptoms was 
examined by comparison of the SCOPA-AUT and the GCSI total score.  All domains of 
the SCOPA-AUT positively correlated with GCSI total scores (Table 2-25).  Using a linear 
regression model to evaluate which autonomic domains were predictive of the GCSI 
total score, the strongest relationships were seen with the gastrointestinal and 
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thermoregulatory domains, which respectively accounted for 22% and 12.9% of the 
variance in GCSI total scores (Figure 2-11). 
Table 2-25 Association between domains of the SCOPA-AUT (autonomic symptoms 
questionnaire) and GCSI total score in young onset PD 
SCOPA-AUT domain Correlation 
coefficient 
P value 
Gastrointestinal 0.413 <0.001 
Urinary 0.279 <0.001 
Cardiovascular 0.352 <0.001 
Thermoregulatory 0.368 <0.001 
Pupilomotor 0.207 <0.001 
Sexual 0.159 0.031 
Total 0.460 <0.001 
Data are presented as Spearman’s rho, 1-tailed significance.  
Figure 2-11 Association between domain scores of the SCOPA-AUT and GCSI total 
scores in participants with young onset PD 
 
Best fit lines are presented with corresponding linear regression models for each component 
of the SCOPA-AUT. 
▬ Gastrointestinal 
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▬ Pupilomotor  
T
o
ta
l 
s
c
o
re
 o
n
 S
C
O
P
A
-A
U
T
 d
o
m
a
in
s
 
GCSI total score 
R2 = 0.024 
R2 = 0.018 
R2 = 0.105 
R2 = 0.129 
R2 = 0.063 
R2 = 0.222 
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All variables identified as being associated with higher GCSI total scores were entered 
into a stepwise multiple regression model.  Autonomic symptoms, depression and the 
MDS UPDRS Part I & III score were all included in the model as significant predictor 
variables (Table 2-26).  Overall the model accounted for 30.8% of the observed 
variance in GCSI total scores. 
Table 2-26 Multiple regression model for predictors of GCSI total score in young onset 
PD patients 
Variables  B S.E. B β 
Constant 0.074 0.111  
SCOPA-AUT total score 0.033 0.008 0.339* 
Depression 0.291 0.114 0.174** 
MDS UPDRS Part III score -0.008 0.004 -0.148** 
MDS UPDRS Part I score 0.023 0.011 0.194** 
R2 = 0.308 for the model, *P<0.001, **P<0.005 
 
2.10.4 Sub-analysis of young onset PD participants: Comparison of cases diagnosed 
before 40 versus diagnosed aged 40 to 50 years. 
Participants diagnosed before the age of 50 were dichotomised into those who were 
diagnosed prior to the age of 40 (n = 67, 21.5%) and those diagnosed aged 40 to 50 
years old (n = 245, 78.5%).  There was no significant difference in the reporting of 
gastroparesis symptoms between these two groups (Chi Square, P = 0.502).  The GCSI 
total scores were non-normally distributed for both groups.  The median GCSI total 
score of the <40 group (0.42 ± 0.83) was not significantly different to that of the ≥ 40 
group (0.44 ± 1.25) (Mann-Whitney test, P = 0.790).  The reporting of constipation in 
both groups was also comparable (18 out of 67 in the < 40 group and 47 out of 243 in 
the ≥ 40 group, Chi Square test, P = 0.180).  Furthermore the proportions reporting 
constipation problems on the MDS UPDRS Part I, was not significantly different 
between the two groups (Chi Square test, P = 0.226). 
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2.11 Gastroparesis symptoms in an unselected cohort of people with Parkinson’s 
disease attending the Newcastle movement disorder clinic 
2.11.1 Background 
The previous two sections of this thesis considered the frequency and clinical features 
associated with gastroparesis symptoms in two large PD groups; those with a recent 
diagnosis and those with young onset PD.  This section presents data concerning 
gastroparesis symptoms in consecutive patients with PD attending the movement 
disorder clinic at the Newcastle upon Tyne Hospitals NHS Foundation Trust.  The aim of 
the study was to determine the frequency of gastroparesis symptoms in a non-
research, out-patients setting.  This service evaluation was approved by the hospitals 
Research and Development (R&D) department, the Directorate lead for Neurosciences 
and the lead consultant for this clinic.  Permission to use the GCSI in this setting was 
obtained from the copyright controllers: MAPI Research Trust, France. 
2.11.2 Methods 
Consecutive patients attending the movement disorder clinic from 12th December 
2012 to 3rd April 2013 were asked if they would be willing to complete an gastroparesis 
symptom questionnaire.  Patients were not required to provide written informed 
consent but were clearly told that they were free to decline the offer to complete this 
questionnaire.  Patients were informed that this questionnaire would be analysed 
anonymously alongside the following information: gender, age, disease duration, 
disease stage and current medications.  The GCSI was used to report gastroparesis 
symptom prevalence and severity as previously described in this chapter. 
2.11.3 Statistical analysis 
Statistical analyses were performed using SPSS 19.0 (IBM, SPSS, Chicago, IL, USA) with 
appropriate parametric and non-parametric tests performed as previously described 
(section 2.6). 
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2.11.4 Results 
90 patients, from 13 clinics in a four month period completed the GCSI.  62 patients 
(68.9%) were male.  Age was normally distributed by visual assessment of histograms 
and formal testing (Kolmogorov-Smirnov test P > 0.05).  The mean age of patients was 
66.6 years (SD 9.6).  Analysis of patients revealed one outlier with a disease duration of 
31 years.  It is possible that this case was erroneously diagnosed as idiopathic PD and 
in fact represented a non-neurodegenerative tremor disorder (e.g.: essential tremor).  
Excluding this outlier from analysis, disease duration for the remaining 89 patients was 
non-normally distributed and positively skewed, with a median disease duration of 6.0 
years (IQR 7.5). 
62.9% of patients reported at least one gastroparesis symptom during the preceding 
two week period.  The most commonly reported gastroparesis symptom was feeling 
excessively full after meals, which was reported by 34.8% of all patients (Table 2-27).   
Table 2-27 Frequency and percentage of gastroparesis symptoms reported by 89 PD 
patients attending the movement disorder clinic 
GCSI question / symptom Positive symptoms 
reported  
Q1 Nausea 27 (30.3%) 
Q2 Retching 11 (12.4%) 
Q3 Vomiting 7 (7.9%) 
Q4 Stomach fullness 28 (31.5%) 
Q5 Not able to finish a normal sized meal 28 (31.5%) 
Q6 Feeling excessively full after meals 31 (34.8%) 
Q7 Loss of appetite 23 (25.8%) 
Q8 Bloating 28 (31.5%) 
Q9 Stomach visibly larger 23 (25.8%) 
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Figure 2-12 Number of gastroparesis symptoms reported by each patient 
 
Patients were dichotomised according to their GCSI total score but no statistically 
significant differences were observed between those with high (≥1.90) versus low 
(<1.90) scores (Table 2-28). 
Table 2-28 Comparison of clinic patients with high and low GCSI total scores. 
Variable High GCSI total score 
n = 9 (10.1%) 
Low GCSI total score 
n = 80 (89.9%) 
P value 
Age yrs  62.4 (10.4) 67.2 (9.5) 0.177a 
Male gender (%) 5 (55.6) 56 (70) 0.376b 
Disease duration yrs 4.0 (7.0) 6.0 (8.0) 0.870c 
mH&Y stage:  0 
                         1 
                         1.5 
                         2 
                         2.5 
                         3 
                         4 
                         5 
0 (0) 
4 (44.4) 
0 (0) 
3 (33.3) 
0 (0) 
2 (22.2) 
0 (0) 
0 (0) 
0 (0) 
13 (16.3) 
1 (1.3) 
37 (46.3) 
9 (11.3) 
18 (22.5) 
2 (2.5) 
0 (0) 
0.414b 
Disease stage: 
  Unilateral (mH&Y<2) 
  Bilateral (mH&Y≥2) 
 
4 (44.4) 
5 (55.6) 
 
14 (17.5) 
66 (82.5) 
0.056b 
Bowel frequency: 
                         <1/d 
                         ≥1/d 
 
4 (44.4) 
5 (55.6) 
 
30 (38) 
49 (62) 
0.706b 
Statistical analysis: aindependent t-test, bChi Square test, cMann-Whitney test. 
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The GCSI total scores for the 89 patients considered in this analysis were non-normally 
distributed (Figure 2-13).  The mean GCSI total score was 0.58 (SD 0.76) and the 
median was 0.24 (IQR 0.9). 
Figure 2-13 GCSI total scores for 89 patients attending the Movement Disorder Clinic 
 
The GCSI total score was not significantly affected by patient gender (Mann Whitney 
test P = 0.137), age (Spearman’s correlation P = 0.535) or disease duration (Spearman’s 
correlation P = 0.734).  GCSI total score was not significantly different by modified H&Y 
stage (Kruskall Wallis, P = 0.412) or bowel frequency (Mann Whitney, P = 0.650).  The 
use of levodopa containing medications, dopamine agonists and anticholinergics each 
had no significant effect upon GCSI total score (Mann Whitney, all P>0.05). 
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2.12 Discussion 
This study was a large scale evaluation of gastroparesis symptoms in people with PD.  
We have been able to characterise the prevalence of gastroparesis symptoms in early 
disease, young onset cases and unselected consecutive outpatient attenders.  The data 
obtained from the PRoBaND study is unsurpassed in scale, with gastroparesis symptom 
data available for over 1,000 patients with PD.  This data was obtained from more than 
50 centres around the United Kingdom, minimising geographical or centre bias. 
2.12.1 Gastroparesis symptoms in recently diagnosed PD 
This study involved over 600 patients with early PD, which is the largest study to date 
to assess gastroparesis symptoms in this patient group.  Demographically our 
participants were typical of early disease and comparable with other studies (Khoo et 
al., 2013).  More than half of all recently diagnosed participants reported at least one 
symptom associated with gastroparesis.  Previous cross-sectional studies have 
reported that approximately 30% of PD patients experience GI symptoms at any point 
in time (Martinez-Martin et al., 2007; Rodriguez-Violante et al., 2010).  However, these 
studies focused upon lower GI symptoms with a relative scarcity of questions relating 
to upper GI dysfunction and none specific to gastroparesis.  Our study is the first to 
evaluate the prevalence of upper GI symptoms in early PD in such a large cohort (691 
participants).  Our findings suggest that in early PD, symptoms of upper GI dysfunction 
are common and may be as frequent as lower GI symptoms.  Although more than half 
of patients (62.5%) reported at least one upper GI symptom, only a small proportion of 
participants (4.1%) had abnormally high GCSI total scores consistent with clinically 
significant gastroparesis. 
Most of our a priori hypotheses proved to be correct in participants with a recent 
diagnosis of PD.  Large epidemiological studies have reported that gastroparesis (of all 
aetiologies) is approximately four-times more common in women compared to men 
(Jung et al., 2009).  Therefore, it was hypothesised that the same gender imbalance 
would be evident in the context of PD.  Indeed upper GI symptoms were nearly twice 
as likely to be reported by women compared with men and GCSI total scores were 
significantly higher in female participants. 
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Advancing age appears not to be a major predictor of delayed gastric emptying 
(Madsen and Graff, 2004) and accordingly, as hypothesised we demonstrated no 
relationship between age and severity of gastroparesis symptoms. 
Evidence regarding the effect of disease duration on gastric emptying is conflicting 
(Hardoff et al., 2001; Goetze et al., 2005; Goetze et al., 2006; Tanaka et al., 2011; 
Unger et al., 2011b).  Our a priori hypothesis that disease duration would not 
significantly influence gastroparesis symptoms was correct.  Although disease duration 
and disease severity are inherently linked in this neurodegenerative condition, there is 
evidence to suggest that gastric emptying is slower in more advanced disease stages 
(Goetze et al., 2005; Goetze et al., 2006).  Accordingly we found that gastroparesis 
symptoms were more marked with advancing disease severity. 
In early PD, the PIGD phenotype has been associated with a greater NMS burden than 
the TD phenotype (Khoo et al., 2013).  Therefore, we hypothesised that gastroparesis 
symptoms would be more severe in those with the PIGD phenotype and this was 
indeed borne out in our results.  We hypothesised that those patients with more 
severe NMS (as assessed by the NMSS questionnaire and MDS UPDRS Part I) would be 
more likely to experience gastroparesis symptoms.  Our data support this relationship 
and suggest that gastroparesis symptoms are an important part of the NMS spectrum 
in early disease.  This is a striking finding as gastroparesis symptoms are not included in 
the current NMS questionnaires used commonly in clinical and research settings. 
The aetiology of delayed gastric emptying in PD is unproven but abnormalities in the 
ENS and the DMNV are strongly implicated.  We hypothesised that patients with 
evidence of autonomic dysfunction would be more likely to experience gastroparesis 
symptoms.  The presence of orthostatic hypotension, an example of autonomic 
impairment associated with PD (Allcock et al., 2006) was not significantly associated 
with gastroparesis symptoms.  However, the reporting of autonomic symptoms in the 
SCOPA-AUT questionnaire did strongly correlate with the presence of gastroparesis 
symptoms.  In people with diabetes, gastroparesis has been shown to be associated 
with fatigue (Cherian et al., 2012) and autonomic and cardiac neuropathies (Campbell 
et al., 1977; Bian et al., 2011).  It has been suggested that in diabetes, gastroparesis is 
part of a wider progressive autonomic neuropathy process (Mayaudon et al., 1999).  
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We would speculate based upon our findings that this could also be the case in PD, 
although further study and evaluation is needed to explore this apparent relationship. 
Impaired motility is evident throughout the GI tract in PD (Pfeiffer, 2003).  The 
suggestion that impaired upper and lower GI motility in PD are consequences of the 
same pathophysiology (Cloud and Greene, 2011) underpinned our a priori hypothesis 
that constipation and gastroparesis symptoms would correlate.  This relationship has 
been demonstrated previously in a small number of patients with PD (Unger et al., 
2011b) but ours is the largest study to date to show an association between 
constipation and gastroparesis in PD.  However, given the continuous nature of the GI 
tract it is important to also consider the possibility that constipation results in ‘back-
pressure’ and consequently causes some upper GI symptomatology. 
The relationship between gastroparesis symptoms and mood was not an a priori 
hypothesis.  However, we found that both anxiety and depression were associated 
with higher GCSI total scores, a relationship also described in the context of people 
with diabetes (de Kort et al., 2012).  From our data, it is not possible to further explore 
the directional nature of this relationship.  Participants with anxiety or depression may 
be more likely to report gastrointestinal symptoms or gastroparesis symptoms could 
be a cause of abnormal mood.   
We demonstrated that worse QoL scores were seen in those participants with more 
gastroparesis symptoms.  The extent to which gastroparesis impacts upon QoL cannot 
be fully explored by our current data but is an interesting association which we feel is 
worthy of further evaluation in future research. 
We hypothesised that gastroparesis symptoms and olfactory dysfunction would be 
associated in early PD as the olfactory bulb and gastric ENS are early sites of alpha-
synuclein deposition in PD (Hawkes et al., 2007).  We were unable to demonstrate a 
relationship between hyposmia and gastroparesis symptoms in our study.  However, 
as discussed it may be that gastric dysfunction in early PD is largely asymptomatic.  To 
further explore this relationship, future work could look at paired comparisons of 
olfactory function and gastric emptying speed rather than gastroparesis symptoms. 
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2.12.2 Gastroparesis symptoms in young onset PD 
The PRoBaND study evaluated young onset PD patients, likely to be at greater risk of 
an underlying genetic cause of Parkinson’s.  Genotype was not considered in this thesis 
but it was assumed that a higher frequency of monogenetic cases would be more likely 
in this young onset cohort. 
The median disease duration of participants in this group was 6.7 years, allowing a 
broader evaluation of the effect of disease duration upon gastroparesis symptoms.  
However, our a priori hypothesis that disease duration would not affect gastroparesis 
symptoms still pertained.   
We dichotomised participants into those diagnosed before the age of 40 and those 
diagnosed aged 40 to 50 years old.  The younger the age of onset, the more likely a 
monogenetic aetiology and hence it was postulated that if genetic Parkinsonism 
affected the reporting of gastroparesis symptoms, then comparing groups in this way 
may reveal different symptom burdens.  However, we did not identify any significant 
differences in gastroparesis symptomatology between these two groups. 
Gastroparesis symptoms were more prevalent in the young onset than the recently 
diagnosed cohort of this study (77.6% vs 62.5%) and severe symptoms suggestive of 
gastroparesis were more common in the young onset (12.5%) than in the recently 
diagnosed cases (4.1%).  As advanced disease severity but not age or age of onset were 
shown to impact upon gastroparesis symptoms, it is likely that the greater 
gastroparesis burden in this young onset group is a reflection of their more advanced 
disease stage.  Factors associated with more severe gastroparesis symptoms in young 
onset PD included; more severe non-motor features (MDS UPDRS Part I & NMSS), 
higher MDS UPDRS Part II scores, autonomic symptoms (SCOPA-AUT), laxative use, 
anxiety and depression.  These correlations were largely in line with our a priori 
hypotheses.  
2.12.3 Gastroparesis symptoms in PD patients attending routine clinic follow-up 
This smaller case series (89 patients) was studied to evaluate the prevalence of 
gastroparesis symptoms in a cross-sectional sample of clinic attenders.  A total of 9 
patients (10.1%) had abnormally high GCSI total scores consistent with gastroparesis.  
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However, when potential influencing variables (gender, disease severity, constipation, 
medications) were considered, none significantly correlated with gastroparesis 
symptom severity.  It is most likely that this reflects a lack of statistical power owing to 
the small sample size, rather than a true discrepancy with the previously proven 
hypotheses. 
2.12.4 Strengths and limitations of the study 
The main strength of the recently diagnosed and young onset data, obtained as part of 
the PRoBaND study is the size of the data set; over 1,000 patients.  Gastroparesis 
symptoms in PD have never previously been evaluated on such a large scale.  Another 
important strength of the study is the breath of clinical data collected for comparison 
with the GCSI.  Again, such comparisons have not been undertaken in the previous 
literature relating to gastroparesis in PD. 
One limitation of the study is that it was not possible to measure the gastric emptying 
speed of participants in the PRoBaND study.  Gastric emptying studies are prolonged 
and impractical outside of a specialist research or tertiary clinic setting.  Although the 
GCSI is not a diagnostic tool, it has been validated as a good indicator of patients’ 
symptoms (Revicki et al., 2003) and in the context of diabetes higher GCSI symptom 
scores have been shown to correlate with slower gastric emptying (Olausson et al., 
2013). 
The scale of our study meant that it was not possible to obtain a detailed 
gastrointestinal past medical history from all participants although we were able to 
consider diabetes as a potential confounder.  The study design did not allow for a 
comparator control group at this stage.  However, the within group analyses did allow 
for full testing of all of our a priori hypotheses.  As the PRoBaND study progresses 
some first degree relatives of enrolled PD participants will be recruited for evaluation 
and the GCSI results from these non-PD participants could serve as a control group. 
The evaluation of gastroparesis symptoms in PD patients attending the movement 
disorder clinic was limited by its small scale.  Hence, there was a major limitation with 
regard to statistical power in this study.  However, the evaluation of gastroparesis 
symptoms in unselected PD outpatients is still a valid project and something which we 
hope to integrate into routine clinical practice. 
98 
 
2.12.5 Summary and future directions 
The major finding of this study is that in all stages of PD, including early disease, upper 
GI symptoms are common.  The estimated rates of symptomatic gastroparesis in PD 
are relatively low (4.1 – 12.5%) which is in contrast to the conclusions of a systematic 
review which suggested that 70-100% of all patients with PD are likely to have delayed 
gastric emptying (Heetun and Quigley, 2012).  The apparent disparity between 
measured gastric emptying delay and associated symptoms of gastroparesis is 
interesting but is not unique to patients with PD.  Similar studies in people with 
diabetes have reported the prevalence of significant gastroparesis symptoms to be 
approximately 5-12% (Haans and Masclee, 2007; Kofod-Andersen and Tarnow, 2012).  
Research into gastroparesis in diabetes is more established than in people with PD and 
in diabetic populations a relatively poor relationship between gastric emptying and 
symptoms has been described (Samsom et al., 2009).  Therefore we have concluded 
that whilst delayed gastric emptying is common in PD, much of this dysfunction 
appears to be asymptomatic.  However, this remains an important finding as even 
asymptomatic impairment of gastric motility could have major implications for the 
absorption and action of Levodopa medications. 
The PRoBaND study is on-going at the time of writing this thesis.  Participants in the 
recent onset group will be evaluated prospectively and will complete the GCSI on three 
occasions in total (baseline, 18 month and 36 month visits).  This will allow prospective 
evaluation of changes in gastroparesis symptoms over time which has not previously 
been undertaken in a PD population. 
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Chapter 3 Exploration of a novel treatment for delayed gastric 
emptying in Parkinson’s disease 
3.1 Background 
This chapter describes the interim findings of a phase II study to investigate the effects 
of a novel treatment for gastroparesis in patients with PD, motor fluctuations and 
delayed gastric emptying. 
Delayed gastric emptying can impair the absorption of Levodopa (Muller et al., 2006; 
Doi et al., 2012) and there is evidence to suggest that this may contribute to motor 
response fluctuations associated with long-term Levodopa therapy (Djaldetti et al., 
1996).  Furthermore, the use of prokinetic agents in patients with fluctuations has 
been reported to improve Levodopa absorption and motor function (Neira et al., 1995; 
Nishikawa et al., 2012).  However, currently there are limited options for the 
treatment of delayed gastric emptying in people with PD. 
Camicinal (GSK962040) is a novel motilin agonist which stimulates phase III of the 
MMC in the stomach thereby enhancing gastric emptying.  In initial studies of 
Camicinal in healthy volunteers and people with diabetes it was found to be an 
effective and safe prokinetic agent.  This project was a phase II, double-blind, placebo 
controlled study to assess the safety and efficacy of Camicinal in people with PD.  The 
results presented are part of an interim analysis of the first 15 participants. 
The study began as a single site project in Newcastle in May 2012.  However, in 
November 2012 the study was paused due to issues with the study design.  This 
facilitated a review of the protocol and a major amendment which was implemented 
from May 2013 until October 2013.  This chapter will describe the methods pertaining 
to the original protocol.  Section 3.3.9 explains the changes made during the second 
phase of this project and the rationale behind redesigning the study. 
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3.2 Aims & objectives 
The aim of this study was to perform an interim analysis to evaluate the safety and 
efficacy of Camicinal in people with Parkinson’s disease with motor fluctuations and 
delayed gastric emptying.  The efficacy of Camicinal was evaluated through its effect 
upon the following parameters: 
o Levodopa pharmacokinetics 
o Gastric emptying 
o Gastroparesis symptoms 
o PD motor function 
o PD non-motor symptoms 
o Bowel function 
3.2.1 Hypotheses 
The a priori hypotheses of this study were that, compared with placebo Camicinal 
would: 
 Accelerate gastric emptying. 
 Improve Levodopa absorption. 
 Improve gastroparesis symptoms. 
 Reduce ‘off’ time and increase ‘on’ time 
 Improve MDS UPDRS scores (reflecting improved PD motor and non-motor 
function). 
 Improve constipation problems. 
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3.3 Methods 
This study was conceived by the Worldwide Development Division of GlaxoSmithKline 
(GSK).  Newcastle University contributed to the protocol design and subsequent 
amendments.  It was a single site study, led by Newcastle University and sponsored by 
the pharmaceutical company GlaxoSmithKline (GSK). 
3.3.1 Study design and overview 
This was a randomised, double-blind, placebo-controlled, parallel group, dose ranging 
study to assess the effect of repeated doses of Camicinal (GSK962040) on Levodopa 
absorption in patients with PD, motor fluctuations and delayed gastric emptying. 
Eligible study participants were assigned to one of two treatment groups according to 
the severity of their gastric emptying delay at baseline.  Cohort 1 comprised subjects 
with severely delayed gastric emptying half times (GE t1/2 > 120 minutes).  Cohort 2 
comprised those with moderately delayed gastric emptying (GE t1/2 > 93.1 ≤ 120 
minutes).  Patients in Cohort 1 were randomised to placebo or Camicinal 25mg, 50mg 
or 125mg in a 1:1:1:1 ratio.  Patients in Cohort 2 were randomised to placebo or 
Camicinal 125mg in a 1:1 ratio.  The intention was to recruit 36 participants to Cohort 1 
and 18 to Cohort 2 (Figure 3-1). 
Figure 3-1 Flow diagram summarising participant randomisation and Cohort structure 
 
1:1:1:1 1:1 
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Randomisation of study participants was pre-determined by the study statistician using 
a validated randomisation software package (RandAll).  The randomisation was 
stratified such that the treatment to placebo ratio within each cohort was maintained. 
Eligible study participants were required to attend a total of five study visits over 
approximately a six week period (Figure 3-2).  The primary aim of the screening visit 
was to measure gastric emptying speed alongside evaluation of baseline Levodopa 
absorption, motor function and non-motor features.  If following the screening visit, 
delayed gastric emptying was demonstrated and other eligibility criteria were met, the 
first dosing day took place within 21 days of the screening date.  The total dosing 
period was 8 days (± 1 day).  For the remainder of this report, the first day of dosing 
will be referred to as ‘day 1’ and the final day (7-9 days later) will be referred to as ‘day 
8.’  The screening visit served as a ‘baseline’ assessment for the study and will be 
referred to as such in the results section.  On the fourth day of dosing (± 1 day) blood 
samples were taken for safety and monitoring purposes, given the investigational 
nature of this phase II study.  A fifth and final follow-up visit was performed 14 days (± 
2 days) after the final dosing day. 
Figure 3-2 Summary of study visit schedule 
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The protocol design included plans for an interim analysis once 15 subjects had 
completed the study.  This was intended to assess futility and allow re-estimation of 
the overall sample size, if necessary.  This interim analysis is the basis of this thesis 
report.  Follow-up data was not presented in this thesis however it was analysed by 
the study team and sponsors, with no major problems identified. 
3.3.2 Patient identification and selection 
The study protocol was approved by the NHS Local Research Ethics Committee (NRES 
Committee North East - Newcastle & North Tyneside 1).  Thereafter, approvals were 
obtained from Medicines and Healthcare products Regulatory Agency (MHRA) and the 
Trust Research and Development (R&D) department.  All potential participants were 
patients attending the movement disorder service in Newcastle upon Tyne Hospitals 
NHS Foundation trust. 
Between June 2012 and November 2012 a total of 36 patients were approached 
regarding the study and provided with patient information sheets.  Of these, 9 
consented to participate.  All patients provided written informed consent prior to 
participation in the study. 
3.3.3 Eligibility criteria for the study 
Inclusion criteria: 
1. Diagnosis of idiopathic Parkinson’s disease (according to modified Hoehn & 
Yahr criteria Stages II-IV) and with suboptimal motor control on Levodopa or 
Levodopa combination therapy (i.e. wearing off, peak dose dyskinesias, delayed 
on or no-on effects). 
2. Subjects receiving a stable regimen of Levodopa for at least four weeks prior to 
screening. 
3. Patient has gastroparesis at screening: 
o A patient is eligible for Cohort 1 if the gastric half-time of 
emptying >120.0 min as determined by 13C-oral breath test. 
o A patient is eligible for Cohort 2 if the gastric half-time of 
emptying >ULN (93.1 min) and ≤120.0 min as determined by 13C-oral 
breath test. 
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4. Between 40 and 80 years of age, inclusive. 
5. Patient has never had a gastrectomy, nor major gastric surgical procedure or 
any evidence of bowel obstruction or strictures within the previous 12 months. 
6. Dosage of any concomitant medications has been stable for at least 4 weeks. 
7. A female subject is eligible to participate if she is of: 
a. Non-childbearing potential defined as pre-menopausal females with a 
documented tubal ligation or hysterectomy; or postmenopausal defined 
as 12 months of spontaneous amenorrhea (in questionable cases a 
blood sample will be used to confirm menopausal status). 
b. Child-bearing potential and is abstinent or agrees to use an appropriate 
contraceptive method prior to the study and for at least five days after 
the last dose. 
8. ALT < 2xULN; alkaline phosphatase and bilirubin ≤ 1.5xULN (isolated 
bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin 
<35%). 
9. ECG shows single or average QTc, QTcB or QTcF< 450 msec; or QTc < 480 msec 
in subjects with Bundle Branch Block. 
 
Exclusion criteria: 
1. Late stage advanced subjects with incapacitating peak dose or biphasic 
dyskinesia on a stable Levodopa regime. 
2. Presence, or history within the previous 3 months, of significant and/or 
uncontrolled psychiatric, neurological (other than Parkinson’s disease), gastro-
intestinal, haematological, endocrine, neurological (other than Parkinson’s 
disease),cardiovascular disease, active malignancy (other than basal cell cancer) 
or other condition that would in the opinion of the investigator or medical 
monitor make the subject unsuitable for inclusion in this clinical study. 
3. A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody 
result within 3 months of screening. 
4. Patient has a gastric pacemaker. 
5. Patient is on chronic enteral or parenteral feeding. 
6. Patient has evidence of severe cardiovascular autonomic neuropathy (e.g. 
history of recurrent syncope in the last 6 months). 
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7. Estimated or measured glomerular filtration rate ≤ 30 mL/min. 
8. Current or chronic history of liver disease, or known hepatic or biliary 
abnormalities (with the exception of Gilbert's syndrome or asymptomatic 
gallstones). 
9. Pregnant females as determined by positive serum or urine hCG test at 
screening or prior to dosing. 
10. Lactating females. 
11. Unable to refrain from consumption of red wine, Seville oranges, grapefruit or 
grapefruit juice from 7 days prior to the first dose of study medication until 
follow-up. 
12. Use of medications potentially influencing upper gastrointestinal motility or 
appetite within one week of the study (e.g., prokinetic drugs, macrolide 
antibiotics (erythromycin), GLP-1 mimetics). 
13. Unable to refrain from use of prohibited medications (listed in Appendix C) 
within the restricted timeframe relative to the first dose of study medication. 
14. The patient has participated in a clinical trial and has received an 
investigational product within the following time period prior to the first dosing 
day in the current study: 30 days, 5 half-lives or twice the duration of the 
biological effect of the investigational product (whichever is longer). 
15. History of sensitivity to any of the study medications, or components thereof or 
a history of drug or other allergy that, in the opinion of the investigator or GSK 
Medical Monitor, contraindicates their participation. 
16. Where participation in the study would result in donation of blood or blood 
products in excess of 500 mL within a 56-day time-period. 
3.3.4 Study visits and general procedures for participants 
All consented and eligible study participants attended for five visits as previously 
outlined (Figure 3-2).  For three of these visits (screening / baseline, day 1 and day 8), 
participants were required to attend the research unit in the morning, having fasted 
overnight and omitted all morning medications.  The overnight fast was necessary in 
order to accurately evaluate gastric emptying speed and the omission of medications 
prior to arrival ensured that baseline assessments were performed in a clinically 
defined ‘off’ state.  At each visit, patients took their usual Levodopa containing 
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medications at a specified time: referred to as time 0.  Thereafter, serial assessments 
were undertaken to measure: Levodopa absorption, gastric emptying and motor 
function.  The timings of all assessments were in minutes, relative to the time of the 
levodopa dose (at time 0) such that a timed assessment 10 minutes prior to Levodopa 
dosing would be at time ‘-10 minutes’. 
At the screening visit, after obtaining written informed consent, a full medical history 
was obtained and details of all current medications were recorded.  A detailed, 
systematic physical examination was performed alongside measurement of postural 
blood pressure (after lying for at least five minutes and standing for three minutes).  
Participants’ height and weight were also recorded.  A 12 lead electrocardiogram (ECG) 
was performed prior to Levodopa ingestion and again at time 0.  Baseline urinalysis 
and blood sampling (including for Hepatitis B and C testing) was performed prior to 
Levodopa dosing on the screening day.  In female participants with reproductive 
capacity (i.e. pre-menopausal with an intact uterus) pregnancy testing (urinary HCG) 
was performed. 
One of the main aims of the screening visit was the evaluation of gastric emptying 
speed.  Gastric emptying was measured with breath testing after a 13C-labelled meal 
which was ingested 10 minutes prior to Levodopa dosing.  Details of the gastric 
emptying breath test are summarised in section 3.3.5. 
After Levodopa dosing, motor function was evaluated serially over the next four hours.  
The MDS UPDRS Part III was repeated on three occasions (120, 180 and 240 minutes 
post-Levodopa).  Motor function was also evaluated with finger tap testing.  This 
required the patient to alternately tap two counters mounted 30 cm apart (Figure 3-3), 
as many times as possible in 60 seconds.  Participants were asked to perform this with 
the same hand: the more affected side or dominant hand in the case of symmetrical 
disease).  This test was repeated twice at 8 specified time points (-90, 0, 30, 60, 90, 120, 
180 and 240 minutes).  Mean scores for each time point were analysed. 
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Figure 3-3 Picture of the finger tap assessment board  
 
Throughout the assessment period, participants were asked to remain in bed in a semi-
supine position (45 degree angle).  They were also asked not to consume any food 
other than the test meal and were asked only to drink 180 ml of tap water.  
Additionally, where possible only Levodopa based medications were taken at time 0 
and other parkinsonian medications (dopamine agonists, monoamine oxidase B-
inhibitors etc.) and second doses of Levodopa were withheld until the end of the four 
hour assessment period.  This restriction was in place to facilitate paired motor and 
pharmacokinetic assessments as patients transitioned from the ‘off’ state, to ‘on’ and 
then ‘off’ again towards the end of the visit.  At the end of the four hour testing period, 
participants were allowed to eat and drink normally and were encouraged to take any 
usual medications which had been omitted that morning.  Table 3-1 summarises the 
procedures performed during the screening / baseline assessment. 
The sequence of assessments and procedures performed on days 1 and 8 were largely 
similar to those described for screening.  The main difference from screening was that 
the study medication was given 90 minutes prior to ingestion of Levodopa and 
additionally four plasma samples for pharmacokinetic testing were obtained prior to 
time 0.  Table 3-2 summarises the sequence of assessments and procedures performed 
on dosing days. 
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Table 3-1 Screening / baseline visit: assessments and procedures 
 Time (min) 
 Pre-
Dose  
-90 
min 
-10 
min 
0 
min 
15 
min 
30 
min 
45 
min 
60 
min 
90 
min 
120 
min 
150 
min 
180 
min 
210 
min 
240 
min 
Post 
Testing 
Complete physical examination                
12-lead ECG                
Blood pressure, height & weight                
Medication Review                
Urinalysis  & blood tests                
13C breath test                 
PK blood sample                
Levodopa dose                
Test Meal                
Full MDS-UPDRS evaluation                
MDS UPDRS Part III                
Finger taps                
End of Fasting period                
PK = pharmacokinetic 
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Table 3-2 Dosing days 1 and 8: assessments and procedures 
 Time (min) 
 Pre-
Dose  
-90 
min 
-75 
min 
-60 
min 
-30 
min 
-10 
min 
0 
min 
15 
min 
30 
min 
45 
min 
60 
min 
90 
min 
120 
min 
150 
min 
180 
min 
210 
min 
240 
min 
Post 
Testing 
Brief physical examination                   
12-lead ECG                   
Blood pressure, height & weight                   
Urinalysis  & blood tests                   
AE assessment                    
Medication Review                   
13C breath test                    
PK blood sample                   
Levodopa dose                   
Study Treatment Dosing                   
Test Meal                   
Full MDS-UPDRS evaluation                   
MDS UPDRS Part III                   
Finger taps                   
End of Fasting period                   
AE = adverse events 
PK = pharmacokinetic 
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3.3.5 Measurement of gastric emptying speed 
Gastric emptying was measured using a 13C oral breath test following a labelled test 
meal.  The test meal was a standardised breakfast consisting of scrambled egg labelled 
with 13C-Spirulina plantensis, six Saltine Crackers and 180ml of tap water at room 
temperature.  The meal was consumed by all participants within 10 minutes and none 
reported significant dysphagia. 
Spirulina plantensis is a non-radioactive, algae-based substance which can be taken as 
a health food supplement.  Breath testing kits and sample analysis were provided by 
GSK and Advanced Breath Diagnostics, Nashville, TN, USA. 
The 13C-Spirulina breath test has previously been validated through comparison with 
scintigraphy (Lee et al., 2000).  After ingestion 13C is absorbed in the intestine, oxidised 
in the liver and excreted in the breath (Perri et al., 2005).  Serial measurement of 13C in 
expired breath is therefore a surrogate marker of gastric emptying speed. 
Standardised test kits were provided by ABDiagnostics (Figure 3-4).  Two baseline 
breath samples were obtained in the fasting state, prior to ingestion of the test meal.  
Following consumption of the 13C-Spirulina plantensis labelled test meal, serial breath 
sampling was performed at designated time intervals up to four hours after 
consumption of the meal (30, 45, 60, 90, 120, 150, 180, 210 and 240 minutes post-
meal).  This collection sequence was followed at screening and dosing visits.  
Contained breath samples were stable stored at room temperature for up to four 
weeks.  However, transport of samples to the ABD Diagnostics laboratories in Nashville 
was typically arranged within 48 hours of sampling. 
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Figure 3-4 Spirulina gastric emptying testing kit (courtesy of ABDiagnostics) 
 
Serial measurement of the 13C content of expired breath allowed the calculation of the 
gastric emptying half time (GE t1/2).  Higher GE t1/2 scores represented slower gastric 
emptying.  Patients in cohort 1 had a GE t1/2 of > 120 minutes and patients in cohort 2 
had a GE t1/2 of >93.1 and ≤ 120 minutes.   
3.3.6 Clinical assessments 
Throughout the study period standardised assessments were used to assess: motor 
function, non-motor symptoms and gastroparesis symptoms as outlined below. 
Motor and non-motor symptoms 
The MDS-UPDRS (Goetz et al., 2008) is a validated tool for the assessment of the motor 
and non-motor features of PD.  The MDS UPDRS was administered by trained and 
experienced raters.  The full MDS UPDRS was performed at screening / baseline, day 1, 
day 8 and follow-up. 
Additionally patients were asked to complete a daily diary, recording their motor 
symptoms when at home.  This diary asked patients, for each 30 minute period of the 
day and night, to report their motor state as one of the following: 
 ‘Off’: time when the medication has worn off and is no longer providing benefit 
with regard to mobility, slowness and stiffness. 
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 ‘On’ without dyskinesia: time when medication is providing benefit with regard 
to mobility, slowness and stiffness. 
 ‘On’ with non-troublesome dyskinesias: dyskinesia does not interfere with 
function or cause meaningful discomfort. 
 ‘On’ with troublesome dyskinesias: interferes with function and causes 
meaningful discomfort. 
 Asleep 
 
Gastroparesis symptoms 
Gastroparesis symptoms were assessed using the Gastroparesis Cardinal Symptom 
Index Daily Diary (GCSI-DD) (Revicki et al., 2009) (Appendix B).  This daily equivalent of 
the nine item self-reported GCSI (which was described extensively in the previous 
chapter), has been validated as a reliable tool for assessing gastroparesis symptoms 
and importantly it has been shown to be responsive to change and hence suitable for 
use in an interventional research study setting (Revicki et al., 2012). 
Patients were asked to complete the GCSI-DD after their evening meal, every night for 
one week following the screening visit, every evening in the dosing week and every 
evening in the two week follow-up period.  Clear verbal and written instructions were 
given regarding how to complete the GCSI-DD and the completed diaries were 
reviewed with participants at each subsequent study visit. 
3.3.7 Study drug 
The following details regarding the study drug have been provided by the 
manufacturer and study sponsor GlaxoSmithKline. 
Camicinal (GSK962040) is a novel motilin agonist believed to enhance gastric emptying 
through a stimulatory effect on phase III of the gastric MMC.  Single and repeated oral 
dosing for periods of up to 14 days in healthy volunteers and patients with type 1 
diabetes have been safe and as well-tolerated as placebo.  Pharmacokinetic 
parameters from these studies have been reported to be dose proportional up to a 
maximum studied dose of 150mg daily.  Improvement in gastric emptying speed has 
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also been described as dose proportional in these initial studies, with mean reduction 
in GE t1/2 of 30-64% compared with placebo. 
The study medication is primarily metabolised by the liver, hence the need to exclude 
patients with underlying significant hepatic impairment at baseline.  Liver function 
tests were performed at all study visits.  Renal elimination is estimated to account for 
approximately 30% of the metabolism of Camicinal.  Patients with an estimated 
glomerular filtration rate (eGFR) of less than 30ml/min were excluded from 
participation in the study. 
3.3.8 Pharmacokinetic analysis 
Plasma samples for pharmacokinetic analysis were obtained serially at screening, and 
on dosing days (Figure 3-5).  At baseline (screening) one sample was taken prior to 
Levodopa ingestion (-90 minutes) and at 10 time points post-dosing (15, 30, 45, 60, 90, 
120, 150, 180, 210 and 240 minutes).  On dosing days 1 and 8 the same sequence of 
post-Levodopa sampling was followed however in the pre-dose period four plasma 
samples were obtained (-90, -75, -60 and -30 minutes). 
Figure 3-5 Time points for plasma pharmacokinetic sampling 
 
-90 -60 -30 0 30 60 90 120 150 180 210 240 Time (minutes) 
screening
dosing days
Levodopa ingestion 
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Two pharmacokinetic measures of Levodopa absorption were evaluated in this study.  
The maximum plasma levodopa concentration (Cmax) measured in the post-dosing 
period at each assessment visit was reported.  A second measure of Levodopa 
absorption; the area under the curve (AUC) was also reported across four time points 
(in hours) post Levodopa ingestion: AUC(0-0.5), AUC(0-1), AUC(0-2) and AUC(0-4). 
3.3.9 Study progression, evaluation and re-design 
Recruitment to the study began in May 2012.  By November 2012 a total of 36 patients 
had been approached and provided with written information regarding the study.  A 
total of 9 patients consented to participate and attended for screening.  The remaining 
27 were not enrolled in the study for the following reasons: 
 Prescribed a prohibited concomitant medication (n = 8) 
 Comorbid illness limiting participation in the study (n = 7) 
 No significant motor fluctuations at the time of evaluation (n = 3) 
 Patient not interested in participation (n = 9) 
One of the 9 participants withdrew from the study mid-way through the screening visit 
as the patient had a delayed ‘on’ during the visit and felt unable to continue with the 
assessments.  Of the remaining 8, two had GEt1/2 > 93.1 minutes and therefore delayed 
gastric emptying as defined by the study protocol.  One of these two participants was 
randomised to active treatment (125mg Camicinal / GSK962040) and one received 
placebo.  These recruitment rates were lower than had been anticipated.  This 
prompted a review of the study design by the team at Newcastle University and GSK. 
Additionally, in November 2012, GSK reviewed interim results from a study of 
Camicinal in patients with diabetes and delayed gastric emptying.  This analysis 
showed that whilst the 125mg dose of Camicinal was well tolerated, the exposure to 
the drug was more variable than anticipated.  Pharmacokinetic analysis of some 
individuals revealed higher exposure levels at the 125mg dose than expected.  
Therefore, the sponsors decided to pause the study and amend the protocol such that, 
as a precautionary measure, the Camicinal 125mg dose was removed from the PD 
study. 
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These two events led to a major protocol amendment which was approved by REC and 
the MHRA in April of 2013.  The methods and study procedures were largely 
unchanged however the following adjustments were implemented in the revised 
protocol: 
1. Gastric emptying criteria for entry into the study were changed from > 93.1 
minutes to GEt1/2 ≥ 70 minutes. 
2. The dose-ranging aspect of the study design was removed and instead a single 
dose of Camicinal (50mg) was compared with placebo (randomised in a 2:1 
ratio). 
3. The two cohort design was removed.  However, participants were 
dichotomised according to the severity of gastric emptying delay (‘Moderate’: 
GEt1/2 ≥ 70 but ≤ 100 min or ‘Severe’: GEt1/2 > 100 min).  Randomisation of 
participants to the treatment and placebo groups was stratified such that an 
even distribution of ‘Moderate’ and ‘Severe’ cases was assigned to each of the 
study arms. 
4. The study was extended from a single centre to involve additional UK and 
international sites (Norwich, Cambridge, Australia and Sweden). 
5. Within in the North East of England, additional participant identification 
centres (PIC sites) were approved to identify potential participants from other 
regional movement disorder clinics. 
Recruitment to the study according to this revised protocol began in May 2013.  Figure 
3-6 summarises study activity (under both protocols) from May 2012 until September 
2013. 
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Figure 3-6 Summary of study activity according to protocol version and study site 
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Between May 2013 until September 2013, 56 patients from Newcastle and the North 
East were approached and provided with details of the study.  14 patients consented 
and attended for screening and a further two agreed to participation but had not 
completed the study at the time of this analysis.  A total of 40 patients were ineligible 
or uninterested in the study for the following reasons: 
 Prescribed a prohibited concomitant medication (n = 4) 
 Comorbid illness limiting participation in the study (n = 4) 
 No significant motor fluctuations (n = 3) 
 Participating in another on-going trial (n = 1) 
 Patient not interested in participation (n = 15) 
 Unable to contact in person / did not respond to invitation (n = 13) 
Of the 14 subjects screened in Newcastle, 11 had delayed gastric emptying (GEt1/2 ≥ 70 
min) and three did not.  One of the 11 eligible patients withdrew after randomisation 
but prior to dosing.  This was due to an acute episode of ill-health (urinary sepsis and 
urinary retention) which was unrelated to the patient’s PD or any of the study 
procedures.  In Newcastle, eight participants were randomised to Camicinal 50mg once 
daily and two were randomised to placebo once daily.  Dosing was double blinded and 
the blind was maintained throughout the study. 
In the additional study centres, over the same time period five subjects were 
consented and screened.  Four had delayed gastric emptying (GEt1/2 ≥ 70 min) and one 
did not.  Two of these subjects received Camicinal 50mg once daily and two received 
placebo once daily. 
A summary of the baseline gastric emptying rates for all screened participants can be 
found in Appendix C.  The range of gastric emptying rates measured at screening is 
represented graphically in Figure 3-7. 
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Figure 3-7 Gastric emptying rates for all consented participants  
 
 
The interim analysis, which forms the basis of this thesis report, considered the first 15 
subjects to complete the study.  Newcastle contributed 11 of these 15 cases.  Data 
from the Newcastle subject (recruited under protocol 1) who received 125mg 
Camicinal is not analysed in this thesis.  The subject experienced no adverse events.  
However, the dose this subject received is not directly comparable with the 50mg dose 
taken by the other 10 subjects.  The participant who received placebo under protocol 
version 1 was included in the interim analysis as their study schedule was comparable 
with that of subjects who received placebo according to protocol 2. 
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3.4 Statistical analysis 
Statistical analyses were performed using SPSS 19 (SPSS, Chicago, IL).  Descriptive 
analyses were used to report trends in the data between groups and within groups.  
Graphical representations of group means and standard deviations are presented to 
support the description of trends. 
Given the small sample size non-parametric tests were used to compare the study 
groups.  Medians were reported with the appropriate interquartile range.  Comparison 
of medians between the treatment and placebo groups was undertaken with the 
Mann-Whitney test.  Paired comparisons within groups over time were performed 
with the Wilcoxon signed rank test.  Comparison of proportions between groups was 
undertaken with Chi square testing. 
For each statistical analysis, a P value of < 0.05 was deemed significant.  Due to the 
small sample size and exploratory nature of this study, no statistical adjustments for 
multiple testing were applied.  Additionally, non-significant trends in the data were 
described as these were considered pertinent to the wider on-going study. 
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3.5 Results 
3.5.1 Baseline characteristics of study participants 
The mean age of the 15 participants was 64.40 (± 10.32) years (range 45 – 80).  All 15 
participants were of Caucasian origin.  There were 9 male participants in the study 
(60%).  Comparison of the treatment and placebo groups showed no significant 
differences in baseline demographics (Table 3-3). 
Table 3-3 Comparison of the treatment and placebo groups according to baseline 
demographic features 
Clinical features Placebo group 
(n = 5) 
Treatment group 
(n = 10) 
P value 
Age (years) 68.60 (8.08) 62.3 (11.05) 0.281a 
Gastric emptying (GEt1/2 minutes) 96.60 (19.58) 94.00 (15.46) 0.782
a 
Number of male participants (%) 2 (40%) 7 (70%) 0.329b 
BMI 27.10 (5.83) 25.55 (2.58) 0.594a 
Orthostatic hypotension present 0 (0%) 2 (20%) 0.524b 
Data presented as mean (standard deviations).  Statistical comparisons: aIndependent t-test, 
bChi square test. 
 
Past medical history of important co-morbidities was recorded for each participant.  
None of the 15 subjects had a current history of angina but one had a past history of 
angina.  No subjects reported any history of myocardial infarction or stroke.  One 
participant had treated hypertension.  Three participants had treated hyperlipidaemia.  
One subject had diabetes, a recognised cause of gastroparesis however their degree of 
gastric emptying delay (GEt1/2 101 minutes) was not particularly longer than that of the 
remainder of the screened population (Figure 3-7). 
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3.5.2 Effect of Camicinal on Levodopa pharmacokinetics 
The Levodopa pharmacokinetic end-points evaluated in this study were the area under 
the curve (AUC) and the maximum plasma concentration (Cmax). 
Plasma Levodopa AUC for 0-0.5 hours, 0-1 hour, 0-2 hours and 0-4 hours were 
calculated for each participant at baseline, day 1 and day 8.   As all subjects had 
different Levodopa equivalent doses, the AUC values were dose-normalised.  For each 
participant, the changes in AUC over time were plotted and visually inspected to assess 
for trends in the data (Appendix C).  Given the small sample size, inspection on a case 
by case basis was an important step prior to analysis of whole group trends. 
It was noted that for six of the 10 participants in the treatment group (subject nos: 10, 
11, 14, 15, 19, 101), there was a trend towards increased AUC in the first 2 hours on 
days 1 and 8, relative to baseline.  This suggested quicker absorption of Levodopa 
during the dosing period in these subjects.  In the remaining four participants in the 
treatment group (subject nos: 401, 16, 20, 22), AUC on the dosing days was either 
unchanged or decreased relative to baseline. 
In the placebo group, four of the five subjects (subject nos: 2, 13, 18, 202) had 
relatively unchanged or decreased AUC levels in the dosing period compared to 
baseline.  Only one subject’s AUC increased on placebo compared to baseline (subject 
no: 201). 
Comparison of mean AUC levels over time suggested no significant differences 
between the treatment and placebo groups at any of the three visits (Figure 3-8).  
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Figure 3-8 Mean Levodopa AUC levels over time by study group and visit day 
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Comparison of the placebo and treatment arms for change in AUC over time showed 
no significant differences between the groups at any time point on either day 1 or day 
8 relative to baseline (Table 3-4). 
Table 3-4 Inter-group comparisons of change in Levodopa AUC from baseline to dosing 
days 1 and 8 
Dose normalised Change in L-dopa AUC from baseline to day 1 
Levodopa AUC 
(ng.h/ml/mg) 
Placebo arm 
n = 5 
Treatment arm 
n = 10 
P value 
AUC: time 0-0.5 hr 0.20 (2.06) 0.39 (1.76) 0.327 
AUC: time 0-1 hr -1.95 (6.21) 1.49 (5.57) 0.086 
AUC: time 0-2 hr -0.49 (7.21) 2.66 (8.71) 0.462 
AUC: time 0-4 hr 0.28 (8.24) -0.14 (11.26) 0.391 
Dose normalised Change in L-dopa AUC from baseline to day 8 
Levodopa AUC 
(ng.h/ml/mg) 
Placebo arm 
n = 5 
Treatment arm 
n = 10 
P value 
AUC: time 0-0.5 hr -0.43 (2.31) 0.04 (1.65) 0.327 
AUC: time 0-1 hr -1.76 (8.82) 0.70 (6.41) 0.142 
AUC: time 0-2 hr -1.00 (15.16) 1.10 (12.20) 0.713 
AUC: time 0-4 hr -1.51 (15.44) -2.99 (16.85) 0.391 
Data are presented as median (interquartile range).  Comparison of medians with the Mann-
Whitney test. 
 
Cmax was calculated as a second measure of Levodopa absorption.  Changes in Cmax 
over the three assessment days were examined visually for each individual in the 
treatment group (Figure 3-9) and placebo group (Figure 3-10).  The change in Cmax 
from baseline to day 8 was compared across the groups.  In the placebo group the 
Cmax fell from baseline to day 8 (median change -2.93 ± 6.90 ng/mL/mg).  In the 
treatment group there was a modest increase in Cmax (median change 0.36 ± 7.74 
ng/mL/mg).  However, the trend towards an increased Cmax in the treatment group 
relative to placebo was not statistically significant (Mann-Whitney, P = 0.462). 
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Figure 3-9 Changes in Cmax over time for each participant in the treatment group 
 
 
Figure 3-10 Changes in Cmax over time for each participant in the placebo group 
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3.5.3 Effects of Camicinal on gastric emptying 
Gastric emptying half time (GEt1/2) was calculated for each subject at each visit.  Higher 
scores represented more severe gastric emptying delay.  The change in GEt1/2 for each 
participant was plotted according to their study group.  Visual inspection of plots for 
participants on active treatment (Figure 3-11) suggested relatively static GEt1/2 levels 
throughout the study.  In some cases there was a modest reduction in GEt1/2 over the 
dosing period which was in keeping with our a priori hypothesis that Camicinal would 
enhance gastric emptying.  However, one subject (subject no: 101) had a marked 
increase in GEt1/2 on day 8, representing slower gastric emptying than baseline.  This 
was an unexpected finding which could not be clearly accounted for.  This anomaly 
was strikingly different to the trend seen in the remainder of the group.  Therefore, 
this outlier case was excluded from subsequent whole group analyses.  Visual 
inspection of the GEt1/2 levels for the placebo group (Figure 3-12) showed some 
variation in gastric emptying over time, perhaps reflecting the fact that even in healthy 
subjects, there is inherent intra-individual heterogeneity in gastric emptying speed. 
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Figure 3-11 Gastric emptying (GE) half times according to assessment visit for 
participants in the treatment group 
 
 
Figure 3-12 Gastric emptying (GE) half times according to assessment visit for 
participants in the placebo group 
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The relative change in GEt1/2 (as a percentage change from baseline to day 8) was 
analysed for each participant.  There was a trend towards a greater reduction (quicker 
gastric emptying) in the treated participants compared with the placebo group (Figure 
3-13). 
Figure 3-13 Comparison of treatment and placebo groups according to percentage 
change in gastric emptying from baseline to day 8 
 
Individual points represent the relative change in GEt1/2 for each subject according to 
treatment group.  Error bars represent group means and standard deviations. Subject 101 
excluded. 
 
In the treatment group, the GEt1/2 fell by an average of 13.75% (median) from baseline 
to day 8, representing approximately a 14% improvement in gastric emptying in the 
treatment group during the dosing period.  There was also an improvement in gastric 
emptying in the placebo group over the same period (median GEt1/2 change of -0.92%).  
Although gastric emptying speed improved more in the treatment than the placebo 
group, the difference was not statistically significant (Mann-Whitney, P = 0.217). 
-40
-30
-20
-10
0
10
20
30
40
50
60
%
 c
h
an
ge
 in
 G
Et
1
/2
 f
ro
m
 b
as
el
in
e 
to
 d
ay
 8
 
Treatment Placebo 
128 
 
It was postulated that participants with the slowest gastric emptying at baseline would 
show the greatest response to treatment with Camicinal.  Therefore the percentage 
change in GEt1/2 from baseline to day 8 was compared with absolute GEt1/2 levels at 
baseline (Figure 3-14).  Although there was a trend towards a greater reduction in 
GEt1/2 in those participants of the treatment group with worse gastroparesis at 
baseline, the same trend was also evident in the placebo group. 
Figure 3-14 Graph representing the effect of baseline gastroparesis severity upon 
change in gastric emptying half time in response to Camicinal or placebo 
  
Data points represent individual study participants.  Lines of best fit represent trends (linear 
regression) for each group. 
 
It was postulated that Camicinal would improve Levodopa absorption through 
enhanced gastric emptying.  Therefore, the relationship between dose adjusted 
plasma Levodopa AUC levels and gastric emptying rates were examined for serial 
paired measurements in the Camicinal treated group.  The expectation was that longer 
GEt1/2 times would correlate with lower AUC levels and this was indeed the case 
(Pearson Correlation coefficient -0.334, 1-tailed significance P = 0.036). 
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3.5.4 Effects of Camicinal on gastroparesis symptoms 
The effect of Camicinal on the symptoms of gastroparesis was assessed via patients’ 
responses on the GCSI daily diary.  For each of the 15 study participants, mean 
gastroparesis symptom scores at baseline (screening week) were compared with mean 
scores for the final two days of the dosing period.  Each symptom was scored on a 
standardised scale (from 0 to 5) with higher scores representing more severe 
gastroparesis symptoms.  If the average score fell by at least one point, this was 
deemed ‘Improved’  if the average score rose by at least one point it was deemed 
‘Deteriorated’ whilst intermediate scores were deemed ‘No change.’ 
For each participant, the relative change in symptoms is summarised in Figure 3-15.  In 
most participants, symptoms were unchanged from baseline.  Two of the 10 
participants on active treatment had improvement in at least two symptoms (subject 
nos: 10 and 101).  In the placebo group, none of the five participants had improvement 
in two or more symptoms. 
 
130 
 
Figure 3-15 Representation of relative change in mean GCSI-DD symptom scores from 
baseline to end of dosing period 
Subject 
number 
GCSI-DD question number 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Participants on active treatment 
401               
10               
11               
14               
15               
16               
19               
20               
22               
101               
Participants on placebo 
2               
13               
18               
201               
202               
GCSI-DD questions by number: 
1: Episodes of vomiting 
2: Episodes of retching 
3: Nausea 
4: Excessively full after meals 
5: Bloating 
6: Early satiety 
7: Retching 
8: Vomiting 
9: Stomach or belly visibly larger 
10: Stomach fullness 
11: Loss of appetite 
12: Upper abdominal pain 
13: Upper abdominal discomfort 
14: Overall severity of gastroparesis 
Key: 
Improved symptom 
No change 
Deteriorated symptom 
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For each participant, symptom scores were combined to give mean severity scores for 
the three gastroparesis symptom clusters: 1) nausea & vomiting, 2) fullness, 3) 
bloating.  Additionally, a global severity score (the GCSI total score) was calculated for 
each participant.  Non-parametric tests were performed to compare changes in these 
scores over time (Table 3-5).  In the treatment group there was a trend towards 
improved fullness and bloating in the dosing period relative to baseline however the 
differences were not statistically significant.   
Table 3-5 Change in symptom scores from baseline to dosing by treatment group 
Symptom cluster Screening week  Dosing week  P value 
                               Treatment group (n = 10) 
Nausea & vomiting 0.00 (0.24) 0.00 (0.06) 0.144 
Fullness 0.22 (0.52) 0.04 (0.64) 0.263 
Bloating 0.43 (1.37) 0.00 (0.98) 0.173 
GCSI total score 0.45 (0.69) 0.70 (0.52) 0.128 
                               Placebo group (n = 5) 
Nausea & vomiting 0.00 (1.08) 0.10 (1.19) 0.180 
Fullness 2.21 (3.02) 1.96 (2.67) 0.273 
Bloating 1.86 (2.75) 2.00 (2.69) 0.655 
GCSI total score 1.63 (2.14) 1.54 (2.06) 0.273 
Data presented as group medians (interquartile range) with intra-group comparisons via the 
Wilcoxon signed rank test. 
 
132 
 
3.5.5 Effects of Camicinal on motor function 
MDS UPDRS Part III 
The MDS UPDRS Part III (motor examination) was undertaken on each assessment day 
just prior to dosing with Levodopa (time 0) and then at three further time points; 120, 
180 and 240 minutes later.  Mean MDS UPDRS Part III scores for the treatment and 
placebo groups at each time point were compared graphically (Figure 3-16).
Figure 3-16 MDS UPDRS Part III scores over time for the treatment and placebo groups 
 
Data points represent group means and standard deviations at each time point. 
 
For each participant, the mean MDS UPDRS Part III score over the post-dosing period 
(times: 120, 180 and 240 minutes) for each visit was calculated.  The change in average 
score from baseline to day 8 was plotted for each participant according to study group 
(Figure 3-17).  There was a trend towards decreased MDS UPDRS Part III scores, 
representing improved motor function (median change from baseline to day 8 was -
0.67 ± 3.58) whilst in the placebo group there was a trend towards deteriorating scores 
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over the dosing period (median change 6.33 ± 17.00) however the difference between 
the two groups was not statistically significant (Mann-Whitney, P = 0.086). 
Figure 3-17 Change in MDS UPDRS Part III scores from baseline to day 8 
 
The average change in MDS UPDRS Part III score within each group over the course of 
the study was analysed.  For those participants given placebo, the group median score 
at baseline (28.33) was not significantly different to that at day 8 (42.67) (Wilcoxon 
signed rank test, P = 0.08).  However, the median scores for the treatment group were 
significantly lower on day 8 than at baseline (26.17 vs 28.00, Wilcoxon signed rank test, 
P = 0.007). 
-10
-5
0
5
10
15
20
25
30
C
h
an
ge
 in
 M
D
S 
U
P
D
R
S 
P
ar
t 
II
I s
co
re
 f
ro
m
 b
as
el
in
e 
to
  d
ay
 8
 
Treatment Placebo 
134 
 
Finger taps 
Mean finger tap frequency at each time point was used as a surrogate marker of 
bradykinesia severity.  Absolute scores varied considerably across the 15 participants, 
therefore the data was analysed as percentage change relative to the score at time 0 
(Figure 3-18).
Figure 3-18 Percentage change in finger tap frequency relative to time 0 at each study 
visit 
 
Data points represent group means with standard deviations. 
 
Comparison of average finger tap frequencies for the placebo and treatment groups at 
the baseline visit, showed no significant inter-group difference (medians 70.5 and 
80.07 respectively, Mann-Whitney test, P = 0.462).  The difference between the two 
groups had increased by day 8 with a higher average finger tap frequency in the 
treatment group but again, relative to placebo, the difference was not statistically 
significant (medians 95.45 and 67.79 respectively, Mann-Whitney test, P = 0.221). 
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Intra-group comparisons showed a non-significant trend towards greater finger tap 
frequency on day 8 in the treatment group relative to the baseline visits (Table 3-6). 
Table 3-6 Comparison of finger tap frequency from baseline to day 8 
Study group: Baseline Day 8 P value 
Placebo 70.50 (17.25) 67.79 (20.78) 0.686 
Treatment 80.07 (46.44) 95.45 (27.99) 0.173 
Data are presented as median (interquartile range) with paired comparisons using the 
Wilcoxon signed rank test.
  
Motor symptom diaries 
Participants reported their motor state in daily diaries completed throughout the 
dosing period and for 48 hours after screening.  The mean number of hours spent in 
the ‘off’ state during the screening and dosing periods was compared (Figure 3-19) 
with a trend towards a reduction in ‘off’ time in the treatment group during the dosing 
period. 
Figure 3-19 Bar chart comparing hours spent in the ‘off’ state during the screening and 
dosing periods 
 
The treatment and placebo groups were compared with regard to percentage change 
in ‘off’ time from baseline to day 8.  In the placebo group; from baseline to day 8, ‘off’ 
time increased (median increase 9.77% relative to baseline) whilst in the treatment 
group ‘off’ time reduced (median decrease from baseline to day 8: 12.61%).  However, 
this difference was not statistically significant (Mann-Whitney test, P = 0.270). 
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Intra-group comparisons of average time spent ‘off’ in the screening and dosing 
periods revealed no significant difference for the placebo group (Wilcoxon signed rank 
test, P = 0.345) or treatment group (Wilcoxon signed rant test, P = 0.445). 
Patient diaries subdivided periods spent in the ‘on’ state into ‘on’ without dyskinesias, 
‘on’ with non-troublesome dyskinesias, and ‘on’ with troublesome dyskinesias.  
Although there was a trend towards more time with non-troublesome dyskinesias in 
the treatment group, there was no significant difference when compared with the 
placebo group (Table 3-7). 
Table 3-7 Percentage change in motor state during the dosing period relative to 
baseline 
 
Motor state 
Placebo group  
(n = 5) 
Treatment 
group  
(n = 10) 
P value 
‘on’ without dyskinesias -3.67 (31.68) -8.28 (30.53) 1.000 
‘on’ with non-troublesome dyskinesias 0.00 (9.67) 7.91 (14.12) 0.061 
‘on’ with troublesome dyskinesias 0.00 (3.49) 0.00 (0.04) 0.307 
Data are presented as medians (interquartile range) with comparisons between groups using 
the Mann-Whitney test. 
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MDS UPDRS Part II 
The MDS UPDRS Part II was completed at each visit to reflect experiences of motor 
activities of daily living during the previous week.  At baseline, mean MDS UPDRS Part 
II scores for the treatment and placebo groups were the similar but by day 8 there was 
a trend towards lower scores in the treatment arm (Figure 3-20).  . 
Figure 3-20 Comparison of mean MDS UPDRS Part II scores according to study visit 
 
Data points represent group means (with standard deviation error bars). 
 
Comparison of Part II scores between the treatment and placebo groups revealed no 
significant differences either at baseline or on day 8 (Table 3-8).  The change in Part II 
score from baseline to day 8 was not significant for the placebo group.  However, in 
the treatment group, there was a significant reduction in Part II scores by day 8 relative 
to baseline, reflecting a significant improvement in motor experiences of daily living. 
Table 3-8 Comparison of MDS UPDRS Part II scores by study group and visit day 
 Placebo group 
(n = 5) 
Treatment group 
(n = 10) 
P value 
Baseline 13.0 (6.0) 12.0 (12.0) 0.805a 
Day 8 13.0 (12.0) 9.5 (8.0) 0.085a 
P value 0.357b 0.021b  
Data are presented as median (interquartile range).  Inter-group comparisons: aMann-Whitney 
test.  Intra-group comparisons: bWilcoxon signed rank test. 
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MDS UPDRS Part IV 
The occurrence of motor complications was recorded in Part IV of the MDS UPDRS 
which was completed at the start of each visit.  Comparison of mean MDS UPDRS Part 
IV scores across the three assessment visits are shown graphically in Figure 3-21. 
Figure 3-21 Mean MDS UPDRS Part IV scores by assessment visits 
 
Data points represent group means (with standard deviation error bars). 
Inter and intra-group differences in MD UPDRS Part IV scores are summarised in Table 
3-9.  Comparison of Part IV scores for the placebo versus treatment group at baseline 
and day 8 revealed no significant inter-group differences.  Between baseline and day 8 
there was a non-significant trend towards reduced part IV scores in the treatment 
group and increased scores in the placebo group. 
Table 3-9 Comparison of MDS UPDRS Part IV scores by study group and visit day 
 Placebo group 
(n = 5) 
Treatment group 
(n = 10) 
P value 
Baseline 6.0 (4.0) 9.5 (4.0) 0.099a 
Day 8 9.0 (6.0) 7.0 (3.0) 0.440a 
P value 0.102b 0.181b  
Data are presented as median (interquartile range).  Inter-group comparisons: aMann-Whitney 
test.  Intra-group comparisons: bWilcoxon signed rank test. 
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Effects of Camicinal on non-motor function 
A global assessment of the severity of non-motor symptoms of PD was undertaken 
through analysis of total MDS UPDRS Part I scores.  Mean MDS UPDRS Part I scores in 
the treatment and placebo groups are represented graphically in Figure 3-22. 
Figure 3-22 Mean MDS UPDRS Part I scores across assessment visits by group  
 
At baseline and day 8, median MDS UPDRS Part I scores were not significantly different 
between the treatment and placebo groups however within the treatment group there 
was a significant reduction in Part I score from baseline to day 8 which was not evident 
in the placebo group (Table 3-10). 
Table 3-10 Comparison of MDS UPDRS Part I scores by study group and visit day 
 Placebo group 
(n = 5) 
Treatment group 
(n = 10) 
P value 
Baseline 9.0 (9.0) 12.5 (3.0) 0.324a 
Day 8 11.0 (8.0) 8.5 (5.0) 0.157a 
P value 1.00b 0.005b  
Data are presented as median (interquartile range).  Inter-group comparisons: aMann-Whitney 
test.  Intra-group comparisons: bWilcoxon signed rank test. 
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At baseline, all participants apart from one reported some constipation difficulties (a 
score of one or more on the MDS UPDRS question 1.11).  Comparing baseline to day 8, 
in the treatment group two participants reported worse constipation, two improved 
and six were unchanged.  In the placebo group, one of the five deteriorated, one 
improved and three reported no change in their constipation symptoms.  On this 
limited evaluation of bowel function, significant differences were not evident between 
the treatment and placebo groups with regard to change in bowel function during the 
study. 
3.5.6 Safety data and adverse events 
No study terminating events occurred during the study.  Two serious adverse events 
(SAEs) were recorded during the study, one in the active treatment group and one in 
the placebo group.  The SAE in the patient receiving Camicinal was an episode of 
pruritus during the dosing period, which required hospital admission but was related 
to an underlying co-morbidity and not felt to be related to the investigational product 
(IP).  The other SAE occurred in a participant receiving placebo.  This subject 
experienced an ‘extreme off’ period with altered sensation in their legs.  Clinicians 
deemed that both participants were suitable to continue with the study and both 
subjects chose to continue in the study. 
There were a further 37 non-serious adverse events (AEs) reported by 12 participants 
(one of whom also reported one of the SAEs).  In the Camicinal treated group, 8 
subjects reported 14 AEs whilst in the placebo group 4 subjects reported 23 AEs.  Table 
3-11 summarises the types of AE reported by each group.  By the end of participation 
in the study, of the 37 AEs reported, all had resolved apart from one; leg cramps which 
were felt to be unrelated to the medicinal product. 
Of the 14 AEs reported in the treatment group, blinded study clinicians reported that 6 
were potentially related to the IP.  These 6 AEs were: fatigue, lower abdominal ache, 
increased dyskinesias, increased bowel motion frequency, upper abdominal pain and 
headache.  All were graded as mild in severity apart from the lower abdominal ache 
which was of moderate severity.  All six had resolved by the end of the study. 
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Serial ECGs and bloods were performed on all subjects on all visit days.  A detailed 
summary of these individual results is not provided here.  However, review of the 
results revealed no significant abnormalities requiring withdrawal of any participants 
on safety grounds. 
It was concluded that Camicinal was as well-tolerated as placebo in this interim 
analysis of 15 subjects with PD and delayed gastric emptying.  Furthermore there were 
no safety concerns limiting the continuation of the study in this patient group. 
Table 3-11 Summary of adverse events reported during the study by treatment group 
Category / system affected Number of AEs reported 
 Treatment 
group 
Placebo 
group 
Gastrointestinal disorders 4 5 
General disorders and administration site conditions 1 1 
Infections and infestations 1 3 
Injury poisoning and procedural complications 2  
Nervous system disorders 6 5 
Ear and labyrinth disorders  1 
Eye disorders  2 
Musculoskeletal and connective tissue disorders  2 
Psychiatric disorders  1 
Renal and urinary disorders  1 
Respiratory, thoracic and mediastinal disorders  1 
Vascular disorders  1 
Total 14 23 
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3.6 Discussion 
In this study we examined the effect of Camicinal 50mg or placebo in people with PD, 
delayed gastric emptying and motor fluctuations.  The effect of Camicinal upon 
Levodopa absorption, gastric emptying, motor and non-motor function was evaluated. 
3.6.1 Summary of the study findings 
We had hypothesised that Camicinal would enhance Levodopa pharmacokinetics.  
There were no significant differences in Cmax or AUC over the course of the study.  
However we have described a non-significant trend towards a slight improvement in 
Cmax for the Camicinal treated participants. We had hypothesised that absorption 
would be enhanced as a result of faster gastric emptying.  However, the gastric 
emptying rates of participants in both groups were heterogeneous and no significant 
improvement was demonstrated with Camicinal.  It has previously been shown that 
delayed gastric emptying can delay Levodopa absorption (Doi et al., 2012).  
Domperidone has been reported to improve Levodopa absorption through its 
prokinetic effect (Shindler et al., 1984; Nishikawa et al., 2012).  At this stage we are 
unable to demonstrate such an effect with Camicinal.  However, the results presented 
in this thesis are interim findings only and the sample size at this stage was not 
sufficiently powered to prove or disprove the study hypotheses.  The non-significant 
trend towards improved Levodopa absorption in some Camicinal treated participants 
has shown that the study is not futile and therefore the study will continue. 
We hypothesised that Camicinal would improve gastroparesis symptoms.  However, 
the GCSI-DD from baseline to the end of the dosing period did not differ significantly 
between the Camicinal and placebo groups.  One explanation for this could be the 
relatively low baseline gastroparesis symptom scores in this study which rendered little 
room for improvement.  It is also possible that these relatively static symptom scores 
reflect an underlying disparity between the severity of gastric emptying delay and the 
symptoms experienced.  Gastroparesis studies in people with diabetes have also 
demonstrated a mismatch between symptoms and severity of gastric emptying delay 
(Samsom et al., 2009).  A recent meta-analysis of studies in which prokinetics were 
evaluated for changes in gastric emptying and symptoms of gastroparesis reported no 
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relationship between changing symptoms and gastric emptying.  We highlighted this 
apparent disparity between pathophysiology and symptoms in Chapter 2 and will 
explore it more directly in the next chapter where were will look at clinical predictors 
of gastric emptying speed in people with PD. 
When considering changes in gastroparesis symptoms over time, it is also important to 
consider the influence of psychosocial factors.  In this study we did not take account of 
patients’ mood.  However, in our previous study of gastroparesis symptom prevalence 
(Chapter 2) we demonstrated a relationship between the severity of gastroparesis 
symptoms and levels of anxiety and depression.  It remains unclear whether 
gastroparesis results in mood disturbance or whether an underlying mood disorder 
may make an individual more prone to report gastrointestinal symptoms.  In a non-PD 
population, it has been reported that psychological factors have a greater influence 
upon gastroparesis symptoms than the severity of the gastric emptying delay (Hasler 
et al., 2010). 
Our results suggest a greater improvement in motor and non-motor symptoms in the 
Camicinal group compared with placebo.  Studies where domperidone was co-
administered with Levodopa, also reported non-significant improvements in motor 
function (Soykan et al., 1997; Nishikawa et al., 2012).  However, in our study we saw 
only modest changes in Levodopa absorption which calls into question the mechanism 
by which the treatment group participants had improved function.  This relationship 
may become clearer with further study and greater patient numbers.   
We had hypothesised that Camicinal would enhance colonic transit time and hence 
improve constipation problems.  We did not see a significant effect of Camicinal upon 
bowel function.  However, our only measure of bowel function in this interim analysis 
was patients reporting of constipation difficulties on Part I of the MDS UPDRS.  This is a 
subjective interpretation of symptom severity and may therefore be influenced by 
psychosocial factors as we previously alluded to.  A more objective measure would be 
the recording of daily bowel motion frequency and consistency and this data will be 
considered in the final study results. 
As this was an experimental medicine study, it was essential to consider the safety of 
Camicinal.  Although most study participants reported at least one adverse event, the 
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rates were similar amongst the treatment and placebo groups.  Analysis of the AEs and 
SAEs reported in both arms of the study suggested that there were no major safety 
concerns with the use of Camicinal 50mg once daily for 7 to 9 days and furthermore 
Camicinal was as well tolerated as placebo in people with PD. 
3.6.2 Strengths and limitations of the study 
This was a ‘proof of principle’ experimental medicine study of a novel treatment for 
delayed gastric emptying in PD.  Initial recruitment to the study was difficult and hence 
a period of review and re-design was needed.  The process of revision and amendment 
described in section 3.3.9 was successful in leading to improved study recruitment 
however it led to a pause in the study and hence at the time of writing this thesis, 
interim and not completed study results are available to report.  This interim analysis 
of 15 participants was not sufficiently powered to definitively report the efficacy of 
Camicinal.  Therefore we have primarily reported trends in the data, which although 
not statistically robust, do suggest that the on-going study of Camicinal is appropriate 
and relevant. 
The dosing period in this study was only 7-9 days in total.  This relatively short 
treatment period may have been too limited to detect change in some of the outcome 
measures for example changes in gastroparesis symptoms.  It is plausible to suggest 
that more striking treatment effects would be seen after longer dosing periods.  
Therefore, in any future studies of Camicinal in people with PD, it might be appropriate 
to extend the dosing period to several weeks or months.   
One of the major strengths of this study is the breadth and depth of clinical 
assessments undertaken.  We undertook parallel assessments of: Levodopa 
pharmacokinetics, gastric emptying, gastroparesis symptoms and PD motor function 
serially in all patients across multiple visits.  From these detailed evaluations we have 
been able to report a trend towards impaired Levodopa absorption in those patients 
with slower gastric emptying. 
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3.6.3 Study progression and future directions 
The interim results from this study have suggested that continued study of Camicinal 
as a novel treatment for delayed gastric emptying in PD is justified.  The study is on-
going at the time of writing this thesis and it is due to conclude once 45 participants 
have completed the study.  Current projections suggest that the study will be complete 
in spring 2014.  Pending the results of the final study, future avenues of research 
would include the evaluation of different doses of Camicinal and longer dosing periods.  
Additionally the scope for this novel therapy could be widened to include use in the 
earlier stages of PD.  If Camicinal is demonstrated to enhance Levodopa absorption, it 
could potentially be used in all disease stages to enhance the efficacy of existing doses 
thereby helping to keep total Levodopa doses as low as possible. 
From the baseline data obtained for this study we were also able to perform a sub-
study looking at predictors of delayed gastric emptying in PD.  This will be reported in 
the next chapter. 
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Chapter 4 Examination of the relationship between gastroparesis 
symptoms and gastric emptying speed in people with Parkinson’s 
disease 
4.1 Background 
The previous two chapters explored the prevalence of gastroparesis symptoms in 
people with PD and a potential novel treatment for delayed gastric emptying in PD.  
This chapter builds upon these two studies, to evaluate the relationship between 
gastroparesis symptoms and gastric emptying delay in PD. 
Previous studies have suggested that 70-100% of people with PD have abnormally slow 
gastric emptying (Heetun and Quigley, 2012) and yet our study of over 1,000 patients 
with PD suggested that the prevalence of significant gastroparesis symptoms is only 4 - 
12%.  This suggests a disparity between pathophysiological abnormalities of gastric 
motility and manifest symptoms of gastroparesis.  This was therefore explored through 
the simultaneous evaluation of gastric emptying and gastroparesis symptoms. 
Existing methods for measuring gastric emptying are time consuming and not widely 
available out with research and specialist centres.  Therefore there is a need to identify 
clinical predictors of delayed gastric emptying in PD.  The ability to identify those 
patients most at risk of delayed gastric emptying would help clinicians to identify those 
individuals who might benefit from a prokinetic agent without the necessity for 
intrusive or poorly available gastric emptying studies. 
Current evidence regarding the association between symptom severity and gastric 
emptying delay in PD is equivocal (Hardoff et al., 2001; Goetze et al., 2005; Goetze et 
al., 2006).  In a non-PD population the severity of symptoms can be a useful indicator 
of the severity of underlying gastroparesis (Stanghellini et al., 1996; Sarnelli et al., 
2003; Stanghellini et al., 2003; Talley et al., 2006; Cassilly et al., 2008; Grad et al., 
2012).  A recent study (Olausson et al., 2013) in over 100 people with diabetes used 
the GCSI in people at risk of gastroparesis and correlated questionnaire scores with 
gastric emptying rates (measured using scintigraphy).  The authors reported that the 
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nausea / vomiting and fullness subsections of the GCSI correlated significantly with the 
severity of gastric emptying delay. 
The apparent disparity between gastric pathology and symptoms of gastroparesis in 
early PD was highlighted by a recent study (Cersosimo et al., 2013).  However, ours is 
the first in PD to perform paired gastric emptying studies and structured gastroparesis 
symptom evaluations in people with PD. 
4.2 Aims and objectives 
The aim of this study was to assess the association between gastroparesis symptoms 
and gastric emptying speed in people with PD.  This was an exploratory analysis to 
assess the potential of the GCSI-DD to be used as a screening tool with which to 
identify PD patients most at risk of gastroparesis.  Additionally, demographic and 
disease characteristics were considered alongside the GCSI-DD as factors potentially 
impacting upon the risk of gastric emptying delay in PD. 
4.3 Methods 
This was a sub-study of the previously described randomised controlled trial 
comparing Camicinal with placebo in people with PD, delayed gastric emptying and 
motor fluctuations.  The methods were described in detail in section 3.3 and will not 
be repeated here. 
All consented patient who attended for screening were asked to complete the GCSI-DD 
for one week after their screening visit.  Questionnaire responses were compiled along 
with all screened subjects’ gastric emptying rates (GEt1/2).  All participants consented 
to have their screening data used in this sub-study, even if they failed screening.  Of 
the 28 screened subjects included in this sub-study, 19 were eligible for participation in 
the randomised controlled trial and nine were ineligible due to a gastric emptying rate 
faster than permitted by the protocol. 
Patients completed a daily diary equivalent of the GCSI; hence reported scores were 
mean values for the whole reported week.  The GCSI total score was calculated as 
previously described (section 2.5.2) and mean scores for each of the three symptom 
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clusters are reported (nausea / vomiting, fullness, bloating).  Four additional composite 
scores were calculated (Table 4-1) based upon the previous work of Revicki (Revicki et 
al., 2012) which suggested that these selective composite scores are most strongly 
associated with the severity of underlying gastric emptying delay. 
Table 4-1 Composite scores to evaluate gastroparesis symptom severity from the GCSI-
DD (Revicki et al., 2012) 
Composite score GCSI-DD question 
number 
Gastroparesis symptom 
1 – mean of items: Q3 
Q5 
Q10 
Q4 
Nausea 
Bloating 
Stomach fullness 
Excessively full after meals 
2 – mean of items: Q3 
Q6 
Q5 
Q12 
Nausea 
Early satiety 
Bloating 
Upper abdominal pain 
3 – mean of items: Q3 
Q5 
Q4 
Nausea 
Bloating 
Excessively full after meals 
4 – mean of items: Q3 
Q5 
Q6 
Nausea 
Bloating 
Early satiety 
The influence of medications upon gastric emptying speed was evaluated by 
calculation of the Levodopa Equivalent Daily Dose (Tomlinson et al., 2010). 
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4.4 Statistical analysis 
Statistical analyses were performed using SPSS 19 (SPSS, Chicago, IL).  Normality of the 
data was assessed visually with histograms and objectively with the Kolmogorov-
Smirnov test. 
Normally distributed data are reported as mean (with standard deviation) whilst for 
non-normally distributed data median values (with interquartile range) are reported.  
Correlations within parametric data sets were performed with Pearson’s correlation 
with 2-tailed significance applied unless there was an a priori directional hypothesis in 
which case the 1-tailed significance level was used (as stated in the text).  Correlations 
within non-normally distributed data sets, was performed with Spearman’s rank 
correlation where again 1 or 2-tailed significance levels were used depending upon the 
relationship being evaluated.  One-way analysis of variance (ANOVA) was used to 
compare means across groups.  Linear and multiple regression models were used in 
some cases to evaluate predictors of gastric emptying speed.   
For all statistical analysis a P value of < 0.05 was deemed significant.  However, given 
the small sample size in this interim, exploratory analysis, non-significant trends in the 
data are also reported and adjustments for multiple comparisons were not applied. 
4.5 Results 
4.5.1 Demographic factors and their relationship to gastric emptying rate 
From May 2012 until 12th November 2013, 28 participants completed a screening 
assessment and underwent gastric emptying measurement.  These participants were 
evaluated across three sites (Newcastle: 24 subjects, Norwich: 3, Australia: 1, Appendix 
C).  Gastric emptying rates (GEt1/2) for these 28 participants were normally distributed 
(Figure 4-1, Kolmogorov-Smirnov, P = 0.200). 
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Figure 4-1 Histogram showing all measured gastric emptying rates for the 28 screened 
study participants 
 
The mean GEt1/2 of the group was 85.16 minutes (± 19.17).  The quickest GEt1/2 
recorded was 50 minutes and the slowest was 131 minutes.  Eight women were 
screened and in there was a trend towards slower gastric emptying rates in these 
participants compared to male subjects (Figure 4-2).  However, the difference was not 
statistically significant (median GEt1/2 85 and 86.5 minutes respectively, Mann-Whitney 
test, P = 0.415). 
Figure 4-2 Scatter plot of gastric emptying speed by gender 
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The age of participants was normally distributed (Kolmogorov-Smirnov, P = 0.200) with 
a mean age of 64.22 years (± 9.19).  Advancing age and slower gastric emptying rates 
were significantly correlated (Pearson Correlation coefficient 0.350, 1-tailed 
significance P = 0.034), with age accounting for 12.3% of the variability in gastric 
emptying rates (Linear Regression, R2 = 12.3) (Figure 4-3). 
Figure 4-3 Scatter plot comparing age with gastric emptying speed (with line of best fit) 
 
4.5.2 Gastroparesis symptoms and their relationship to gastric emptying rate 
The GCSI total scores of the 28 screened participants were non-normally distributed 
(Kolmogorov-Smirnov, P < 0.001) with a median score of 0.24 (minimum: 0, maximum: 
3.6).  There was a trend which just failed to reach significance towards higher GCSI 
total scores in those participants with slower gastric emptying rates (Pearson’s 
correlation coefficient 0.314, 1-tailed significance P = 0.059) with gastric emptying 
speed accounting for 9.9% of the variance in GCSI total scores (Figure 4-4). 
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Figure 4-4 Scatter plot comparing change in GCSI total score with gastric emptying 
speed (with line of best fit) 
 
The correlation between gastric emptying speed and each individual symptom 
component of the GCSI-DD was explored.  Only one symptom of the 11 evaluated was 
significantly associated.  The severity of an individual’s abdominal distension (question 
9) was positively correlated with the severity of their gastric emptying delay 
(Spearman correlation coefficient: 0.335, 1-tailed significance P = 0.047). 
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The relationship between gastroparesis symptom clusters and gastric emptying speed 
was also evaluated.  Mean scores for the three nausea items positively correlated with 
GEt1/2 rates (more severe symptoms associated with slower gastric emptying) although 
the association did not reach statistical significance (Spearman’s correlation coefficient 
0.304, 1-tailed significance P = 0.066, linear regression model, R2 = 0.100).  There were 
also non-significant trends towards slower gastric emptying in those subjects with 
higher mean fullness and bloating scores (Correlation 0.243, P = 0.116 and correlation 
0.244, P = 0.115, respectively) (Figure 4-5). 
Figure 4-5 Scatter plots of mean scores on the GCSI-DD by symptom clusters compared 
with gastric emptying speed (with lines of best fit) 
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The relationship between gastric emptying speed and four composite symptom scores 
was examined.  There was a non-significant trend towards slower gastric emptying in 
those with more severe symptom scores.  The correlation between GEt1/2 and 
composite score 1was the strongest (Table 4-2). 
Table 4-2 Relationship between composite scores derived from the GCSI-DD and 
gastric emptying speed 
Composite Constituent symptoms Correlation 
coefficient 
P value 
1 Nausea 
Bloating 
Stomach fullness 
Excessively full after meals 
0.323 0.054 
2 Nausea 
Early satiety 
Bloating 
Upper abdominal pain 
0.297 0.070 
3 Nausea 
Bloating 
Excessively full after meals 
0.304 0.066 
4 Nausea 
Bloating 
Early satiety 
0.293 0.073 
Spearman’s correlation with 1-tailed significance test. 
4.5.3 Disease characteristics and their relationship to gastric emptying rate 
The disease duration of participants was non-normally distributed (Kolmogorov-
Smirnov, P = 0.010) with a median PD duration of 9.5 years.  Disease duration and 
gastric emptying speed were not significantly associated with each other (Pearson 
Correlation coefficient -0.045, 1-tailed significance P = 0.821).  This is especially 
noteworthy in light of the association between age and gastric emptying rate. 
Using participants’ baseline MDS UPDRS Part III scores, they were classified into one of 
three motor phenotypes: tremor dominant, PIGD or indeterminate.  Comparison of 
mean gastric emptying rates between these groups showed no significant differences 
(one-way ANOVA, P = 0.184). 
The influence of disease severity upon gastric emptying was evaluated through 
analysis of sub-section and total MDS UPDRS scores.  The MDS UPDRS total scores of 
the 28 screened participants were normally distributed (Kolmogorov-Smirnov test, P = 
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0.142) with a mean score of 78.93 (± 18.89).  The average scores for each sub-section 
of the MDS UPDRS were compared with trends in gastric emptying speed (Table 4-3).  
There was a non-significant trend towards slower gastric emptying in those 
participants with higher Part I, III, IV and total MDS UPDRS scores. 
Table 4-3 Correlation between MDS UPDRS sections and gastric emptying speed 
MDS UPDRS 
section 
Mean score Correlation 
coefficient 
P value 
Part I 11.50 (± 6.00)* 0.358b 0.061 
Part II 15.79 (± 7.50) -0.074a 0.708 
Part III 43.54 (± 13.11) 0.147a 0.456 
Part IV 7.00 (± 4.00)* 0.156b 0.429 
Total 78.93 (± 18.89) 0.134a 0.497 
Data presented as mean (± standard deviation) except * for medians (± interquartile range).   
aPearson’s correlation.  bSpearman’s correlation.  All P values represent 2-tailed tests. 
 
Participants reported their motor state in a detailed diary for the 48 hours after 
screening.  26 participants completed this diary in its entirety and for these subjects 
the mean percentage of the waking day spent in the ‘off’ state was 32.51 ± 18.23  
There was a trend towards slower gastric emptying in participants with more ‘off’ time 
but the relationship did not reach the threshold of statistical significance (Spearman’s 
correlation 0.106, 2-tailed significance P = 0.303). 
Figure 4-6 Scatter plot of the relationship between gastric emptying rate and 
percentage of the waking day spent in the ‘off’ state 
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The Levodopa equivalent daily doses of the 28 participants were normally distributed 
with a mean of 1,042.64mg/day (± 324.43, minimum 400, and maximum 
1,681mg/day).  There was a strong negative correlation between LEDD and GEt1/2, with 
lower daily doses associated with slower rates of gastric emptying (Pearson Correlation 
coefficient -0.561, 2-tailed significance value P = 0.002).  Using a linear regression 
model, participants’ LEDD accounted for 31.5% of the observed variation in gastric 
emptying speed. 
Figure 4-7 Scatter plot (with line of best fit) showing the relationship between 
Levodopa equivalent daily dose (LEDD) and gastric emptying speed 
 
 
Constipation difficulties were reported by participants in Part I of the MDS UPDRS 
(question 1.11).  Comparing the average gastric emptying rate of those participants (n 
= 7) with no constipation problems (median 72.00 ± 28.1 minutes) and those with 
‘Mild’ to ‘Severe’ constipation problems (median 87.00 ± 25.5 minutes) there were no 
significant differences between the two groups (Mann-Whitney test, P = 0.137).  
Similarly, when those participants with orthostatic hypotension (n = 3) were compared 
to those without, no difference in gastric emptying rates was apparent (medians 87 
and 85 minutes, respectively). 
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4.5.4 Predictors of delayed gastric emptying in Parkinson’s disease  
From the above analyses, the following variables were identified as potential 
predictors of delayed gastric emptying in people with PD: advancing age, higher GCSI 
total score, lower LEDD and higher MDS UPDRS part I scores.  When these variables 
were entered into a multiple regression model, they were shown to account for 43.8% 
of the variance in gastric emptying rate (Table 4-4). 
Table 4-4 Multiple regression model for predictors of gastric emptying rate in people 
with PD 
Variables  B S.E. B β 
Constant 55.715 28.541  
Age 0.801 0.350 0.399* 
GCSI total score 6.935 3.496 0.356 
LEDD -0.025 0.010 -0.414* 
MDS UPDRS Part I 0.011 0.545 0.003 
R2 = 0.438 for the model, *P<0.005 
A further model including only the patient age and LEDD showed that 39.8% of the 
variance in gastric emptying speed was accounted for by this model. 
4.6 Discussion 
This study explored the relationship between gastroparesis symptoms and gastric 
emptying speed in people with PD and was a sub-study of the previously described 
phase II pharmacokinetic study. 
4.6.1 Summary of the study findings 
In our series of 28 patients with paired gastric emptying measures and gastroparesis 
symptom diaries, we found a non-significant trend towards slower gastric emptying in 
those with higher GCSI total scores.  An American study (Cassilly et al., 2008) of over 
200 patients referred for gastric emptying studies, reported that certain gastroparesis 
symptom scores (nausea, early satiety and post-prandial fullness) were better 
predictors of gastric emptying than global gastroparesis severity scores.  However, in 
our participants, when mean scores for each of 11 typical gastroparesis symptoms 
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were compared with gastric emptying speed, the only significant correlation was for 
stomach distension (P = 0.047).  None of the symptom clusters significantly correlated 
with gastric emptying speed but there was a trend towards slower emptying in those 
with more symptoms of nausea and vomiting.  Of the composite scores evaluated, 
composite 1 (comprising: nausea, bloating, stomach fullness, excessive fullness after 
meals) was most closely correlated with gastric emptying speed which was in keeping 
with the findings of Revicki’s validation study (Revicki et al., 2012). 
Ours is the first study in people with PD to compare gastric emptying and gastroparesis 
symptom severity.  The relationship was not particularly close which is in keeping with 
recent studies in people with diabetes where a relatively poor association between 
changing gastric symptoms and gastric emptying has been demonstrated (Sanger, 
2014). 
The most striking feature of this exploratory data was our demonstration of a 
significant negative relationship between LEDD and gastric emptying.  This may seem a 
somewhat unexpected finding as in healthy individuals Levodopa has been shown to 
slow gastric emptying (Berkowitz and McCallum, 1980; Robertson et al., 1990; 
Robertson et al., 1992).  However, there is evidence from two studies (Murata et al., 
1996; Hardoff et al., 2001) to suggest that in the context of PD patients on long-term 
Levodopa with motor fluctuations, Levodopa may paradoxically pseudo-normalise 
gastric emptying.  Hardoff et al (Hardoff et al., 2001) postulate that when first 
introduced, Levodopa therapy does indeed delay gastric emptying, as has been 
demonstrated in healthy volunteers but suggested that long-term exposure of the 
basal ganglia to Levodopa may result in changes to the dopaminergic system of the 
DMNV, resulting in hypersensitivity and enhanced vagal activity in the ‘on’ state 
resulting in enhanced gastric emptying (Hardoff et al., 2001).  This is of course 
speculative but may go some way towards explaining the negative relationship we 
demonstrated between Levodopa dose and gastric emptying. 
We also evaluated demographic and disease specific measures as predictors of gastric 
emptying speed in people with established PD.  There was a non-significant trend 
towards slower gastric emptying in female participants.  With additional participant 
numbers we would anticipate that this gender difference may become more marked, 
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as previous studies have reported that women are at greater risk of gastroparesis 
(Stanghellini et al., 2003) and in our earlier prevalence study (Chapter 2) we also 
showed this association in early PD.  We demonstrated a significant relationship 
between advancing age and slower gastric emptying (p = 0.034).  Some studies have 
reported no effect of age upon gastric emptying (Madsen and Graff, 2004) whilst 
others have reported slower gastric emptying in older individuals (Moore et al., 1983; 
Brogna et al., 1999).  The fact that we found slower gastric emptying in older 
individuals may in fact be a surrogate marker of advancing disease severity, as PD is a 
neurodegenerative disease of older people.  Indeed in our data series there was a 
slight trend towards more severe disease (higher MDS UPDRS total score) in older 
participants (Pearson Correlation 0.213, 2 tailed significance P = 0.227).  Accordingly, 
we saw a trend towards slower gastric emptying in those participants with higher MDS 
UPDRS Part III scores. 
4.6.2 Strengths and limitations 
The main limitation of this sub-study was the relatively small number of participants.  
The original intention was to present results from all screened patients in the 
completed study.  However, due to the need to re-design the main study at the end of 
2012, there was a delay in recruitment which meant that only an interim analysis could 
be performed.  However, given the exploratory nature of this evaluation which has 
never previously been undertaken in people with PD, we feel that even these 
preliminary findings and trends in the data are of academic and clinical relevance.  The 
data we have obtained certainly forms the basis of a potential power calculation for 
future studies.  One further limitation of this study was that it did not include a control 
group.  Comparison with healthy volunteers with respect to gastric emptying speed 
and gastroparesis symptoms would be of interest.  However, we were specifically 
interested in variations within PD patients and the relevance of their PD characteristics 
to gastric emptying rates.  Future study including comparisons with healthy age 
matched controls would, nevertheless be of value. 
A major strength is that the study represents the first parallel assessment of 
gastroparesis symptoms and gastric emptying rates in patients with PD.  As has been 
reported in people with diabetes, the relationship between the degree of gastric 
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emptying delay and the severity of gastroparesis symptoms is complex and not direct 
(Samsom et al., 2009).  Our results suggest that whilst the GCSI-DD alone may have a 
low predictive value, when used in conjunction with the identification of higher risk 
demographic and disease characteristics, it may be a useful tool for identifying people 
with PD at risk of gastroparesis, especially in individuals with prominent ‘off’ periods 
and low Levodopa equivalent daily doses. 
4.6.3 Study progression and future directions 
In order to further evaluate the relationship between gastric emptying and 
gastroparesis symptoms, this sub-study will continue in tandem with the main 
investigational study.  When the study concludes, paired gastric emptying and GCSI 
results will be available for 60-70 people, allowing more meaningful statistical analysis 
to be undertaken.  Ultimately we would hope to identify symptom and clinical 
parameters predictive of delayed gastric emptying in PD, such that patients could be 
stratified for their risk of gastroparesis and then managed or investigated as 
appropriate. 
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Chapter 5 Conclusions and future studies 
Parkinson’s disease is increasingly thought of as a multi-system disorder, with an array 
of non-motor symptoms present at all stages of the disease.  Gastroparesis is an 
example of gastric dysfunction which can occur in early and advanced PD.  
Gastroparesis is important not only because of the symptomatic implications but also 
because of its potential detrimental effect upon Levodopa absorption and action.  The 
broad aims of our studies were: 1) to characterise the prevalence and associations of 
gastroparesis symptoms in people with PD, 2) to explore a novel treatment for delayed 
gastric emptying in PD. 
5.1 Gastroparesis symptoms in Parkinson’s disease 
5.1.1 Summary of main findings 
As part of the PRoBaND study, gastroparesis symptoms in over 1,000 people with PD 
were evaluated alongside detailed clinical evaluations.  This represents the largest 
study of gastroparesis symptoms in PD to date.  In early PD we demonstrated that 
upper GI symptoms were reported by more than half of all patients suggesting that 
upper GI symptoms are as prevalent as lower GI symptoms in early disease.  However, 
the prevalence of significant gastroparesis symptoms was low at just over 4%.  This 
was lower than might have been anticipated given that the overall prevalence of 
delayed gastric emptying in PD is estimated to exceed 70% (Heetun and Quigley, 
2012).  The prevalence of probable gastroparesis in those patients who had young 
onset disease was higher at 12.5%.  However, it is likely that this reflects more 
advanced disease stage in these participants rather than a true increased gastroparesis 
risk in those participants diagnosed prior to the age of 50. 
Based upon small studies of gastric motility in PD, we had identified several clinical 
variables which we hypothesised would be associated with a greater risk of 
gastroparesis symptoms.  In early PD, female gender, PIGD phenotype, advanced 
disease severity, a greater number of NMS, the presence of autonomic symptoms, 
anxiety, depression and constipation were all significantly correlated with a greater 
gastroparesis symptom burden.  These were generally in accordance with our a priori 
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hypotheses.  The early, parallel appearance of alpha-synuclein in the DMNV and the 
olfactory centre led us to hypothesise that in early PD, hyposmia and gastroparesis 
symptoms would be associated however we were unable to demonstrate any such 
relationship in our study. 
5.1.2 Conclusions 
Upper GI symptoms are common in PD although rates of symptomatic gastroparesis 
are relatively low.  In those patients who do report gastroparesis symptoms, these 
abnormalities form part of a wider spectrum of non-motor and autonomic symptoms.  
It is possible that some of these cases may ultimately be diagnosed with an alternative 
atypical parkinsonian disorder (e.g. multiple system atrophy).  We are unable to 
discount this possibility in some cases; however on-going prospective evaluation of 
recently diagnosed participants will allow diagnostic re-evaluation as the study 
progresses. 
The discrepancy seen between high rates of gastric emptying delay and relatively low 
rates of gastroparesis symptoms in PD suggests that this gastric motility abnormality 
may be asymptomatic in many cases.  The strength of the relationship between 
motility and symptoms has also been called into question in the context of people with 
diabetes (Samsom et al., 2009).  Furthermore, a dissociation between alpha-synuclein 
burden and functional abnormalities of the upper GI tract has been reported in PD 
(Cersosimo et al., 2013).  Therefore it appears that the progression from pathological 
abnormality to functional impairment and then symptoms is indirect and 
heterogeneous in people with PD. 
5.1.3 Future directions 
The PRoBaND study, from which our gastroparesis symptom study was derived, is on-
going.  Participants with a recent diagnosis of PD will be asked to complete the GCSI 
again at 18 months and 36 months after baseline.  This will allow longitudinal 
evaluation of gastroparesis symptoms.  Such a prospective evaluation of changes in 
gastroparesis symptoms has not been undertaken before in PD.  The results of this 
study have suggested a disparity between functional and symptomatic abnormalities 
of the stomach in PD.  A sub-study of our evaluation of a novel treatment for delayed 
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gastric emptying has begun to assess this relationship between gastric motility and 
symptoms but this remains an area worthy of investigation.  Matched assessments of 
1) gastric ENS pathology, 2) gastric emptying, 3) gastroparesis symptoms in all stages 
of PD would be the optimal way to explore the relationship between pathology, 
physiology and symptoms. 
There is extensive research on-going to identify biomarkers of early PD, with particular 
interest in non-motor features of the disease, as many of these pre-date the onset of 
motor dysfunction.  A retrospective study reported that gastroparesis symptoms 
precede motor symptoms in PD although the prevalence of gastroparesis symptoms 
was not significantly different to that of the control group (Cersosimo et al., 2013).  
Given the apparent discrepancy between symptoms and dysfunction of the stomach in 
early PD, measurement of gastric emptying may serve as a more reliable early 
biomarker.  To date only one study (Unger et al., 2011b) has tried to address this by 
measuring gastric emptying in healthy controls, early PD and people with idiopathic 
REM sleep behaviour disorder (iRBD), a recognised premotor feature of PD.  Relative to 
the healthy controls, gastric emptying rates in the early untreated PD patients were 
abnormally slow but no significant difference was evident between controls and iRBD 
cases.  However, the median disease duration for the iRBD subjects was 48 months 
and it is recognised that the interval from onset of iRBD to diagnosis with PD may be 
up to 15 years in many cases (Postuma, 2014).  Therefore, further research to establish 
when in the chronology of pre-motor PD, gastric motility becomes impaired.  
Thereafter, in conjunction with other non-motor features such as RBD, constipation 
and hyposmia, gastroparesis may prove a useful biomarker for idiopathic PD. 
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5.2 Exploration of a novel treatment for delayed gastric emptying in Parkinson’s 
disease 
5.2.1 Summary of main findings 
We have presented interim findings from an on-going phase II study to assess the 
efficacy of Camicinal as a novel treatment for delayed gastric emptying in PD.  We 
recruited 15 participants with PD who experienced motor fluctuations on oral 
Levodopa and had proved delayed gastric emptying.  In those participants treated with 
Camicinal, by the end of the 7-9 day dosing period there was a trend towards 
improved Levodopa absorption (increased Cmax) relative to baseline, although the 
improvement was not statistically significant.  It was hypothesised that Levodopa 
absorption would improve as a consequence of faster gastric emptying.  However, the 
interim analysis of the first 15 participants did not reveal a significant difference in 
gastric emptying between the two study groups.  Gastroparesis symptoms from 
baseline to the end of the dosing period did not differ significantly in either group 
although baseline gastroparesis severity scores were relatively low in most cases.  We 
noted some significant improvements in motor function, non-motor function and 
reduced off time in the Camicinal treated participants.  Given the modest 
improvements in Levodopa absorption seen, at this interim analysis phase, it is not 
possible to conclude that Camicinal has improved PD function through enhanced 
gastric emptying and Levodopa absorption.  Camicinal was as well tolerated as placebo 
with no safety issues evident in this study. 
A sub-study was undertaken looking at all screened study participants with the aim of 
trying to assess the relationship between gastroparesis symptoms and gastric 
emptying in people with PD.  This sub-study also explored other potential clinical and 
demographic predictors of delayed gastric emptying.  This was the first such study to 
perform paired physiological and symptom evaluations alongside detailed PD 
assessments.  A total of 28 screened participants were considered in the sub-study 
which demonstrated a non-significant trend towards higher GCSI total score in those 
participants with slower gastric emptying.  The only individual gastroparesis symptom 
which positively and significantly correlated with gastric emptying speed was ‘Stomach 
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distension.’  Participants’ ages and Levodopa equivalent daily dose (LEDD) were the 
only other variables which significantly correlated with gastric emptying speed.  
Advancing age was associated with significantly slower gastric emptying, which has 
been demonstrated in studies with healthy older people (Moore et al., 1983; Brogna et 
al., 1999).  Contrary to expectation we saw a negative correlation between LEDD and 
gastric emptying.  Levodopa is typically thought to result in slowed gastric motility 
(Berkowitz and McCallum, 1980; Robertson et al., 1990; Robertson et al., 1992) 
however the reverse was evident in our study results.  This inverse relationship has 
previously been described in the literature on two occasions (Murata et al., 1996; 
Hardoff et al., 2001), where it was postulated that in the short term Levodopa delays 
gastric emptying but with long-term use, plastic changes in the DMNV result in a 
pseudo-normalisation of gastric motility in the presence of Levodopa (Hardoff et al., 
2001).  The average disease duration of the 28 participants in this sub-study was just 
under a decade.  To further explore the suggestion that chronic Levodopa use pseudo-
normalises gastric emptying, it would be of interest to study gastric motility in people 
who have taken Levodopa for different durations of time; additionally paired measures 
before and after the introduction of dopaminergic therapies would be valuable. 
5.2.2 Conclusions 
This was an experimental medicine study.  The intention of the interim analysis 
presented in this thesis was not to definitively report upon the efficacy of Camicinal, 
but rather to evaluate the potential of this novel agent, its safety and also suitability 
for the study to continue.  The conclusion of the interim review was that the 
investigation should continue to explore the potential of Camicinal as a treatment for 
delayed gastric emptying in PD. 
The sub-study has suggested that gastroparesis symptoms alone are not predictive of 
gastric emptying speed.  However, when used in conjunction with clinical and 
demographic parameters, gastroparesis symptoms evaluated using the GCSI-DD, can 
be helpful in identifying those patients with PD most at risk of delayed gastric 
emptying. 
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5.2.3 Future directions 
Following the interim analysis, the study statisticians at GSK concluded that a sample 
size of 45 should be sufficient to evaluate the efficacy of Camicinal in enhancing 
Levodopa absorption.  The study is on-going at the time of writing this thesis and 
based upon current recruitment rates it is forecast that the study will conclude in the 
spring of 2014.  Pending the final results of this mechanism of action study, future 
directions for this project could include the study of Camicinal over longer and titrated 
dosing periods, to evaluate its longer term effects upon pharmacokinetic and clinical 
parameters.  If Camicinal is shown to be effective at enhancing Levodopa absorption 
and motor function, it could also be evaluated in earlier stages of PD as an adjunct 
therapy to help keep total Levodopa doses as low as possible. 
The sub-study to evaluate clinical predictors of delayed gastric emptying is also on-
going and will run in parallel to the main study until its conclusion.  It is envisaged that 
from this work a list of risk factors will be identified to help clinicians identify those 
patients with PD at greatest risk of delayed gastric emptying such that prokinetic 
agents could be most appropriately prescribed. 
5.3 Summary 
Severe gastroparesis symptoms are rare in PD despite gastric motility problems being 
common in all stages of the disease.  There may not be a direct relationship between 
gastroparesis symptoms in the presence of impaired gastric emptying.  However, our 
work has helped to identify symptoms and clinical factors which may identify those 
patients most at risk of delayed gastric emptying.  Even if relatively asymptomatic, it is 
important for clinicians to be able to identify such patients so that they can be 
considered for appropriate therapies to improve gastric motility and potentially 
enhance Levodopa absorption and action. 
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Appendix A - Publications, awards and presentations arising from 
this thesis 
Review article in Movement Disorders (Marrinan et al., 2014) 
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Publications and posters 
 Marrinan S, Emmanuel AV, Burn DJ.  Delayed gastric emptying in Parkinson's 
disease.  Movement Disorders. 2013 Oct 21. doi: 10.1002/mds.25708. [Epub 
ahead of print]. 
 Duncan GW, Yarnall AJ, Marrinan S, Burn DJ.  New horizons in the 
pathogenesis, assessment and management of movement disorders.  Age 
Ageing 2013; 42 (1): 2-10. 
 S Marrinan, N Bajaj, R Barker, Y Ben-Shlomo, A Emmanuel, T Foltynie, D 
Grosset, H Morris, N Williams, N Wood, D Burn.  Gastroparesis symptoms in 
early Parkinson’s disease.  Poster presented at the Spring BGS, November 2013, 
Harrogate. 
 Sarah Marrinan, Anton Emmanuel, Donald Grosset, David Burn.  Prevalence of 
gastroparesis symptoms in patients with early Parkinson’s disease.  Poster 
presented at the 17th International Congress of Parkinson's Disease and 
Movement Disorders, June 2013, Sydney, Australia. 
 Sarah Marrinan, George Dukes, Rachel Gibson, Anton Emmanuel, Donald 
Grosset, David Burn.  Gastroparesis in Parkinson’s disease.  Parkinson’s UK 
Research Conference, November 2012, York. 
 
Awards 
 North East Postgraduate Research Conference 2013 – second place for best 
oral presentation.  S Marrinan, N Bajaj, R Barker, Y Ben-Shlomo, A Emmanuel, T 
Foltynie, D Grosset, H Morris, N Williams, N Wood, D Burn.  Gastroparesis 
symptoms in early Parkinson’s disease. 
 
Presentations 
 Newcastle University Ageing Symposium: ‘Parkinson’s disease and the stomach’ 
– Institute for Ageing and Health – 06/09/2013. 
 Parkinson’s UK South of Tyne branch meeting: ‘Parkinson’s disease and the 
stomach’ – Stockton – 20/07/2013. 
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 MDS International Congress: ‘Prevalence of gastroparesis symptoms in patients 
with early Parkinson’s disease’ – Sydney - 18/06/2013. 
 Regional BGS meeting: ‘Prevalence of gastroparesis symptoms in patients with 
early Parkinson’s disease’ – Newcastle University - 14/03/2013. 
 Parkinson’s UK Research Conference, Patient group meeting: ‘Gastroparesis in 
Parkinson’s disease’ – 04/11/2012. 
 Parkinson’s Interest Group Meeting: ‘Gastroparesis in Parkinson’s disease’ – 
Gateshead - 18/10/2012. 
 Demands Journal club meeting: ‘Gastroparesis in Parkinson’s disease’ – 
Institute for Ageing and Health - 07/01/2013. 
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Appendix B - Gastroparesis questionnaires 
 
The Gastroparesis Cardinal Symptom Index (GCSI) 
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Gastroparesis Cardinal Symptom Index – Daily Diary (GCSI-DD) 
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Appendix C – Study of Camicinal in people with PD and delayed 
gastric emptying 
Summary of prohibited concomitant medications 
Use of medications that potentially influence upper gastrointestinal motility or 
appetite or medication that may influence gastric emptying rate: 
 Prokinetic drugs 
 Macrolide antibiotics (erythromycin, azithromycin) 
 GLP-1 mimetics 
 Anticholinergics known to affect gastric emptying (oxybutynin) 
 Opiates 
Strong inhibitors of P-glycoprotein (quinidine, cyclosporine) 
Strong CYP3A4 inducers or inhibitors are prohibited: 
 Cardiac (verapamil, amiodarone) 
 Antibiotics (clarithromycin, erythromycin, troleandomycin) 
 Anti-fungals (oral azoles) 
 Antidepressants (fluvoxamine, nefazadone) 
 Antiepileptics (carbamazepine, phenytoin, phenobarbital) 
 Antiretrovirals (ritonavir, delaviridine, indanavir, nelfinavir, saquinavir) 
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Gastric emptying rates for all screened subjects by study centre 
Subject number Study site Screening date GEt1/2 (min) Outcome 
Protocol 1 (May – November 2012) 
000001 Newcastle  29 June 2012 65 Ineligible 
000002 Newcastle 10 Aug 2012 93 Eligible  
000003 Newcastle 13 Sept 2012 65 Ineligible 
000004 Newcastle 11 Oct 2012 86 Ineligible 
000005 Newcastle 12 Oct 2012 50 Ineligible 
000006 Newcastle 19 Oct 2012 103 Eligible 
000007 Newcastle 1 Nov 2012 85 Ineligible 
000008 Newcastle 9 Nov 2012 83 Ineligible 
000009 Newcastle 16 Nov 2012 incomplete Withdrew 
Protocol 2 (May – September 2013) 
000010 Newcastle 22 May 2013 101 Eligible 
000011 Newcastle 31 May 2013 72 Eligible 
000012 Newcastle 11 June 2013 61 Ineligible 
000013 Newcastle 13 June 2013 131 Eligible 
000014 Newcastle 25 June 2013 87 Eligible 
000015 Newcastle 5 July 2013 101 Eligible 
000016 Newcastle 9 July 2013 110 Eligible 
000017 Newcastle 1 Aug 2013 53 Ineligible 
000018 Newcastle 15 Aug 2013 90 Eligible 
000019 Newcastle 22 Aug 2013 87 Eligible 
000020 Newcastle 23 Aug 2013 121 Eligible 
000021 Newcastle 10 Sept 2013 71 Eligible (Withdrew) 
000022 Newcastle 17 Sept 2013 79 Eligible 
000023 Newcastle 3 Oct 2013 65 Ineligible 
000101 Australia 14 Aug 2013 102 Eligible 
000201 Norwich 16 July 2013 84 Eligible 
000202 Norwich 24 Sept 2013 85 Eligible 
000400 Sweden 24 Sept 2013 69 Ineligible 
000401 Sweden 24 Sept 2013 80 Eligible 
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Assessment GEt1/2 (minutes) 
Baseline 101 
Day 1 77 
Day 8 67 
Assessment GEt1/2 (minutes) 
Baseline 80 
Day 1 82 
Day 8 69 
Dose adjusted Levodopa AUC profiles over time for each subject with parallel gastric emptying measures 
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Assessment GEt1/2 (minutes) 
Baseline 87 
Day 1 93 
Day 8 69 
Assessment GEt1/2 (minutes) 
Baseline 72 
Day 1 82 
Day 8 81 
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 Assessment GEt1/2 (minutes) 
Baseline 101 
Day 1 85 
Day 8 77 
Assessment GEt1/2 (minutes) 
Baseline 110 
Day 1 143 
Day 8 101 
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Assessment GEt1/2 (minutes) 
Baseline 87 
Day 1 94 
Day 8 76 
Assessment GEt1/2 (minutes) 
Baseline 121 
Day 1 98 
Day 8 94 
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Assessment GEt1/2 (minutes) 
Baseline 79 
Day 1 82 
Day 8 94 
Assessment GEt1/2 (minutes) 
Baseline 102 
Day 1 90 
Day 8 158 
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Assessment GEt1/2 (minutes) 
Baseline 93 
Day 1 81 
Day 8 missing 
Assessment GEt1/2 (minutes) 
Baseline 131 
Day 1 122 
Day 8 106 
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Assessment GEt1/2 (minutes) 
Baseline 90 
Day 1 85 
Day 8 82 
Assessment GEt1/2 (minutes) 
Baseline 84 
Day 1 112 
Day 8 123 
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Assessment GEt1/2 (minutes) 
Baseline 85 
Day 1 88 
Day 8 91 
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